PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15084463-4	2004	DeltaNbeta-cateninER was expressed in the epidermis of transgenic mice under the control of the keratin 14 promoter and beta-catenin activity was induced in adult epidermis by topical application of 4-hydroxytamoxifen (4OHT).	hydroxytamoxifen	199-217	catenin (cadherin associated protein), beta 1	Mus musculus	6-18
14967725-4	2004	Application of 4-hydroxytamoxifen (4-OHT) induced Cre-ER(T)-mediated deletion of the floxed Cx43 allele.	hydroxytamoxifen	15-33	gap junction protein, alpha 1	Mus musculus	92-96
14751226-2	2004	However, 4-hydroxytamoxifen and diethylstilbestrol were recently shown to bind to and inhibit ERRgamma activity.	hydroxytamoxifen	9-27	estrogen related receptor gamma	Homo sapiens	94-102
14617632-2	2004	In transient transfections of ER-positive HepG2-ER7 cells, PI-9 was strongly induced by estrogen, moxestrol (MOX), and 4-hydroxytamoxifen (OHT).	hydroxytamoxifen	119-137	estrogen receptor 1	Homo sapiens	30-32
14617632-2	2004	In transient transfections of ER-positive HepG2-ER7 cells, PI-9 was strongly induced by estrogen, moxestrol (MOX), and 4-hydroxytamoxifen (OHT).	hydroxytamoxifen	119-137	serpin family B member 9	Homo sapiens	59-63
14673139-0	2004	Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins.	hydroxytamoxifen	39-57	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	110-115
14715875-0	2004	Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.	hydroxytamoxifen	211-229	nuclear receptor coactivator 1	Homo sapiens	49-79
14715875-0	2004	Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.	hydroxytamoxifen	211-229	nuclear receptor corepressor 2	Homo sapiens	84-137
14734052-4	2004	To ablate Cx43 in adult mice in all cells that express Cx43 at a certain time, we targeted the 4-hydroxytamoxifen inducible Cre recombinase, Cre-ER(T), into the endogenous Cx43 locus.	hydroxytamoxifen	95-113	gap junction protein, alpha 1	Mus musculus	10-14
14673139-0	2004	Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins.	hydroxytamoxifen	39-57	nuclear receptor coactivator 3	Homo sapiens	120-125
14673139-3	2004	Here, we examined the effects that different ERalpha ligands have on coactivator protein steady-state levels and demonstrate that the selective ER modulators (SERMs) 4-hydroxytamoxifen (4HT) and raloxifene are able to elevate SRC-1 and SRC-3 protein levels.	hydroxytamoxifen	166-184	estrogen receptor 1	Homo sapiens	45-52
14673139-3	2004	Here, we examined the effects that different ERalpha ligands have on coactivator protein steady-state levels and demonstrate that the selective ER modulators (SERMs) 4-hydroxytamoxifen (4HT) and raloxifene are able to elevate SRC-1 and SRC-3 protein levels.	hydroxytamoxifen	166-184	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	226-231
14673139-3	2004	Here, we examined the effects that different ERalpha ligands have on coactivator protein steady-state levels and demonstrate that the selective ER modulators (SERMs) 4-hydroxytamoxifen (4HT) and raloxifene are able to elevate SRC-1 and SRC-3 protein levels.	hydroxytamoxifen	166-184	nuclear receptor coactivator 3	Homo sapiens	236-241
14709801-5	2003	In transfection experiments BPA and NPH activated in a direct manner the endogenous ERalpha in MCF7wt and MCF7SH cells, as the antiestrogen hydroxytamoxifen was able to reverse both responses.	hydroxytamoxifen	140-156	estrogen receptor 1	Homo sapiens	84-91
14553828-4	2003	RESULTS: The treatment of CM and CF with either 4-OH tamoxifen or ICI 182,780 decreased DNA synthesis in the absence of apoptosis via an estrogen receptor-independent pathway.	hydroxytamoxifen	48-62	estrogen receptor 1	Rattus norvegicus	137-154
14672741-0	2003	Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens.	hydroxytamoxifen	107-123	estrogen receptor 1	Homo sapiens	41-64
14629178-0	2003	Simple and efficient production of (Z)-4-hydroxytamoxifen, a potent estrogen receptor modulator.	hydroxytamoxifen	35-57	estrogen receptor 1	Homo sapiens	68-85
14665721-7	2003	Co-treatment with 4-hydroxytamoxifen partially reverses the suppressive effect of estrogen on MIP-1alpha levels.	hydroxytamoxifen	18-36	chemokine (C-C motif) ligand 3	Mus musculus	94-104
12907598-3	2003	We now show that in hydroxytamoxifen-treated cells, transduction of the cell cycle inhibitor p27(Kip1) induces quiescence and insensitivity to growth stimulation by insulin/insulin-like growth factor I and epidermal growth factor/transforming growth factor alpha.	hydroxytamoxifen	20-36	interferon alpha inducible protein 27	Homo sapiens	93-96
12907598-3	2003	We now show that in hydroxytamoxifen-treated cells, transduction of the cell cycle inhibitor p27(Kip1) induces quiescence and insensitivity to growth stimulation by insulin/insulin-like growth factor I and epidermal growth factor/transforming growth factor alpha.	hydroxytamoxifen	20-36	cyclin dependent kinase inhibitor 1B	Homo sapiens	97-101
12907598-3	2003	We now show that in hydroxytamoxifen-treated cells, transduction of the cell cycle inhibitor p27(Kip1) induces quiescence and insensitivity to growth stimulation by insulin/insulin-like growth factor I and epidermal growth factor/transforming growth factor alpha.	hydroxytamoxifen	20-36	tumor necrosis factor	Homo sapiens	230-262
12907598-4	2003	Furthermore, reinitiation of cell cycle progression by insulin/insulin-like growth factor I in hydroxytamoxifen-arrested cells involves dissociation of the corepressors nuclear receptor corepressor (N-CoR) and silencing mediator for retinoid and thyroid hormone receptor (SMRT) from nuclear estrogen receptor alpha and redistribution to the cytoplasm, a process that is inhibited by mitogen-activated protein/extracellular signal-regulated kinase, but not phosphatidylinositol 3"-kinase, inhibitors.	hydroxytamoxifen	95-111	nuclear receptor corepressor 1	Homo sapiens	169-197
12907598-4	2003	Furthermore, reinitiation of cell cycle progression by insulin/insulin-like growth factor I in hydroxytamoxifen-arrested cells involves dissociation of the corepressors nuclear receptor corepressor (N-CoR) and silencing mediator for retinoid and thyroid hormone receptor (SMRT) from nuclear estrogen receptor alpha and redistribution to the cytoplasm, a process that is inhibited by mitogen-activated protein/extracellular signal-regulated kinase, but not phosphatidylinositol 3"-kinase, inhibitors.	hydroxytamoxifen	95-111	nuclear receptor corepressor 1	Homo sapiens	199-204
12907598-4	2003	Furthermore, reinitiation of cell cycle progression by insulin/insulin-like growth factor I in hydroxytamoxifen-arrested cells involves dissociation of the corepressors nuclear receptor corepressor (N-CoR) and silencing mediator for retinoid and thyroid hormone receptor (SMRT) from nuclear estrogen receptor alpha and redistribution to the cytoplasm, a process that is inhibited by mitogen-activated protein/extracellular signal-regulated kinase, but not phosphatidylinositol 3"-kinase, inhibitors.	hydroxytamoxifen	95-111	estrogen receptor 1	Homo sapiens	291-314
12738788-6	2003	In vivo and in vitro binding assays revealed that whereas 4-hydroxytamoxifen (OHT) induced binding of ERalpha to both an AF-1 coactivator complex (p68/p72 and p300) and corepressor complexes (N-CoR/SMRT), BBP selectively enhanced the binding to the AF-1 coactivators.	hydroxytamoxifen	58-76	estrogen receptor 1	Homo sapiens	102-109
12738788-6	2003	In vivo and in vitro binding assays revealed that whereas 4-hydroxytamoxifen (OHT) induced binding of ERalpha to both an AF-1 coactivator complex (p68/p72 and p300) and corepressor complexes (N-CoR/SMRT), BBP selectively enhanced the binding to the AF-1 coactivators.	hydroxytamoxifen	58-76	GATA zinc finger domain containing 2B	Homo sapiens	147-150
12738788-6	2003	In vivo and in vitro binding assays revealed that whereas 4-hydroxytamoxifen (OHT) induced binding of ERalpha to both an AF-1 coactivator complex (p68/p72 and p300) and corepressor complexes (N-CoR/SMRT), BBP selectively enhanced the binding to the AF-1 coactivators.	hydroxytamoxifen	58-76	DEAD-box helicase 17	Homo sapiens	151-154
12738788-6	2003	In vivo and in vitro binding assays revealed that whereas 4-hydroxytamoxifen (OHT) induced binding of ERalpha to both an AF-1 coactivator complex (p68/p72 and p300) and corepressor complexes (N-CoR/SMRT), BBP selectively enhanced the binding to the AF-1 coactivators.	hydroxytamoxifen	58-76	E1A binding protein p300	Homo sapiens	159-163
12738788-6	2003	In vivo and in vitro binding assays revealed that whereas 4-hydroxytamoxifen (OHT) induced binding of ERalpha to both an AF-1 coactivator complex (p68/p72 and p300) and corepressor complexes (N-CoR/SMRT), BBP selectively enhanced the binding to the AF-1 coactivators.	hydroxytamoxifen	58-76	nuclear receptor corepressor 1	Homo sapiens	192-197
12738788-6	2003	In vivo and in vitro binding assays revealed that whereas 4-hydroxytamoxifen (OHT) induced binding of ERalpha to both an AF-1 coactivator complex (p68/p72 and p300) and corepressor complexes (N-CoR/SMRT), BBP selectively enhanced the binding to the AF-1 coactivators.	hydroxytamoxifen	58-76	nuclear receptor corepressor 2	Homo sapiens	198-202
12738788-6	2003	In vivo and in vitro binding assays revealed that whereas 4-hydroxytamoxifen (OHT) induced binding of ERalpha to both an AF-1 coactivator complex (p68/p72 and p300) and corepressor complexes (N-CoR/SMRT), BBP selectively enhanced the binding to the AF-1 coactivators.	hydroxytamoxifen	58-76	TM2 domain containing 1	Homo sapiens	205-208
12767224-6	2003	Our results show that the Y295A/T333I/Y365L triple mutant is significantly suppressed by the known ERR inverse agonists 4-hydroxytamoxifen (OHT) and diethylstilbestrol (DES), in comparison to the wild-type dERR receptor, which was inefficiently suppressed by these substances.	hydroxytamoxifen	120-138	estrogen-related receptor	Drosophila melanogaster	99-102
12767224-6	2003	Our results show that the Y295A/T333I/Y365L triple mutant is significantly suppressed by the known ERR inverse agonists 4-hydroxytamoxifen (OHT) and diethylstilbestrol (DES), in comparison to the wild-type dERR receptor, which was inefficiently suppressed by these substances.	hydroxytamoxifen	120-138	estrogen-related receptor	Drosophila melanogaster	206-210
12591955-5	2003	When such transfectants were treated with an estrogen analogue, 4-hydroxytamoxifen (OHT), CSR was induced within 1 h. Cycloheximide or puromycin drastically suppressed OHT-induced CSR in AID-ER expressing AID-/- B cells when added 1 h before OHT but not after OHT, suggesting that de novo protein synthesis is required for an event downstream to AID expression in CSR.	hydroxytamoxifen	64-82	activation induced cytidine deaminase	Homo sapiens	187-190
12576490-2	2003	17Beta-estradiol (E2) and the antiestrogens 4-hydroxytamoxifen and ICI 182,780 induced reporter gene activity in MCF-7 and MDA-MB-231 cells cotransfected with human or mouse ERalpha (hERalpha or MOR), but not ERbeta and GC-rich constructs containing three tandem Sp1 binding sites (pSp13) or other E2-responsive GC-rich promoters.	hydroxytamoxifen	44-62	estrogen receptor 1 (alpha)	Mus musculus	174-181
12576490-2	2003	17Beta-estradiol (E2) and the antiestrogens 4-hydroxytamoxifen and ICI 182,780 induced reporter gene activity in MCF-7 and MDA-MB-231 cells cotransfected with human or mouse ERalpha (hERalpha or MOR), but not ERbeta and GC-rich constructs containing three tandem Sp1 binding sites (pSp13) or other E2-responsive GC-rich promoters.	hydroxytamoxifen	44-62	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	183-191
12576490-2	2003	17Beta-estradiol (E2) and the antiestrogens 4-hydroxytamoxifen and ICI 182,780 induced reporter gene activity in MCF-7 and MDA-MB-231 cells cotransfected with human or mouse ERalpha (hERalpha or MOR), but not ERbeta and GC-rich constructs containing three tandem Sp1 binding sites (pSp13) or other E2-responsive GC-rich promoters.	hydroxytamoxifen	44-62	opioid receptor, mu 1	Mus musculus	195-198
12576490-2	2003	17Beta-estradiol (E2) and the antiestrogens 4-hydroxytamoxifen and ICI 182,780 induced reporter gene activity in MCF-7 and MDA-MB-231 cells cotransfected with human or mouse ERalpha (hERalpha or MOR), but not ERbeta and GC-rich constructs containing three tandem Sp1 binding sites (pSp13) or other E2-responsive GC-rich promoters.	hydroxytamoxifen	44-62	estrogen receptor 2 (beta)	Mus musculus	209-215
12725382-8	2003	The determined hormonal activities of estrogens on the interaction of YFP-hERalpha with ERE were as follows in their decreasing order: diethylstilbestrol (DES) > 17beta-estradiol (E2) <==> ethynylestradiol (EE2) > 4-hydroxy tamoxifen (OHT) > clomiphene (Clo).	hydroxytamoxifen	226-245	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	74-82
12769667-10	2003	The formation 4-hydroxytamoxifen is catalyzed by CYP2D6 and at a much lower level by CYP2C19.	hydroxytamoxifen	14-32	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	49-55
12769667-10	2003	The formation 4-hydroxytamoxifen is catalyzed by CYP2D6 and at a much lower level by CYP2C19.	hydroxytamoxifen	14-32	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	85-92
12611887-4	2003	First, an estrogen receptor-E2F1 fusion protein (ER-E2F1) potently activates the endogenous cyclin D3 mRNA upon treatment with 4-hydroxytamoxifen, which induces nuclear accumulation of the otherwise cytosolic fusion protein.	hydroxytamoxifen	127-145	E2F transcription factor 1 L homeolog	Xenopus laevis	28-32
12611887-4	2003	First, an estrogen receptor-E2F1 fusion protein (ER-E2F1) potently activates the endogenous cyclin D3 mRNA upon treatment with 4-hydroxytamoxifen, which induces nuclear accumulation of the otherwise cytosolic fusion protein.	hydroxytamoxifen	127-145	E2F transcription factor 1 L homeolog	Xenopus laevis	52-56
12554772-6	2003	Similarly, treatment with the antagonists 4-hydroxytamoxifen and EM-652 abolished all interactions between ERalpha and the SRC RIDs.	hydroxytamoxifen	42-60	estrogen receptor 1	Homo sapiens	107-114
12591955-5	2003	When such transfectants were treated with an estrogen analogue, 4-hydroxytamoxifen (OHT), CSR was induced within 1 h. Cycloheximide or puromycin drastically suppressed OHT-induced CSR in AID-ER expressing AID-/- B cells when added 1 h before OHT but not after OHT, suggesting that de novo protein synthesis is required for an event downstream to AID expression in CSR.	hydroxytamoxifen	64-82	activation induced cytidine deaminase	Homo sapiens	205-208
12591955-5	2003	When such transfectants were treated with an estrogen analogue, 4-hydroxytamoxifen (OHT), CSR was induced within 1 h. Cycloheximide or puromycin drastically suppressed OHT-induced CSR in AID-ER expressing AID-/- B cells when added 1 h before OHT but not after OHT, suggesting that de novo protein synthesis is required for an event downstream to AID expression in CSR.	hydroxytamoxifen	64-82	activation induced cytidine deaminase	Homo sapiens	205-208
12623757-7	2003	CYP2D6 was the prime catalyst of tam-4-hydroxylation, whereas CYP2B6, 2C9 and 2C19 yielded only low levels of 4-OH-tam; nevertheless, in all cases the 4-OH-tam was radioactive, apparently resulting from reactions involving an NIH shift.	hydroxytamoxifen	151-159	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
12732288-4	2003	To study the effect of 4EM on ER-alpha and ER-beta activity, we performed transient transfection assays and showed that 4EM activated ER-dependent gene transcription in a dose-dependent manner on both ER subtypes and this activity was inhibited by trans-4-hydroxytamoxifen (4HT).	hydroxytamoxifen	248-272	estrogen receptor 1	Homo sapiens	30-38
12732288-4	2003	To study the effect of 4EM on ER-alpha and ER-beta activity, we performed transient transfection assays and showed that 4EM activated ER-dependent gene transcription in a dose-dependent manner on both ER subtypes and this activity was inhibited by trans-4-hydroxytamoxifen (4HT).	hydroxytamoxifen	248-272	estrogen receptor 2	Homo sapiens	43-50
12124303-0	2002	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4"-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.	hydroxytamoxifen	158-182	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	45-60
12475720-6	2003	Tamoxifen and 4-hydroxytamoxifen showed partial ERalpha agonistic effects with a maximal response of 12% and raloxifene of 3-5%.	hydroxytamoxifen	14-32	estrogen receptor 1	Rattus norvegicus	48-55
12409264-4	2002	A novel 4-hydroxytamoxifen (4-OHT)-dependent transcriptional regulator (called HEA-3) was constructed by fusing in-frame the DNA binding domain of the human hepatocyte nuclear factor-1alpha (HNF1alpha), which is not expressed in muscle cells, a G(521)R mutant of the ligand binding domain of human estrogen receptor-alpha (ERalpha), and the activation domain derived from human nuclear factor-kappaB p65 subunit (NF-kappaB p65).	hydroxytamoxifen	8-26	HNF1 homeobox A	Homo sapiens	157-189
12409264-4	2002	A novel 4-hydroxytamoxifen (4-OHT)-dependent transcriptional regulator (called HEA-3) was constructed by fusing in-frame the DNA binding domain of the human hepatocyte nuclear factor-1alpha (HNF1alpha), which is not expressed in muscle cells, a G(521)R mutant of the ligand binding domain of human estrogen receptor-alpha (ERalpha), and the activation domain derived from human nuclear factor-kappaB p65 subunit (NF-kappaB p65).	hydroxytamoxifen	8-26	HNF1 homeobox A	Homo sapiens	191-200
12409264-4	2002	A novel 4-hydroxytamoxifen (4-OHT)-dependent transcriptional regulator (called HEA-3) was constructed by fusing in-frame the DNA binding domain of the human hepatocyte nuclear factor-1alpha (HNF1alpha), which is not expressed in muscle cells, a G(521)R mutant of the ligand binding domain of human estrogen receptor-alpha (ERalpha), and the activation domain derived from human nuclear factor-kappaB p65 subunit (NF-kappaB p65).	hydroxytamoxifen	8-26	estrogen receptor 1	Homo sapiens	298-321
12409264-4	2002	A novel 4-hydroxytamoxifen (4-OHT)-dependent transcriptional regulator (called HEA-3) was constructed by fusing in-frame the DNA binding domain of the human hepatocyte nuclear factor-1alpha (HNF1alpha), which is not expressed in muscle cells, a G(521)R mutant of the ligand binding domain of human estrogen receptor-alpha (ERalpha), and the activation domain derived from human nuclear factor-kappaB p65 subunit (NF-kappaB p65).	hydroxytamoxifen	8-26	estrogen receptor 1	Homo sapiens	323-330
12409264-4	2002	A novel 4-hydroxytamoxifen (4-OHT)-dependent transcriptional regulator (called HEA-3) was constructed by fusing in-frame the DNA binding domain of the human hepatocyte nuclear factor-1alpha (HNF1alpha), which is not expressed in muscle cells, a G(521)R mutant of the ligand binding domain of human estrogen receptor-alpha (ERalpha), and the activation domain derived from human nuclear factor-kappaB p65 subunit (NF-kappaB p65).	hydroxytamoxifen	8-26	RELA proto-oncogene, NF-kB subunit	Homo sapiens	378-411
12409264-4	2002	A novel 4-hydroxytamoxifen (4-OHT)-dependent transcriptional regulator (called HEA-3) was constructed by fusing in-frame the DNA binding domain of the human hepatocyte nuclear factor-1alpha (HNF1alpha), which is not expressed in muscle cells, a G(521)R mutant of the ligand binding domain of human estrogen receptor-alpha (ERalpha), and the activation domain derived from human nuclear factor-kappaB p65 subunit (NF-kappaB p65).	hydroxytamoxifen	8-26	RELA proto-oncogene, NF-kB subunit	Homo sapiens	413-426
12419016-6	2002	Tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and 3-hydroxytamoxifen also reversibly inhibited the activity of cDNA-expressed CYP3A4, CYP3A5 and CYP1B1.	hydroxytamoxifen	33-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-138
12419016-6	2002	Tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and 3-hydroxytamoxifen also reversibly inhibited the activity of cDNA-expressed CYP3A4, CYP3A5 and CYP1B1.	hydroxytamoxifen	33-51	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	140-146
12419016-6	2002	Tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and 3-hydroxytamoxifen also reversibly inhibited the activity of cDNA-expressed CYP3A4, CYP3A5 and CYP1B1.	hydroxytamoxifen	33-51	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	151-157
12154049-2	2002	We have developed an in vitro system in which some SERMs (4-hydroxytamoxifen and resveratrol) demonstrate estrogenic response through wild-type (wt) ER, whereas others (raloxifene and GW7604) remain antiestrogenic.	hydroxytamoxifen	58-76	estrogen receptor 1	Homo sapiens	52-54
12354757-4	2002	By terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling and cytoplasmic nucleosome enzyme-linked immunosorbent assay, we demonstrated that 4-hydroxytamoxifen-induced apoptosis was totally lost in PTPL1/FAP-1 antisense transfectants in which enzyme expression was abrogated, revealing the crucial role of this phosphatase in the apoptotic process in human breast cancer cells.	hydroxytamoxifen	162-180	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	219-224
12354757-4	2002	By terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling and cytoplasmic nucleosome enzyme-linked immunosorbent assay, we demonstrated that 4-hydroxytamoxifen-induced apoptosis was totally lost in PTPL1/FAP-1 antisense transfectants in which enzyme expression was abrogated, revealing the crucial role of this phosphatase in the apoptotic process in human breast cancer cells.	hydroxytamoxifen	162-180	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	225-230
12413861-0	2002	Synthesis and estrogen receptor affinity of a 4-hydroxytamoxifen-labeled ligand for diagnostic imaging.	hydroxytamoxifen	46-64	estrogen receptor 1	Homo sapiens	14-31
12413861-2	2002	Tamoxifen and its primary metabolite 4-hydroxytamoxifen are common estrogen receptor ligands.	hydroxytamoxifen	37-55	estrogen receptor 1	Homo sapiens	67-84
12419790-1	2002	BACKGROUND: Human sulfotransferase 1A1 (SULT1A1) catalyzes the sulfation of a variety of phenolic and estrogenic compounds, including 4-hydroxytamoxifen (4-OH TAM), the active metabolite of tamoxifen.	hydroxytamoxifen	134-152	sulfotransferase family 1A member 1	Homo sapiens	18-38
12419790-1	2002	BACKGROUND: Human sulfotransferase 1A1 (SULT1A1) catalyzes the sulfation of a variety of phenolic and estrogenic compounds, including 4-hydroxytamoxifen (4-OH TAM), the active metabolite of tamoxifen.	hydroxytamoxifen	134-152	sulfotransferase family 1A member 1	Homo sapiens	40-47
12147685-7	2002	Activation of STAT3 in fetal hepatocytes of transgenic mice expressing the STAT3-estrogen receptor fusion protein by 4-hydroxytamoxifen resulted in the suppression of cyclin D1 and D2 expression.	hydroxytamoxifen	117-135	signal transducer and activator of transcription 3	Mus musculus	14-19
12147685-7	2002	Activation of STAT3 in fetal hepatocytes of transgenic mice expressing the STAT3-estrogen receptor fusion protein by 4-hydroxytamoxifen resulted in the suppression of cyclin D1 and D2 expression.	hydroxytamoxifen	117-135	signal transducer and activator of transcription 3	Mus musculus	75-80
12147685-7	2002	Activation of STAT3 in fetal hepatocytes of transgenic mice expressing the STAT3-estrogen receptor fusion protein by 4-hydroxytamoxifen resulted in the suppression of cyclin D1 and D2 expression.	hydroxytamoxifen	117-135	cyclin D1	Mus musculus	167-176
12373635-3	2002	To study the function and regulation of the transcription factor FKHR in hepatic cells, we constructed a hydroxytamoxifen-inducible version of FKHR by fusing a part of the hormone binding domain of the estrogen receptor (ER) to the C-terminus of FKHR (FKHR-ER).	hydroxytamoxifen	105-121	forkhead box O1	Rattus norvegicus	65-69
12373635-3	2002	To study the function and regulation of the transcription factor FKHR in hepatic cells, we constructed a hydroxytamoxifen-inducible version of FKHR by fusing a part of the hormone binding domain of the estrogen receptor (ER) to the C-terminus of FKHR (FKHR-ER).	hydroxytamoxifen	105-121	forkhead box O1	Rattus norvegicus	143-147
12373635-3	2002	To study the function and regulation of the transcription factor FKHR in hepatic cells, we constructed a hydroxytamoxifen-inducible version of FKHR by fusing a part of the hormone binding domain of the estrogen receptor (ER) to the C-terminus of FKHR (FKHR-ER).	hydroxytamoxifen	105-121	estrogen receptor 1	Rattus norvegicus	202-219
12373635-3	2002	To study the function and regulation of the transcription factor FKHR in hepatic cells, we constructed a hydroxytamoxifen-inducible version of FKHR by fusing a part of the hormone binding domain of the estrogen receptor (ER) to the C-terminus of FKHR (FKHR-ER).	hydroxytamoxifen	105-121	estrogen receptor 1	Rattus norvegicus	221-223
12373635-3	2002	To study the function and regulation of the transcription factor FKHR in hepatic cells, we constructed a hydroxytamoxifen-inducible version of FKHR by fusing a part of the hormone binding domain of the estrogen receptor (ER) to the C-terminus of FKHR (FKHR-ER).	hydroxytamoxifen	105-121	forkhead box O1	Rattus norvegicus	143-147
12373635-3	2002	To study the function and regulation of the transcription factor FKHR in hepatic cells, we constructed a hydroxytamoxifen-inducible version of FKHR by fusing a part of the hormone binding domain of the estrogen receptor (ER) to the C-terminus of FKHR (FKHR-ER).	hydroxytamoxifen	105-121	forkhead box O1	Rattus norvegicus	252-259
12373635-4	2002	In HepG2-cells transiently transfected with plasmids encoding the FKHR-ER fusion protein and a glucose-6-phosphatase reporter construct, hydroxytamoxifen induced a marked induction of glucose-6-phosphatase promoter activity, whereas no effect was observed in control cells.	hydroxytamoxifen	137-153	forkhead box O1	Rattus norvegicus	66-73
12373635-4	2002	In HepG2-cells transiently transfected with plasmids encoding the FKHR-ER fusion protein and a glucose-6-phosphatase reporter construct, hydroxytamoxifen induced a marked induction of glucose-6-phosphatase promoter activity, whereas no effect was observed in control cells.	hydroxytamoxifen	137-153	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	95-116
12373635-4	2002	In HepG2-cells transiently transfected with plasmids encoding the FKHR-ER fusion protein and a glucose-6-phosphatase reporter construct, hydroxytamoxifen induced a marked induction of glucose-6-phosphatase promoter activity, whereas no effect was observed in control cells.	hydroxytamoxifen	137-153	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	184-205
12124303-1	2002	The cytochrome P450 (P450)-mediated biotransformation of tamoxifen is important in determining both the clearance of the drug and its conversion to the active metabolite, trans-4-hydroxytamoxifen.	hydroxytamoxifen	171-195	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-19
12124303-10	2002	CYP1B1 was the principal catalyst of 4-hydroxytamoxifen trans-cis isomerization but CYP2B6 and CYP2C19 also contributed.	hydroxytamoxifen	37-55	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	0-6
11904289-4	2002	Transfection of tissue culture cells with expression vectors encoding this hybrid protein allows the signal transduction function of beta-catenin to be induced by the synthetic estrogen, 4-hydroxytamoxifen, leading to regulated activation of a beta-catenin-lymphocyte enhancer-binding factor-dependent reporter gene as well as induction of endogenous cyclin D1 expression.	hydroxytamoxifen	187-205	catenin beta 1	Homo sapiens	133-145
12161509-6	2002	An ER alpha-mixed agonist/antagonist and ER beta antagonist, 4-hydroxytamoxifen, also down-regulated CRH gene expression.	hydroxytamoxifen	61-79	estrogen receptor 1	Homo sapiens	3-11
12161509-6	2002	An ER alpha-mixed agonist/antagonist and ER beta antagonist, 4-hydroxytamoxifen, also down-regulated CRH gene expression.	hydroxytamoxifen	61-79	estrogen receptor 2	Homo sapiens	41-48
12161509-6	2002	An ER alpha-mixed agonist/antagonist and ER beta antagonist, 4-hydroxytamoxifen, also down-regulated CRH gene expression.	hydroxytamoxifen	61-79	corticotropin releasing hormone	Homo sapiens	101-104
12004054-10	2002	The cooperational function of these two pathways was confirmed by experiments with cell lines stably expressing 4-hydroxytamoxifen-inducible oncogenic Raf-1 (DeltaRaf-1:ER[DD]).	hydroxytamoxifen	112-130	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	151-156
12122114-5	2002	Crucially, addition of the anti-estrogen 4-hydroxytamoxifen caused a differential recruitment in vivo of ERalpha and ERbeta onto the hTERT promoter and inhibited telomerase activity.	hydroxytamoxifen	41-59	estrogen receptor 1	Homo sapiens	105-112
12122114-5	2002	Crucially, addition of the anti-estrogen 4-hydroxytamoxifen caused a differential recruitment in vivo of ERalpha and ERbeta onto the hTERT promoter and inhibited telomerase activity.	hydroxytamoxifen	41-59	estrogen receptor 2	Homo sapiens	117-123
12122114-5	2002	Crucially, addition of the anti-estrogen 4-hydroxytamoxifen caused a differential recruitment in vivo of ERalpha and ERbeta onto the hTERT promoter and inhibited telomerase activity.	hydroxytamoxifen	41-59	telomerase reverse transcriptase	Homo sapiens	133-138
12113885-9	2002	Furthermore, we showed that the estrogen-induced increase in the FasL protein and mRNA levels could be abolished by 4-hydroxytamoxifen, which suggests that the observed increase in FasL expression was mediated by estrogen receptor.	hydroxytamoxifen	116-134	Fas ligand	Homo sapiens	65-69
12113885-9	2002	Furthermore, we showed that the estrogen-induced increase in the FasL protein and mRNA levels could be abolished by 4-hydroxytamoxifen, which suggests that the observed increase in FasL expression was mediated by estrogen receptor.	hydroxytamoxifen	116-134	Fas ligand	Homo sapiens	181-185
12113885-9	2002	Furthermore, we showed that the estrogen-induced increase in the FasL protein and mRNA levels could be abolished by 4-hydroxytamoxifen, which suggests that the observed increase in FasL expression was mediated by estrogen receptor.	hydroxytamoxifen	116-134	estrogen receptor 1	Homo sapiens	213-230
12067725-4	2002	100 nM 17beta-estradiol and 4-hydroxytamoxifen blocked high calcium-induced cytochrome c release from mitochondria but not mitochondrial swelling.	hydroxytamoxifen	28-46	cytochrome c, somatic	Homo sapiens	76-88
11904289-4	2002	Transfection of tissue culture cells with expression vectors encoding this hybrid protein allows the signal transduction function of beta-catenin to be induced by the synthetic estrogen, 4-hydroxytamoxifen, leading to regulated activation of a beta-catenin-lymphocyte enhancer-binding factor-dependent reporter gene as well as induction of endogenous cyclin D1 expression.	hydroxytamoxifen	187-205	catenin beta 1	Homo sapiens	244-256
11981757-4	2002	By placing 2 mutated hormone-binding domains of murine estrogen receptor (Mer) at both termini of the Cre, we show that the fusion protein is active only on administration of the synthetic estrogen antagonist 4-hydroxytamoxifen (4-OHT) without any background in the absence of the inducing agent.	hydroxytamoxifen	209-227	estrogen receptor 1 (alpha)	Mus musculus	55-72
12082641-2	2002	In Ba/F3 cells, activation of exogenous AML1 (RUNX1)-ER with 4-hydroxytamoxifen prevents inhibition of G1 progression mediated by CBFbeta-SMMHC, a CBF oncoprotein.	hydroxytamoxifen	61-79	runt related transcription factor 1	Mus musculus	40-44
12082641-2	2002	In Ba/F3 cells, activation of exogenous AML1 (RUNX1)-ER with 4-hydroxytamoxifen prevents inhibition of G1 progression mediated by CBFbeta-SMMHC, a CBF oncoprotein.	hydroxytamoxifen	61-79	runt related transcription factor 1	Mus musculus	46-51
12082641-2	2002	In Ba/F3 cells, activation of exogenous AML1 (RUNX1)-ER with 4-hydroxytamoxifen prevents inhibition of G1 progression mediated by CBFbeta-SMMHC, a CBF oncoprotein.	hydroxytamoxifen	61-79	core binding factor beta	Mus musculus	130-137
12082641-2	2002	In Ba/F3 cells, activation of exogenous AML1 (RUNX1)-ER with 4-hydroxytamoxifen prevents inhibition of G1 progression mediated by CBFbeta-SMMHC, a CBF oncoprotein.	hydroxytamoxifen	61-79	myosin, heavy polypeptide 11, smooth muscle	Mus musculus	138-143
12168826-0	2002	NAD(P)H: quinone oxidoreductase enhances proliferation inhibition by 4-hydroxytamoxifen.	hydroxytamoxifen	69-87	crystallin zeta	Homo sapiens	9-31
11950795-0	2002	Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen.	hydroxytamoxifen	127-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-32
11950795-0	2002	Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen.	hydroxytamoxifen	127-145	nuclear receptor subfamily 1 group I member 2	Homo sapiens	90-109
11950795-5	2002	Here, we report that tamoxifen and its metabolite 4-hydroxytamoxifen markedly induce cytochrome P450 3A4, a drug-metabolizing enzyme of central importance, in primary cultures of human hepatocytes.	hydroxytamoxifen	50-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-104
11950795-6	2002	Tamoxifen and 4-hydroxytamoxifen (1-10 microM) significantly increased the CYP3A4 expression and activity (measured as the rate of testosterone 6beta-hydroxylation).	hydroxytamoxifen	14-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
11950795-8	2002	At this level, tamoxifen and 4-hydroxytamoxifen caused a 1.5- to 3.3-fold (mean, 2.1-fold) and 3.4- to 17-fold (mean, 7.5-fold) increase in the CYP3A4 activity, respectively.	hydroxytamoxifen	29-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-150
11950795-11	2002	Furthermore, tamoxifen and 4-hydroxytamoxifen efficaciously activated the human pregnane X receptor (hPXR; also known as the steroid xenobiotic receptor), a key regulator of CYP3A4 expression.	hydroxytamoxifen	27-45	nuclear receptor subfamily 1 group I member 2	Homo sapiens	80-99
11950795-11	2002	Furthermore, tamoxifen and 4-hydroxytamoxifen efficaciously activated the human pregnane X receptor (hPXR; also known as the steroid xenobiotic receptor), a key regulator of CYP3A4 expression.	hydroxytamoxifen	27-45	nuclear receptor subfamily 1 group I member 2	Homo sapiens	101-105
11950795-11	2002	Furthermore, tamoxifen and 4-hydroxytamoxifen efficaciously activated the human pregnane X receptor (hPXR; also known as the steroid xenobiotic receptor), a key regulator of CYP3A4 expression.	hydroxytamoxifen	27-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
11950795-12	2002	The efficacy of tamoxifen and 4-hydroxytamoxifen relative to rifampicin for hPXR activation was approximately 30 and 60%, respectively.	hydroxytamoxifen	30-48	nuclear receptor subfamily 1 group I member 2	Homo sapiens	76-80
11823467-0	2002	Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydroxytamoxifen.	hydroxytamoxifen	153-171	estrogen receptor 1	Homo sapiens	93-116
12481303-9	2002	Human phenol-sulfating sulfotransferase and human estrogen sulfotransferase are the major enzymes for the sulfation of 4-OH-TAM.	hydroxytamoxifen	119-127	sulfotransferase family 1E member 1	Homo sapiens	50-75
12007790-3	2002	NIH 3T3 cells expressing a hydroxytamoxifen-inducible oncogenic c-Raf-1-oestrogen receptor fusion protein (c-Raf-1-BxB-ER, N-BxB-ER cells) undergo morphological transformation upon stimulation of the Raf kinase.	hydroxytamoxifen	27-43	v-raf-leukemia viral oncogene 1	Mus musculus	64-69
12007790-3	2002	NIH 3T3 cells expressing a hydroxytamoxifen-inducible oncogenic c-Raf-1-oestrogen receptor fusion protein (c-Raf-1-BxB-ER, N-BxB-ER cells) undergo morphological transformation upon stimulation of the Raf kinase.	hydroxytamoxifen	27-43	v-raf-leukemia viral oncogene 1	Mus musculus	107-112
12007790-3	2002	NIH 3T3 cells expressing a hydroxytamoxifen-inducible oncogenic c-Raf-1-oestrogen receptor fusion protein (c-Raf-1-BxB-ER, N-BxB-ER cells) undergo morphological transformation upon stimulation of the Raf kinase.	hydroxytamoxifen	27-43	zinc fingers and homeoboxes 2	Mus musculus	66-69
11751902-2	2002	4-Hydroxytamoxifen is a full agonist at a transforming growth factor alpha target gene in situ in MDA-MB-231 human breast cancer cells stably transfected with the wild-type ERalpha.	hydroxytamoxifen	0-18	tumor necrosis factor	Homo sapiens	42-74
11751902-2	2002	4-Hydroxytamoxifen is a full agonist at a transforming growth factor alpha target gene in situ in MDA-MB-231 human breast cancer cells stably transfected with the wild-type ERalpha.	hydroxytamoxifen	0-18	estrogen receptor 1	Homo sapiens	173-180
11751902-4	2002	Because D351G ERalpha allosterically silences activation function-1 activity in the 4-hydroxytamoxifen-ERalpha complex with the complete loss of estrogen-like activity, we examined the converse interaction of amino acid 351 and the piperidine ring of the antiestrogen side chain of raloxifene to enhance estrogen-like action.	hydroxytamoxifen	84-102	estrogen receptor 1	Homo sapiens	103-110
11861507-3	2002	We report that SHP interacts with 4-hydroxytamoxifen (4-OHT) or E2-occupied ER(alpha) in a temperature-dependent manner in vitro.	hydroxytamoxifen	34-52	nuclear receptor subfamily 0 group B member 2	Homo sapiens	15-18
11864604-3	2002	Docking of the previously reported ERR antagonists, diethylstilbestrol and 4-hydroxytamoxifen, requires structural rearrangements enlarging the ligand binding pocket that can only be accommodated with an antagonist LBD conformation.	hydroxytamoxifen	75-93	solute carrier family 7 member 1	Homo sapiens	35-38
12017331-7	2002	The in vitro experiments showed that TAM and 4-OH-TAM stimulate established glioma cell lines to increase their secretion of TGF-beta2.	hydroxytamoxifen	45-53	transforming growth factor beta 2	Homo sapiens	125-134
12439862-7	2002	The most conspicuous difference between beta-HCH and HRG in MCF-7 foci formation test was their response to 4-hydroxytamoxifen and LY294002, a PI3K inhibitor, i.e., the action of beta-HCH was inhibited by 4-hydroxytamoxifen but stimulated by LY294002, whereas that of heregulin was suppressed by LY294002 but stimulated by 4-hydroxytamoxifen.	hydroxytamoxifen	108-126	histidine rich glycoprotein	Homo sapiens	53-56
12439862-7	2002	The most conspicuous difference between beta-HCH and HRG in MCF-7 foci formation test was their response to 4-hydroxytamoxifen and LY294002, a PI3K inhibitor, i.e., the action of beta-HCH was inhibited by 4-hydroxytamoxifen but stimulated by LY294002, whereas that of heregulin was suppressed by LY294002 but stimulated by 4-hydroxytamoxifen.	hydroxytamoxifen	205-223	histidine rich glycoprotein	Homo sapiens	53-56
12439862-7	2002	The most conspicuous difference between beta-HCH and HRG in MCF-7 foci formation test was their response to 4-hydroxytamoxifen and LY294002, a PI3K inhibitor, i.e., the action of beta-HCH was inhibited by 4-hydroxytamoxifen but stimulated by LY294002, whereas that of heregulin was suppressed by LY294002 but stimulated by 4-hydroxytamoxifen.	hydroxytamoxifen	205-223	histidine rich glycoprotein	Homo sapiens	53-56
11432835-3	2001	The anti-estrogen 4-hydroxytamoxifen blocks Rsk2-mediated activation of ERalpha, by inducing a conformation of ERalpha in which the Rsk2 docking site is masked.	hydroxytamoxifen	18-36	ribosomal protein S6 kinase A3	Homo sapiens	44-48
11682626-8	2001	Binding of 4-hydroxytamoxifen (OHT) to the hERalpha C-terminal region induced a functional AF-1 conformation in vitro through this N- and C-terminal interaction.	hydroxytamoxifen	11-29	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	43-51
11682626-8	2001	Binding of 4-hydroxytamoxifen (OHT) to the hERalpha C-terminal region induced a functional AF-1 conformation in vitro through this N- and C-terminal interaction.	hydroxytamoxifen	11-29	interferon gamma receptor 2	Homo sapiens	91-95
11773441-6	2002	PAK6 also bound to the ERalpha, and binding was enhanced by 4-hydroxytamoxifen.	hydroxytamoxifen	60-78	p21 (RAC1) activated kinase 6	Homo sapiens	0-4
11773441-6	2002	PAK6 also bound to the ERalpha, and binding was enhanced by 4-hydroxytamoxifen.	hydroxytamoxifen	60-78	estrogen receptor 1	Homo sapiens	23-30
11447273-0	2001	4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma.	hydroxytamoxifen	0-18	estrogen related receptor gamma	Homo sapiens	48-79
11447273-2	2001	By using a peptide sensor assay, we have identified the stilbenes diethylstilbestrol (DES), tamoxifen (TAM), and 4-hydroxytamoxifen (4-OHT) as high-affinity ligands for ERR gamma.	hydroxytamoxifen	113-131	estrogen related receptor gamma	Homo sapiens	169-178
11432835-3	2001	The anti-estrogen 4-hydroxytamoxifen blocks Rsk2-mediated activation of ERalpha, by inducing a conformation of ERalpha in which the Rsk2 docking site is masked.	hydroxytamoxifen	18-36	estrogen receptor 1	Homo sapiens	72-79
11432835-3	2001	The anti-estrogen 4-hydroxytamoxifen blocks Rsk2-mediated activation of ERalpha, by inducing a conformation of ERalpha in which the Rsk2 docking site is masked.	hydroxytamoxifen	18-36	estrogen receptor 1	Homo sapiens	111-118
11432835-3	2001	The anti-estrogen 4-hydroxytamoxifen blocks Rsk2-mediated activation of ERalpha, by inducing a conformation of ERalpha in which the Rsk2 docking site is masked.	hydroxytamoxifen	18-36	ribosomal protein S6 kinase A3	Homo sapiens	132-136
11325832-1	2001	4-Hydroxytamoxifen (4-OHT), a selective estrogen receptor modulator, is an agonist at a transforming growth factor-alpha (TGF-alpha) target gene in situ in MDA-MB-231 human breast cancer cells stably transfected with wild-type human ERalpha.	hydroxytamoxifen	0-18	tumor necrosis factor	Homo sapiens	88-120
11530283-0	2001	Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.	hydroxytamoxifen	105-123	estrogen receptor 1	Homo sapiens	0-23
11530283-0	2001	Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.	hydroxytamoxifen	105-123	tumor necrosis factor	Homo sapiens	50-82
11530283-1	2001	The selective estrogen receptor modulator, 4-hydroxytamoxifen (4-OHT) is a full agonist at the transforming growth factor (TGF) alpha gene in ER negative breast cancer cells stably transfected with ER alpha cDNA (Levenson et al., Br.	hydroxytamoxifen	43-61	transforming growth factor alpha	Homo sapiens	123-133
11530283-1	2001	The selective estrogen receptor modulator, 4-hydroxytamoxifen (4-OHT) is a full agonist at the transforming growth factor (TGF) alpha gene in ER negative breast cancer cells stably transfected with ER alpha cDNA (Levenson et al., Br.	hydroxytamoxifen	43-61	estrogen receptor 1	Homo sapiens	198-206
11325832-1	2001	4-Hydroxytamoxifen (4-OHT), a selective estrogen receptor modulator, is an agonist at a transforming growth factor-alpha (TGF-alpha) target gene in situ in MDA-MB-231 human breast cancer cells stably transfected with wild-type human ERalpha.	hydroxytamoxifen	0-18	transforming growth factor alpha	Homo sapiens	122-131
11325832-1	2001	4-Hydroxytamoxifen (4-OHT), a selective estrogen receptor modulator, is an agonist at a transforming growth factor-alpha (TGF-alpha) target gene in situ in MDA-MB-231 human breast cancer cells stably transfected with wild-type human ERalpha.	hydroxytamoxifen	0-18	estrogen receptor 1	Homo sapiens	233-240
11274368-4	2001	We found that activation of a Myc-estrogen receptor fusion protein by 4-hydroxytamoxifen in mouse cells resulted in suppression of endogenous p21 transcription.	hydroxytamoxifen	70-88	myelocytomatosis oncogene	Mus musculus	30-33
11320145-5	2001	Addition of the specific estradiol-receptor antagonist hydroxytamoxifen suppressed the estradiol-induced formation of micronuclei in MCF-7 cells.	hydroxytamoxifen	55-71	estrogen receptor 1	Homo sapiens	25-43
11274368-4	2001	We found that activation of a Myc-estrogen receptor fusion protein by 4-hydroxytamoxifen in mouse cells resulted in suppression of endogenous p21 transcription.	hydroxytamoxifen	70-88	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	142-145
11181531-8	2001	Because it is known that some antiestrogens can also display tissue-specific agonistic properties, 4-hydroxytamoxifen was tested for its capacity in repressing NF-kappa B activity and was found to be active (albeit less efficient than 17 beta-estradiol) and, interestingly, only with ER alpha.	hydroxytamoxifen	99-117	nuclear factor kappa B subunit 1	Homo sapiens	160-170
11306549-2	2001	One approach to regulate Cre activity utilizes a mutant estrogen hormone-binding domain (ERT) to keep Cre inactive unless the non-steroidal estrogen analog 4-hydroxytamoxifen (OHT) is present.	hydroxytamoxifen	156-174	SH2 domain containing 1B2	Mus musculus	89-92
11306182-5	2001	ERalpha, occupied by estradiol (E2) or 4-hydroxytamoxifen (4-OHT), was incubated with select EREs and digested by chymotrypsin followed by a Western analysis with antibodies to ERalpha.	hydroxytamoxifen	39-57	estrogen receptor 1	Homo sapiens	0-7
11181531-8	2001	Because it is known that some antiestrogens can also display tissue-specific agonistic properties, 4-hydroxytamoxifen was tested for its capacity in repressing NF-kappa B activity and was found to be active (albeit less efficient than 17 beta-estradiol) and, interestingly, only with ER alpha.	hydroxytamoxifen	99-117	estrogen receptor 1	Homo sapiens	284-292
11134296-6	2001	The Nef-ER is kept in an inactive state due to steric hindrance, and addition of the membrane-permeable drug 4-hydroxytamoxifen (4-HT), which binds to the ER domain, leads to inducible activation of Nef-ER within cells.	hydroxytamoxifen	109-127	S100 calcium binding protein B	Homo sapiens	4-7
11384868-5	2001	Incubation of cells in E(2)-containing growth medium caused cell proliferation and hyperphosphorylation of pRB; the latter effect was seen maximally between 24-72 h. The E(2)-induced hyperphosphorylation of pRB and increase in the level of p53 were sensitive to the presence of ICI and 4-hydroxy tamoxifen (OHT).	hydroxytamoxifen	286-305	RB transcriptional corepressor 1	Homo sapiens	107-110
11384868-5	2001	Incubation of cells in E(2)-containing growth medium caused cell proliferation and hyperphosphorylation of pRB; the latter effect was seen maximally between 24-72 h. The E(2)-induced hyperphosphorylation of pRB and increase in the level of p53 were sensitive to the presence of ICI and 4-hydroxy tamoxifen (OHT).	hydroxytamoxifen	286-305	RB transcriptional corepressor 1	Homo sapiens	207-210
11134296-6	2001	The Nef-ER is kept in an inactive state due to steric hindrance, and addition of the membrane-permeable drug 4-hydroxytamoxifen (4-HT), which binds to the ER domain, leads to inducible activation of Nef-ER within cells.	hydroxytamoxifen	109-127	S100 calcium binding protein B	Homo sapiens	199-202
11162936-5	2000	Antiestrogens such as hydroxytamoxifen, which are mixed agonist/antagonists through ERalpha, are pure antagonists through ERbeta at estrogen response element-containing gene sites.	hydroxytamoxifen	22-38	estrogen receptor 1	Homo sapiens	84-91
11113208-7	2001	CIA-ERalpha interactions were found to be independent of AF-2 and enhanced by the antiestrogens EM-652 and ICI 182,780 but not by 4-hydroxytamoxifen and raloxifene.	hydroxytamoxifen	130-148	nuclear receptor coactivator 5	Homo sapiens	0-3
11113208-7	2001	CIA-ERalpha interactions were found to be independent of AF-2 and enhanced by the antiestrogens EM-652 and ICI 182,780 but not by 4-hydroxytamoxifen and raloxifene.	hydroxytamoxifen	130-148	estrogen receptor 1	Homo sapiens	4-11
11162936-5	2000	Antiestrogens such as hydroxytamoxifen, which are mixed agonist/antagonists through ERalpha, are pure antagonists through ERbeta at estrogen response element-containing gene sites.	hydroxytamoxifen	22-38	estrogen receptor 2	Homo sapiens	122-128
10873560-2	2000	4-Hydroxytamoxifen (4-OHTam), a metabolite found in the bloodstream, has much higher affinity for the estrogen receptor than tamoxifen itself.	hydroxytamoxifen	0-18	estrogen receptor 1	Homo sapiens	102-119
11063868-4	2000	Proliferation, cell-cycle status, and apoptosis of myeloid progenitor 32D cell lines engineered to permit the conditional induction of the constitutively active intracellular domain of mNotch1 (mN1(IC)) by the 4-hydroxytamoxifen(OHT)-inducible system were analyzed in the presence or absence of OHT.	hydroxytamoxifen	210-228	notch 1	Mus musculus	185-192
11059777-3	2000	We validated proper expression, specific DNA binding, corepressor interaction, and nuclear localization for the KRAB-PAX3-HBD protein and showed it to be a 4-hydroxytamoxifen-dependent transcriptional repressor of transiently transfected and integrated PAX3 reporters in ARMS cells.	hydroxytamoxifen	158-174	paired box 3	Mus musculus	117-121
10966511-6	2000	An antiestrogen, 4-hydroxytamoxifen, significantly inhibited E2-mediated transactivation and interaction between hER alpha and TIF2 through hER alpha binding (p < 0.05).	hydroxytamoxifen	17-35	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	113-122
10966511-6	2000	An antiestrogen, 4-hydroxytamoxifen, significantly inhibited E2-mediated transactivation and interaction between hER alpha and TIF2 through hER alpha binding (p < 0.05).	hydroxytamoxifen	17-35	nuclear receptor coactivator 2	Homo sapiens	127-131
10966511-6	2000	An antiestrogen, 4-hydroxytamoxifen, significantly inhibited E2-mediated transactivation and interaction between hER alpha and TIF2 through hER alpha binding (p < 0.05).	hydroxytamoxifen	17-35	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	140-149
11075819-0	2000	MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells.	hydroxytamoxifen	95-113	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	0-5
11075819-8	2000	More importantly, the expression of the constitutively active MEKK1 increased the agonistic activity of 4-hydroxytamoxifen to a level comparable to that of 17beta-estradiol and fully blocked its antagonistic activity.	hydroxytamoxifen	104-122	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	62-67
11059777-3	2000	We validated proper expression, specific DNA binding, corepressor interaction, and nuclear localization for the KRAB-PAX3-HBD protein and showed it to be a 4-hydroxytamoxifen-dependent transcriptional repressor of transiently transfected and integrated PAX3 reporters in ARMS cells.	hydroxytamoxifen	158-174	paired box 3	Mus musculus	253-257
11059777-6	2000	SCID mice that were engrafted with the KRAB-PAX3-HBD ARMS cell lines and were implanted with 4-hydroxytamoxifen timed-release pellets exhibited suppression of tumor growth and an altered vascularity that was not observed in the control mice.	hydroxytamoxifen	93-111	paired box 3	Mus musculus	44-48
10861205-5	2000	The PKB activity of this recombinant protein was rapidly activated in hepatocytes challenged with 4-hydroxytamoxifen (OHT), as was endogenous PKB in hepatocytes challenged with insulin.	hydroxytamoxifen	98-116	protein tyrosine kinase 2 beta	Homo sapiens	4-7
10937835-4	2000	This method measures the ability of various estrogenic compounds to compete with a known estrogen-receptor-mediated antihormonal drug, 4-hydroxytamoxifen, using the 1-[4,5-dimethylthiazol-2-yl]-3,5-diphenylformazan (MTT) assay to assess mitochondrial activity.	hydroxytamoxifen	135-153	estrogen receptor 1	Homo sapiens	89-106
10937835-5	2000	Because 4-hydroxytamoxifen treatment of cells results in a dramatic decrease in mitochondrial dehydrogenase activity which is directly related to their estrogen-receptor content, inhibition of this effect with estrogenic compounds represents an estrogen-receptor interaction, or estrogenic rescue.	hydroxytamoxifen	8-26	estrogen receptor 1	Homo sapiens	152-169
10937835-5	2000	Because 4-hydroxytamoxifen treatment of cells results in a dramatic decrease in mitochondrial dehydrogenase activity which is directly related to their estrogen-receptor content, inhibition of this effect with estrogenic compounds represents an estrogen-receptor interaction, or estrogenic rescue.	hydroxytamoxifen	8-26	estrogen receptor 1	Homo sapiens	245-262
10788561-7	2000	From the maximal level, GFP expression plateaued, and then declined when E2 was increased to the highest concentration tested, 10(-7) M. 4-Hydroxytamoxifen (TFN-OH) treatment of cells produced a dose-dependent inhibition of E2-induced GFP expression, indicating the interaction of ER in the regulation of GFP gene expression.	hydroxytamoxifen	137-155	estrogen receptor 1	Homo sapiens	281-283
10725863-6	2000	Abrogation of the mifepristone- and 4-hydroxytamoxifen-induced cytotoxicity by TGFbeta(1)-neutralizing antibody and by the addition of mannose-6-phosphate confirmed the correlation between induction of active TGFbeta(1) and subsequent prostate cancer cell death.	hydroxytamoxifen	36-54	transforming growth factor beta 1	Homo sapiens	79-89
10770489-5	2000	Addition of E2, 4-hydroxytamoxifen, or ICI 182,780 causes ERalpha to partition with the NM-bound fraction on a similar time course (10-20 min) as the spatial reorganization suggesting that the two events are related.	hydroxytamoxifen	16-34	estrogen receptor 1	Homo sapiens	58-65
10725863-6	2000	Abrogation of the mifepristone- and 4-hydroxytamoxifen-induced cytotoxicity by TGFbeta(1)-neutralizing antibody and by the addition of mannose-6-phosphate confirmed the correlation between induction of active TGFbeta(1) and subsequent prostate cancer cell death.	hydroxytamoxifen	36-54	transforming growth factor beta 1	Homo sapiens	209-219
10649967-17	2000	However, in the presence of tyrosinase and GSH, 4-hydroxytamoxifen was primarily converted to o-quinone GSH conjugates.	hydroxytamoxifen	48-66	tyrosinase	Homo sapiens	28-38
10810385-7	2000	The stimulation of NES1 by estradiol can be dramatically blocked by the estrogen antagonists ICI 182,780 and 4-hydroxytamoxifen.	hydroxytamoxifen	109-127	kallikrein related peptidase 10	Homo sapiens	19-23
10617642-0	2000	Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis.	hydroxytamoxifen	81-99	mitogen-activated protein kinase 14	Homo sapiens	18-21
10617642-0	2000	Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis.	hydroxytamoxifen	81-99	estrogen receptor 1	Homo sapiens	114-131
10617642-1	2000	17beta-Estradiol (E(2)) or the antiestrogen, 4-hydroxytamoxifen (OHT), induce apoptosis in stably transfected estrogen receptor (ER)-positive HeLa-ER5 cells.	hydroxytamoxifen	45-63	estrogen receptor 1	Homo sapiens	110-127
10617642-1	2000	17beta-Estradiol (E(2)) or the antiestrogen, 4-hydroxytamoxifen (OHT), induce apoptosis in stably transfected estrogen receptor (ER)-positive HeLa-ER5 cells.	hydroxytamoxifen	45-63	estrogen receptor 1	Homo sapiens	129-131
10619353-3	1999	COUP-TF binding to half-site estrogen response elements (EREs) was increased by the addition of estradiol (E2) -liganded ER (E2-ER), but not by ER liganded with the antiestrogens 4-hydroxytamoxifen (4-OHT-ER) or tamoxifen aziridine (TAz-ER).	hydroxytamoxifen	179-197	estrogen receptor 1	Homo sapiens	57-59
10556809-4	1999	Activation of an inducible PKCtheta AE-estrogen receptor fusion mutant led to a CaN-dependent and rapid FasL reporter activity detected as early as 4 h after addition of 4-hydroxytamoxifen, incidating a direct effect of PKCtheta action on FasL expression.	hydroxytamoxifen	170-188	Fas ligand	Homo sapiens	104-108
10704907-4	1999	On both cell lines the IGF-I or heregulin- induced proliferation was enhanced further by 4-OH-TAM.	hydroxytamoxifen	89-97	insulin like growth factor 1	Homo sapiens	23-28
10559241-8	1999	Caveolin-1-mediated activation of ERalpha was sensitive to a well known ER antagonist, 4-hydroxytamoxifen.	hydroxytamoxifen	87-105	caveolin 1	Homo sapiens	0-10
10559241-8	1999	Caveolin-1-mediated activation of ERalpha was sensitive to a well known ER antagonist, 4-hydroxytamoxifen.	hydroxytamoxifen	87-105	estrogen receptor 1	Homo sapiens	34-41
10630357-0	1999	Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines.	hydroxytamoxifen	37-55	estrogen receptor 1	Homo sapiens	59-76
10630357-4	1999	Here we reported that paclitaxel and 4-hydroxytamoxifen (4-HT) have a synergistic cytotoxic effect on the ER-negative colon cancer cell line HCT15, which is refractory to paclitaxel alone.	hydroxytamoxifen	37-55	estrogen receptor 1	Homo sapiens	106-108
10402064-5	1999	To further delineate whether tamoxifen may be of benefit in altering the course of HCC, we documented the effects of 4-hydroxytamoxifen and 17beta-estradiol on TGF-beta1 mRNA and protein levels and cell proliferation in a human HCC cell line.	hydroxytamoxifen	117-135	transforming growth factor beta 1	Homo sapiens	160-169
10428964-7	1999	This construction (STAT3ER) induced expression of junB (one of the targets of STAT3) in ES cells in the presence of the synthetic ligand 4-hydroxytamoxifen (4HT), thereby indicating that STAT3ER is a conditionally active form.	hydroxytamoxifen	137-155	jun B proto-oncogene	Mus musculus	50-54
10428964-7	1999	This construction (STAT3ER) induced expression of junB (one of the targets of STAT3) in ES cells in the presence of the synthetic ligand 4-hydroxytamoxifen (4HT), thereby indicating that STAT3ER is a conditionally active form.	hydroxytamoxifen	137-155	signal transducer and activator of transcription 3	Mus musculus	19-24
10428964-7	1999	This construction (STAT3ER) induced expression of junB (one of the targets of STAT3) in ES cells in the presence of the synthetic ligand 4-hydroxytamoxifen (4HT), thereby indicating that STAT3ER is a conditionally active form.	hydroxytamoxifen	137-155	signal transducer and activator of transcription 3	Mus musculus	78-83
10400647-2	1999	In order to selectively turn on the Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1 activity to a similar extent as the activation of endogenous Akt by insulin.	hydroxytamoxifen	71-87	thymoma viral proto-oncogene 1	Mus musculus	108-111
10400647-2	1999	In order to selectively turn on the Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1 activity to a similar extent as the activation of endogenous Akt by insulin.	hydroxytamoxifen	71-87	thymoma viral proto-oncogene 1	Mus musculus	127-131
10400647-2	1999	In order to selectively turn on the Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1 activity to a similar extent as the activation of endogenous Akt by insulin.	hydroxytamoxifen	71-87	thymoma viral proto-oncogene 1	Mus musculus	163-167
10400647-2	1999	In order to selectively turn on the Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1 activity to a similar extent as the activation of endogenous Akt by insulin.	hydroxytamoxifen	71-87	thymoma viral proto-oncogene 1	Mus musculus	163-167
10400647-2	1999	In order to selectively turn on the Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1 activity to a similar extent as the activation of endogenous Akt by insulin.	hydroxytamoxifen	71-87	thymoma viral proto-oncogene 1	Mus musculus	108-111
10400647-2	1999	In order to selectively turn on the Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1 activity to a similar extent as the activation of endogenous Akt by insulin.	hydroxytamoxifen	211-227	thymoma viral proto-oncogene 1	Mus musculus	36-39
10400647-2	1999	In order to selectively turn on the Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1 activity to a similar extent as the activation of endogenous Akt by insulin.	hydroxytamoxifen	211-227	thymoma viral proto-oncogene 1	Mus musculus	108-111
10400647-2	1999	In order to selectively turn on the Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1 activity to a similar extent as the activation of endogenous Akt by insulin.	hydroxytamoxifen	211-227	thymoma viral proto-oncogene 1	Mus musculus	108-111
10400647-3	1999	Our studies reveal that stimulation of MER-Akt1 by hydroxytamoxifen induces GLUT1 mRNA and protein accumulation to levels comparable to that induced by insulin; therefore, activation of the Akt cascade suffices to induce GLUT1 gene expression in this cell system.	hydroxytamoxifen	51-67	thymoma viral proto-oncogene 1	Mus musculus	43-47
10400647-3	1999	Our studies reveal that stimulation of MER-Akt1 by hydroxytamoxifen induces GLUT1 mRNA and protein accumulation to levels comparable to that induced by insulin; therefore, activation of the Akt cascade suffices to induce GLUT1 gene expression in this cell system.	hydroxytamoxifen	51-67	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	76-81
10400647-3	1999	Our studies reveal that stimulation of MER-Akt1 by hydroxytamoxifen induces GLUT1 mRNA and protein accumulation to levels comparable to that induced by insulin; therefore, activation of the Akt cascade suffices to induce GLUT1 gene expression in this cell system.	hydroxytamoxifen	51-67	thymoma viral proto-oncogene 1	Mus musculus	43-46
10400647-3	1999	Our studies reveal that stimulation of MER-Akt1 by hydroxytamoxifen induces GLUT1 mRNA and protein accumulation to levels comparable to that induced by insulin; therefore, activation of the Akt cascade suffices to induce GLUT1 gene expression in this cell system.	hydroxytamoxifen	51-67	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	221-226
10402064-7	1999	4-Hydroxytamoxifen and 17beta-estradiol decreased TGF-beta1 mRNA and protein levels in a time- and dose-dependent manner.	hydroxytamoxifen	0-18	transforming growth factor beta 1	Homo sapiens	50-59
10493022-3	1999	METHODS: Based on the finding that the progression of DNA/RNA polymerases on templates might be blocked by bulky DNA adducts, we successfully developed and used a polymerase stop assay to map the sites of adduct formation in the target lacI gene following its reaction in vitro with alpha-acetoxytamoxifen and horseradish peroxidase/H2O2 (HRP/H2O2) activated 4-hydroxytamoxifen.	hydroxytamoxifen	359-377	tissue factor pathway inhibitor	Rattus norvegicus	236-240
10493022-4	1999	RESULTS: Using a T4 DNA polymerase stop assay, adduct formation in the lacI gene of the plasmid constructs, after the reaction in vitro with alpha-acetoxytamoxifen and HRP/H2O2 activated 4-hydroxytamoxifen, was found to mainly occur with guanines.	hydroxytamoxifen	187-205	tissue factor pathway inhibitor	Homo sapiens	71-75
10022879-5	1999	We first demonstrated that the individual activation function 1 (AF-1) domains act in a dominant manner within the ERalpha-ERbeta heterodimer: the mixed agonist-antagonist 4-hydroxytamoxifen acts as an agonist in a promoter- and cell context-dependent manner via the ERalpha AF-1, while activation of the complex by the mitogen-activated protein kinase (MAPK) pathway requires only the ERalpha- or ERbeta-responsive MAPK site.	hydroxytamoxifen	172-190	estrogen receptor 1	Homo sapiens	115-122
10402064-8	1999	TGF-beta1 significantly inhibited PLC/PRF/5 cell proliferation, whereas both 4-hydroxytamoxifen and 17beta-estradiol stimulated PLC/PRF/5 cell proliferation.	hydroxytamoxifen	77-95	heparan sulfate proteoglycan 2	Homo sapiens	128-131
10402064-9	1999	The stimulatory effects of 4-hydroxytamoxifen on PLC/PRF/5 cell proliferation raise concerns regarding its use in the treatment of HCC in human patients and suggest that 4-hydroxytamoxifen may have no beneficial effects in some patients with HCC.	hydroxytamoxifen	27-45	heparan sulfate proteoglycan 2	Homo sapiens	49-52
10066447-5	1999	Maximal stimulation of PCDGF mRNA and protein expression by 17-beta-estradiol was observed at a concentration of 10(-8) M. The stimulation of PCDGF expression by 17-beta-estradiol was completely inhibited by treatment with actinomycin D and with the antiestrogen 4-hydroxytamoxifen.	hydroxytamoxifen	263-281	granulin precursor	Homo sapiens	23-28
10066447-5	1999	Maximal stimulation of PCDGF mRNA and protein expression by 17-beta-estradiol was observed at a concentration of 10(-8) M. The stimulation of PCDGF expression by 17-beta-estradiol was completely inhibited by treatment with actinomycin D and with the antiestrogen 4-hydroxytamoxifen.	hydroxytamoxifen	263-281	granulin precursor	Homo sapiens	142-147
10400647-2	1999	In order to selectively turn on the Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1 activity to a similar extent as the activation of endogenous Akt by insulin.	hydroxytamoxifen	71-87	thymoma viral proto-oncogene 1	Mus musculus	36-39
10076999-5	1999	While hERbeta did not confer estrogen responsiveness on this promoter, it did elicit transcriptional activation in the presence of 4-hydroxytamoxifen (4-OH-Tam).	hydroxytamoxifen	131-149	estrogen receptor 2	Homo sapiens	6-13
10076999-5	1999	While hERbeta did not confer estrogen responsiveness on this promoter, it did elicit transcriptional activation in the presence of 4-hydroxytamoxifen (4-OH-Tam).	hydroxytamoxifen	151-159	estrogen receptor 2	Homo sapiens	6-13
10022879-5	1999	We first demonstrated that the individual activation function 1 (AF-1) domains act in a dominant manner within the ERalpha-ERbeta heterodimer: the mixed agonist-antagonist 4-hydroxytamoxifen acts as an agonist in a promoter- and cell context-dependent manner via the ERalpha AF-1, while activation of the complex by the mitogen-activated protein kinase (MAPK) pathway requires only the ERalpha- or ERbeta-responsive MAPK site.	hydroxytamoxifen	172-190	estrogen receptor 2	Homo sapiens	123-129
10022879-5	1999	We first demonstrated that the individual activation function 1 (AF-1) domains act in a dominant manner within the ERalpha-ERbeta heterodimer: the mixed agonist-antagonist 4-hydroxytamoxifen acts as an agonist in a promoter- and cell context-dependent manner via the ERalpha AF-1, while activation of the complex by the mitogen-activated protein kinase (MAPK) pathway requires only the ERalpha- or ERbeta-responsive MAPK site.	hydroxytamoxifen	172-190	estrogen receptor 1	Homo sapiens	267-274
10022879-5	1999	We first demonstrated that the individual activation function 1 (AF-1) domains act in a dominant manner within the ERalpha-ERbeta heterodimer: the mixed agonist-antagonist 4-hydroxytamoxifen acts as an agonist in a promoter- and cell context-dependent manner via the ERalpha AF-1, while activation of the complex by the mitogen-activated protein kinase (MAPK) pathway requires only the ERalpha- or ERbeta-responsive MAPK site.	hydroxytamoxifen	172-190	estrogen receptor 1	Homo sapiens	267-274
10022879-5	1999	We first demonstrated that the individual activation function 1 (AF-1) domains act in a dominant manner within the ERalpha-ERbeta heterodimer: the mixed agonist-antagonist 4-hydroxytamoxifen acts as an agonist in a promoter- and cell context-dependent manner via the ERalpha AF-1, while activation of the complex by the mitogen-activated protein kinase (MAPK) pathway requires only the ERalpha- or ERbeta-responsive MAPK site.	hydroxytamoxifen	172-190	estrogen receptor 2	Homo sapiens	398-404
9990040-2	1999	We explored an inducible system in which Smad4 protein is activated by translocation to the nucleus when cell lines that stably express wild-type or mutant Smad4 proteins fused to a murine estrogen receptor domain are treated with 4-hydroxytamoxifen.	hydroxytamoxifen	231-249	SMAD family member 4	Mus musculus	41-46
10076999-10	1999	Through the use of mutant and chimeric receptors, it was shown that the 4-OH-Tam activity via ERbeta from the hRARalpha-1 promoter in Hep G2 cells required the amino-terminal region of ERbeta, a region that was not necessary for estrogen-induced ERbeta activity from an ERE in Hep G2 cells.	hydroxytamoxifen	72-80	estrogen receptor 2	Homo sapiens	94-100
10076999-10	1999	Through the use of mutant and chimeric receptors, it was shown that the 4-OH-Tam activity via ERbeta from the hRARalpha-1 promoter in Hep G2 cells required the amino-terminal region of ERbeta, a region that was not necessary for estrogen-induced ERbeta activity from an ERE in Hep G2 cells.	hydroxytamoxifen	72-80	estrogen receptor 2	Homo sapiens	185-191
10076999-10	1999	Through the use of mutant and chimeric receptors, it was shown that the 4-OH-Tam activity via ERbeta from the hRARalpha-1 promoter in Hep G2 cells required the amino-terminal region of ERbeta, a region that was not necessary for estrogen-induced ERbeta activity from an ERE in Hep G2 cells.	hydroxytamoxifen	72-80	estrogen receptor 2	Homo sapiens	185-191
9990040-2	1999	We explored an inducible system in which Smad4 protein is activated by translocation to the nucleus when cell lines that stably express wild-type or mutant Smad4 proteins fused to a murine estrogen receptor domain are treated with 4-hydroxytamoxifen.	hydroxytamoxifen	231-249	SMAD family member 4	Mus musculus	156-161
9920887-5	1999	Estrogen receptor antagonists 4-hydroxytamoxifen and 7alpha-[9-(4,4, 5,5,5-pentafluoro-pentylsulfinyl)nonyl]estra-1,3,5(10)-tr iene3, 17beta-diol restored TCDD-induced CYP1A1 transcription, steady-state mRNA levels, and enzymatic activity in ECC-1 cells.	hydroxytamoxifen	30-48	estrogen receptor 1	Homo sapiens	0-17
9875847-3	1998	Here we report the crystal structure of the human estrogen receptor alpha (hER alpha) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hER alpha LBD bound to the selective antagonist 4-hydroxytamoxifen (OHT).	hydroxytamoxifen	319-337	estrogen receptor 1	Homo sapiens	50-73
9892606-5	1999	In parallel, TGF-beta1 inhibited c-Myc expression in T cell hybridomas, and ectopic expression of a chimeric molecule composed of c-Myc and the steroid binding domain of the estrogen receptor (Myc-ER) blocked both the inhibition of FasL and the decrease of AICD induced by TGF-beta1, providing that 4-hydroxytamoxifen was present.	hydroxytamoxifen	299-317	estrogen receptor 1	Homo sapiens	174-191
9914518-7	1999	Moreover, this enhancement of transcriptional activation by COUP-TFI requires specifically the AF-1 transactivation function of ER and can be observed in the presence of E2 or 4-hydroxytamoxifen but not ICI 164384.	hydroxytamoxifen	176-194	nuclear receptor subfamily 2 group F member 1	Gallus gallus	60-68
9875216-1	1998	In this study we demonstrate that physiologic concentrations of genistein are sufficient to mediate agonism and to reverse the repressive effects of 4-hydroxytamoxifen on estrogen receptor (ER alpha)-responsive reporter genes.	hydroxytamoxifen	149-167	estrogen receptor 1	Homo sapiens	190-198
9833770-3	1998	We confirmed reports of ER disappearance in the presence of estrogens (Es; E2 and DES) and pure anti-estrogens (AEs; RU 58,668 and ICI 164,384) as well as its increase with partial AEs (4-OH-TAM and RU 39,119).	hydroxytamoxifen	186-194	estrogen receptor 1	Homo sapiens	24-26
9875216-5	1998	More importantly, coincubation with genistein and 4-hydroxytamoxifen or genistein treatment following preincubation of the ER with 4-hydroxytamoxifen also resulted in a strong physical interaction with SRC-1.	hydroxytamoxifen	50-68	nuclear receptor coactivator 1	Homo sapiens	202-207
9875216-5	1998	More importantly, coincubation with genistein and 4-hydroxytamoxifen or genistein treatment following preincubation of the ER with 4-hydroxytamoxifen also resulted in a strong physical interaction with SRC-1.	hydroxytamoxifen	131-149	nuclear receptor coactivator 1	Homo sapiens	202-207
9778038-1	1998	Activation of high ectopic levels of c-Myc in serum-deprived Rat1-MycER cells by 4-hydroxytamoxifen induces both proliferation and apoptosis.	hydroxytamoxifen	81-99	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	37-42
9879983-4	1998	The estradiol-induced effect was blocked by 100 nM of the estrogen receptor antagonist 4-hydroxytamoxifen, indicating dephosphorylation of FAK is an estrogen receptor-mediated event.	hydroxytamoxifen	87-105	protein tyrosine kinase 2	Homo sapiens	139-142
9790998-3	1998	Therefore, the effect of 17beta-estradiol (E2), tamoxifen, or its more potent metabolite, 4-hydroxytamoxifen (OH-tamoxifen), on PTHrP expression in an estrogen receptor (ER)-positive breast carcinoma cell line (MCF-7) was evaluated.	hydroxytamoxifen	90-108	parathyroid hormone like hormone	Homo sapiens	128-133
9790998-3	1998	Therefore, the effect of 17beta-estradiol (E2), tamoxifen, or its more potent metabolite, 4-hydroxytamoxifen (OH-tamoxifen), on PTHrP expression in an estrogen receptor (ER)-positive breast carcinoma cell line (MCF-7) was evaluated.	hydroxytamoxifen	90-108	estrogen receptor 1	Homo sapiens	151-168
9790998-3	1998	Therefore, the effect of 17beta-estradiol (E2), tamoxifen, or its more potent metabolite, 4-hydroxytamoxifen (OH-tamoxifen), on PTHrP expression in an estrogen receptor (ER)-positive breast carcinoma cell line (MCF-7) was evaluated.	hydroxytamoxifen	90-108	estrogen receptor 1	Homo sapiens	170-172
9879777-4	1998	Abrogation of the mifepristone- and/or 4-hydroxytamoxifen-induced cytotoxicity by TGFbeta1 neutralizing antibody confirms the correlation between induction of active TGFbeta1 and subsequent cell death.	hydroxytamoxifen	39-57	latent transforming growth factor beta binding protein 1	Homo sapiens	82-90
9879777-4	1998	Abrogation of the mifepristone- and/or 4-hydroxytamoxifen-induced cytotoxicity by TGFbeta1 neutralizing antibody confirms the correlation between induction of active TGFbeta1 and subsequent cell death.	hydroxytamoxifen	39-57	latent transforming growth factor beta binding protein 1	Homo sapiens	166-174
9879777-5	1998	The effect of a combination of mifepristone and 4-hydroxytamoxifen on cell growth inhibition, on the increase in DNA fragmentation, bcl2 downregulation, and induction of TGFbeta1 protein was additive and significantly different (P < 0.05) from the effect of monotherapy.	hydroxytamoxifen	48-66	BCL2 apoptosis regulator	Homo sapiens	132-136
9879777-5	1998	The effect of a combination of mifepristone and 4-hydroxytamoxifen on cell growth inhibition, on the increase in DNA fragmentation, bcl2 downregulation, and induction of TGFbeta1 protein was additive and significantly different (P < 0.05) from the effect of monotherapy.	hydroxytamoxifen	48-66	latent transforming growth factor beta binding protein 1	Homo sapiens	170-178
9581811-2	1998	To address this issue, the survival of Rat-1 fibroblasts containing a 4-hydroxytamoxifen-regulated c-Myc allele, c-MycER (T. D. Littlewood et al., Nucleic Acids Res., 23: 1686-1690, 1995), after single and fractionated doses of radiation was investigated.	hydroxytamoxifen	70-88	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	99-104
9667651-0	1998	The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.	hydroxytamoxifen	29-47	tumor necrosis factor	Homo sapiens	64-96
9667651-4	1998	We now report that 4-hydroxytamoxifen (4-OHT) shows oestrogen-like effects on the induction of TGF-alpha gene expression in our transfectants.	hydroxytamoxifen	19-37	transforming growth factor alpha	Homo sapiens	95-104
9565622-3	1998	In the present study, a conditionally active version of Akt was constructed by fusing the Akt containing the myristoylation sequence to the hormone binding domain of a mutant murine estrogen receptor that selectively binds 4-hydroxytamoxifen.	hydroxytamoxifen	223-241	thymoma viral proto-oncogene 1	Mus musculus	56-59
9806352-3	1998	When ER is bound by 4-hydroxytamoxifen (4-OHT), the active metabolite of the widely used therapeutic antiestrogen tamoxifen (TAM), the receptor binds to EREs with high affinity.	hydroxytamoxifen	20-38	estrogen receptor 1	Homo sapiens	5-7
9686563-4	1998	Activation of STAT6:ER* by 4-hydroxytamoxifen leads to specific activation of STAT6-regulated gene expression including the activation of a STAT6 reporter construct and induction of CD23 in B cell lines.	hydroxytamoxifen	27-45	signal transducer and activator of transcription 6	Homo sapiens	14-19
9686563-4	1998	Activation of STAT6:ER* by 4-hydroxytamoxifen leads to specific activation of STAT6-regulated gene expression including the activation of a STAT6 reporter construct and induction of CD23 in B cell lines.	hydroxytamoxifen	27-45	signal transducer and activator of transcription 6	Homo sapiens	78-83
9686563-4	1998	Activation of STAT6:ER* by 4-hydroxytamoxifen leads to specific activation of STAT6-regulated gene expression including the activation of a STAT6 reporter construct and induction of CD23 in B cell lines.	hydroxytamoxifen	27-45	signal transducer and activator of transcription 6	Homo sapiens	78-83
9686563-4	1998	Activation of STAT6:ER* by 4-hydroxytamoxifen leads to specific activation of STAT6-regulated gene expression including the activation of a STAT6 reporter construct and induction of CD23 in B cell lines.	hydroxytamoxifen	27-45	Fc epsilon receptor II	Homo sapiens	182-186
9764805-4	1998	We report that agents which reduced cell attachment to plastic and invasion through fibronectin in vitro (tamoxifen, N-desmethyltamoxifen and 17beta-oestradiol) caused increases in levels of F-actin and vimentin, whereas agents which did not affect attachment or invasion (4-hydroxytamoxifen and dihydrotestosterone) had little or no effect on the cytoskeletal proteins.	hydroxytamoxifen	273-291	fibronectin 1	Homo sapiens	84-95
9764805-4	1998	We report that agents which reduced cell attachment to plastic and invasion through fibronectin in vitro (tamoxifen, N-desmethyltamoxifen and 17beta-oestradiol) caused increases in levels of F-actin and vimentin, whereas agents which did not affect attachment or invasion (4-hydroxytamoxifen and dihydrotestosterone) had little or no effect on the cytoskeletal proteins.	hydroxytamoxifen	273-291	vimentin	Homo sapiens	203-211
9738981-4	1998	The ligand-binding domain of MfasER was replaced with that of a mutant estrogen receptor which is unable to bind estrogen yet retains affinity for a synthetic ligand, 4-hydroxytamoxifen (Tm).	hydroxytamoxifen	167-185	estrogen receptor 1 (alpha)	Mus musculus	71-88
9636226-11	1998	Activating PKB with 4-hydroxytamoxifen mimicked insulin by decreasing mTOR reactivity with mTAb1 and by increasing the PHAS-I kinase activity of mTOR.	hydroxytamoxifen	20-38	insulin	Homo sapiens	48-55
9636226-11	1998	Activating PKB with 4-hydroxytamoxifen mimicked insulin by decreasing mTOR reactivity with mTAb1 and by increasing the PHAS-I kinase activity of mTOR.	hydroxytamoxifen	20-38	mechanistic target of rapamycin kinase	Homo sapiens	70-74
9636226-11	1998	Activating PKB with 4-hydroxytamoxifen mimicked insulin by decreasing mTOR reactivity with mTAb1 and by increasing the PHAS-I kinase activity of mTOR.	hydroxytamoxifen	20-38	TGF-beta activated kinase 1/MAP3K7 binding protein 1	Mus musculus	91-96
9636226-11	1998	Activating PKB with 4-hydroxytamoxifen mimicked insulin by decreasing mTOR reactivity with mTAb1 and by increasing the PHAS-I kinase activity of mTOR.	hydroxytamoxifen	20-38	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	119-125
9636226-11	1998	Activating PKB with 4-hydroxytamoxifen mimicked insulin by decreasing mTOR reactivity with mTAb1 and by increasing the PHAS-I kinase activity of mTOR.	hydroxytamoxifen	20-38	mechanistic target of rapamycin kinase	Homo sapiens	145-149
9563474-1	1998	The selection of NIH 3T3 cells expressing a hydroxytamoxifen-inducible c-Raf-1-estrogen receptor fusion protein (c-Raf-1-BxB-ER) in the absence or presence of the inducer results in dramatic differences in the expression levels of the fusion protein.	hydroxytamoxifen	44-60	v-raf-leukemia viral oncogene 1	Mus musculus	71-76
9563474-1	1998	The selection of NIH 3T3 cells expressing a hydroxytamoxifen-inducible c-Raf-1-estrogen receptor fusion protein (c-Raf-1-BxB-ER) in the absence or presence of the inducer results in dramatic differences in the expression levels of the fusion protein.	hydroxytamoxifen	44-60	v-raf-leukemia viral oncogene 1	Mus musculus	113-118
9563474-2	1998	Hydroxytamoxifen-mediated constitutive activation of the Raf signal favors the selection of cells expressing low levels of c-Raf-1-BxB-ER.	hydroxytamoxifen	0-16	zinc fingers and homeoboxes 2	Mus musculus	57-60
9563474-2	1998	Hydroxytamoxifen-mediated constitutive activation of the Raf signal favors the selection of cells expressing low levels of c-Raf-1-BxB-ER.	hydroxytamoxifen	0-16	v-raf-leukemia viral oncogene 1	Mus musculus	123-128
9563474-3	1998	Cells selected in the absence of hydroxytamoxifen express up to 20 times higher levels of the inducible Raf kinase.	hydroxytamoxifen	33-49	zinc fingers and homeoboxes 2	Mus musculus	104-107
9584839-5	1998	4-Hydroxytamoxifen and the pure anti-estrogen ICI 164,384 reduced receptor transcriptional activity in the presence of PKC delta.	hydroxytamoxifen	0-18	protein kinase C, delta	Mus musculus	119-128
9544987-7	1998	In the presence of unliganded thyroid hormone receptor (TR) or ER complexed with the antiestrogen 4-hydroxytamoxifen, which presumably sequesters a limiting pool of the inhibitory cofactor, RU486-PR-B functions as a transcriptional activator of a progesterone-responsive gene even in the absence of hormone agonist.	hydroxytamoxifen	98-116	estrogen receptor 1	Homo sapiens	63-65
9566718-1	1998	We have shown that 4-hydroxytamoxifen (4-OHT) has estrogen-like effects on induction of TGFalpha mRNA in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, transfected with either wildtype (S30 cells) or a codon 351asp-->tyr mutant ER (BC-2 cells).	hydroxytamoxifen	19-37	transforming growth factor alpha	Homo sapiens	88-96
9566718-1	1998	We have shown that 4-hydroxytamoxifen (4-OHT) has estrogen-like effects on induction of TGFalpha mRNA in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, transfected with either wildtype (S30 cells) or a codon 351asp-->tyr mutant ER (BC-2 cells).	hydroxytamoxifen	19-37	estrogen receptor 1	Homo sapiens	105-122
9566718-1	1998	We have shown that 4-hydroxytamoxifen (4-OHT) has estrogen-like effects on induction of TGFalpha mRNA in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, transfected with either wildtype (S30 cells) or a codon 351asp-->tyr mutant ER (BC-2 cells).	hydroxytamoxifen	19-37	estrogen receptor 1	Homo sapiens	124-126
9605415-3	1998	As measured by competition studies, the affinity of EM-652, the active metabolite of the prodrug EM-800, for the estrogen receptor is 7-11 times higher than that of 17beta-estradiol (E2), ICI 182780, and hydroxy-tamoxifen (OH-TAM), the active metabolite of Tamoxifen.	hydroxytamoxifen	204-221	estrogen receptor 1	Rattus norvegicus	113-130
9271411-2	1997	We show that ectopic expression of cyclin D1 can stimulate the transcriptional activity of the estrogen receptor in the absence of estradiol and that this activity can be inhibited by 4-hydroxytamoxifen and ICI 182,780.	hydroxytamoxifen	184-202	cyclin D1	Homo sapiens	35-44
9405735-8	1998	Interestingly, 4-hydroxytamoxifen (10(-7) M), a documented pure antiestrogen in reproductive tissues, also increased IGF-I mRNA to levels similar to those observed in E2-treated cells.	hydroxytamoxifen	15-33	insulin like growth factor 1	Homo sapiens	117-122
9395481-8	1997	When ER was liganded by the antiestrogen 4-hydroxytamoxifen (4-OHT), COUP-TF-half-site interaction decreased.	hydroxytamoxifen	41-59	estrogen receptor 1	Gallus gallus	5-7
9395481-8	1997	When ER was liganded by the antiestrogen 4-hydroxytamoxifen (4-OHT), COUP-TF-half-site interaction decreased.	hydroxytamoxifen	41-59	nuclear receptor subfamily 2 group F member 1	Bos taurus	69-76
9371770-6	1997	Activation of a Myc-estrogen receptor fusion protein by 4-hydroxytamoxifen was sufficient to repress gas1 gene transcription.	hydroxytamoxifen	56-74	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	16-19
9371770-6	1997	Activation of a Myc-estrogen receptor fusion protein by 4-hydroxytamoxifen was sufficient to repress gas1 gene transcription.	hydroxytamoxifen	56-74	growth arrest specific 1	Homo sapiens	101-105
9815609-3	1997	We demonstrate that the antiestrogens 4-hydroxytamoxifen (4-OH tamoxifen) and ICI 182780 (ICI) stimulate MDGI expression in vitro.	hydroxytamoxifen	38-56	fatty acid binding protein 3	Homo sapiens	105-109
9815609-3	1997	We demonstrate that the antiestrogens 4-hydroxytamoxifen (4-OH tamoxifen) and ICI 182780 (ICI) stimulate MDGI expression in vitro.	hydroxytamoxifen	58-72	fatty acid binding protein 3	Homo sapiens	105-109
9815609-5	1997	Both 4-OH tamoxifen and ICI stabilized MDGI mRNA without affecting the transcription rate of the MDGI gene.	hydroxytamoxifen	5-19	fatty acid binding protein 3	Homo sapiens	39-43
9815609-6	1997	Under estrogen-free conditions, the half-life of MDGI mRNA in control explants was approximately 6 h. This half-life was increased to 7.5 h in the presence of 10(-7) M 4-OH tamoxifen and to greater than 12 h in the presence of 10(-7) M ICI.	hydroxytamoxifen	168-182	fatty acid binding protein 3	Homo sapiens	49-53
9464539-4	1998	Fusion of the c-Raf-1 kinase domain with the hormone binding domain of the estrogen receptor (c-Raf-1-BxB-ER) provides a 4-hydroxytamoxifen regulated form of the oncogenic c-Raf-1 kinase.	hydroxytamoxifen	121-139	v-raf-leukemia viral oncogene 1	Mus musculus	14-19
9464539-4	1998	Fusion of the c-Raf-1 kinase domain with the hormone binding domain of the estrogen receptor (c-Raf-1-BxB-ER) provides a 4-hydroxytamoxifen regulated form of the oncogenic c-Raf-1 kinase.	hydroxytamoxifen	121-139	estrogen receptor 1 (alpha)	Mus musculus	75-92
9464539-4	1998	Fusion of the c-Raf-1 kinase domain with the hormone binding domain of the estrogen receptor (c-Raf-1-BxB-ER) provides a 4-hydroxytamoxifen regulated form of the oncogenic c-Raf-1 kinase.	hydroxytamoxifen	121-139	v-raf-leukemia viral oncogene 1	Mus musculus	94-99
9464539-4	1998	Fusion of the c-Raf-1 kinase domain with the hormone binding domain of the estrogen receptor (c-Raf-1-BxB-ER) provides a 4-hydroxytamoxifen regulated form of the oncogenic c-Raf-1 kinase.	hydroxytamoxifen	121-139	v-raf-leukemia viral oncogene 1	Mus musculus	94-99
9464539-6	1998	4-hydroxytamoxifen mediated activation of the fusion protein in serum starved N-BxB-ER induces the expression of the c-myc gene within 2-6 h. Deletion of the c-Raf-1 kinase domain generates a mutant c-Raf-1 protein (c-Raf-1-C4B), which can directly interact with the effector domain of the Ras protein and thereby block Ras mediated signalling.	hydroxytamoxifen	0-18	v-raf-leukemia viral oncogene 1	Mus musculus	158-163
9464539-6	1998	4-hydroxytamoxifen mediated activation of the fusion protein in serum starved N-BxB-ER induces the expression of the c-myc gene within 2-6 h. Deletion of the c-Raf-1 kinase domain generates a mutant c-Raf-1 protein (c-Raf-1-C4B), which can directly interact with the effector domain of the Ras protein and thereby block Ras mediated signalling.	hydroxytamoxifen	0-18	v-raf-leukemia viral oncogene 1	Mus musculus	199-204
9464539-6	1998	4-hydroxytamoxifen mediated activation of the fusion protein in serum starved N-BxB-ER induces the expression of the c-myc gene within 2-6 h. Deletion of the c-Raf-1 kinase domain generates a mutant c-Raf-1 protein (c-Raf-1-C4B), which can directly interact with the effector domain of the Ras protein and thereby block Ras mediated signalling.	hydroxytamoxifen	0-18	v-raf-leukemia viral oncogene 1	Mus musculus	199-204
9366526-6	1997	When compared with controls, both clonal and polyclonal populations of FGF-1 overexpressing cells exhibited increased anchorage-independent growth and decreased population doubling times in estrogen-depleted or 4-hydroxytamoxifen containing medium.	hydroxytamoxifen	211-229	fibroblast growth factor 1	Mus musculus	71-76
9010347-5	1996	Interestingly, the binding of ER liganded with the antiestrogen 4-hydroxytamoxifen (4-OHT-ER) was non-cooperative with an apparent stoichiometry of 0.5 4-OHT-ER dimer per ERE, regardless of ER purity or ERE flanking sequence.	hydroxytamoxifen	64-82	estrogen receptor 1	Bos taurus	30-32
9205071-11	1997	RXR compounds also potentiated the action of the antiestrogen 4-hydroxytamoxifen to inhibit the growth of T-47D cells.	hydroxytamoxifen	62-80	retinoid X receptor alpha	Homo sapiens	0-3
9207217-7	1997	4-Hydroxy tamoxifen had anti-estrogenic activity only in yeast lacking the transporter Pdr5.	hydroxytamoxifen	0-19	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	87-91
9207217-8	1997	Whole cell binding assays indicated that 4-hydroxy tamoxifen is exported by Pdr5.	hydroxytamoxifen	41-60	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	76-80
8982077-4	1996	Co-transfection experiments in NIH 3T3 fibroblasts showed that the resulting chimeric protein, Myb/En/ER, repressed transactivation of a c-Myb-responsive reporter only in the presence of the synthetic steroid, 4-hydroxytamoxifen (OHT).	hydroxytamoxifen	210-228	myeloblastosis oncogene	Mus musculus	95-98
8982077-4	1996	Co-transfection experiments in NIH 3T3 fibroblasts showed that the resulting chimeric protein, Myb/En/ER, repressed transactivation of a c-Myb-responsive reporter only in the presence of the synthetic steroid, 4-hydroxytamoxifen (OHT).	hydroxytamoxifen	210-228	myeloblastosis oncogene	Mus musculus	137-142
9178906-8	1997	When a chimeric protein comprised of c-myc and the estrogen binding domain of estrogen receptor was activated by addition of 4-hydroxytamoxifen (OHT), expression of RCC1 mRNA increased twofold.	hydroxytamoxifen	125-143	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	37-42
9178906-8	1997	When a chimeric protein comprised of c-myc and the estrogen binding domain of estrogen receptor was activated by addition of 4-hydroxytamoxifen (OHT), expression of RCC1 mRNA increased twofold.	hydroxytamoxifen	125-143	estrogen receptor 1	Homo sapiens	78-95
9178906-8	1997	When a chimeric protein comprised of c-myc and the estrogen binding domain of estrogen receptor was activated by addition of 4-hydroxytamoxifen (OHT), expression of RCC1 mRNA increased twofold.	hydroxytamoxifen	125-143	regulator of chromosome condensation 1	Homo sapiens	165-169
9010347-5	1996	Interestingly, the binding of ER liganded with the antiestrogen 4-hydroxytamoxifen (4-OHT-ER) was non-cooperative with an apparent stoichiometry of 0.5 4-OHT-ER dimer per ERE, regardless of ER purity or ERE flanking sequence.	hydroxytamoxifen	64-82	estrogen receptor 1	Bos taurus	90-92
9010347-5	1996	Interestingly, the binding of ER liganded with the antiestrogen 4-hydroxytamoxifen (4-OHT-ER) was non-cooperative with an apparent stoichiometry of 0.5 4-OHT-ER dimer per ERE, regardless of ER purity or ERE flanking sequence.	hydroxytamoxifen	64-82	estrogen receptor 1	Bos taurus	90-92
9010347-5	1996	Interestingly, the binding of ER liganded with the antiestrogen 4-hydroxytamoxifen (4-OHT-ER) was non-cooperative with an apparent stoichiometry of 0.5 4-OHT-ER dimer per ERE, regardless of ER purity or ERE flanking sequence.	hydroxytamoxifen	64-82	estrogen receptor 1	Bos taurus	90-92
8752163-7	1996	The antiestrogens tamoxifen, 4-OH tamoxifen, and nafoxidine produce similar increases in uterine VEGF mRNA levels within 6 h, with 1 mg/kg tamoxifen producing a maximum response of 15-20-fold.	hydroxytamoxifen	29-43	vascular endothelial growth factor A	Rattus norvegicus	97-101
8800639-3	1995	Antiestrogens, 4-hydroxytamoxifen and ICI 164,384, prevented the effects of the xenobiotics, indicating that the induction of gene expression is mediated by the ER.	hydroxytamoxifen	15-33	estrogen receptor	Oncorhynchus mykiss	161-163
22358926-4	1996	We have developed a "switchable" chimaeric c-Myc protein whose activity is dependent on the synthetic ligand, 4-hydroxytamoxifen.	hydroxytamoxifen	110-128	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	43-48
22358926-5	1996	In cells expressing this switchable c-Myc, proliferation and apoptosis in cultured fibroblasts can be regulated by addition of 4-hydroxytamoxifen.	hydroxytamoxifen	127-145	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	36-41
8761295-2	1996	The protein product of this gene, p53ERTM, is expressed in cells constitutively but is not functional unless associated with tamoxifen or 4-hydroxytamoxifen.	hydroxytamoxifen	138-156	transformation related protein 53, pseudogene	Mus musculus	34-37
8761295-4	1996	Activation of p53 in these transformed cells by the addition of tamoxifen or 4-hydroxytamoxifen resulted in apoptosis.	hydroxytamoxifen	77-95	transformation related protein 53, pseudogene	Mus musculus	14-17
8625307-5	1996	In both these cell lines, the nonsteroidal antiestrogen 4-hydroxytamoxifen has little effect on the mRNA level but causes a net accumulation of the ER protein over time.	hydroxytamoxifen	56-74	estrogen receptor 1	Homo sapiens	148-150
8738832-0	1996	Site-directed estrogen receptor antibodies stabilize 4-hydroxytamoxifen ligand, but not estradiol, and indicate ligand-specific differences in the recognition of estrogen response element DNA in vitro.	hydroxytamoxifen	53-71	estrogen receptor 1	Homo sapiens	14-31
8738832-3	1996	Although 4-hydroxytamoxifen-liganded-ER (4-OHT-ER) and E2-ER bind a consensus ERE with equal high affinity, the stoichiometry of 4-OHT-ER-ERE binding at saturation is approximately 50% lower than that of E2-ER binding to all ERE sequences tested.	hydroxytamoxifen	9-27	estrogen receptor 1	Homo sapiens	37-39
8738832-3	1996	Although 4-hydroxytamoxifen-liganded-ER (4-OHT-ER) and E2-ER bind a consensus ERE with equal high affinity, the stoichiometry of 4-OHT-ER-ERE binding at saturation is approximately 50% lower than that of E2-ER binding to all ERE sequences tested.	hydroxytamoxifen	9-27	estrogen receptor 1	Homo sapiens	47-49
8738832-3	1996	Although 4-hydroxytamoxifen-liganded-ER (4-OHT-ER) and E2-ER bind a consensus ERE with equal high affinity, the stoichiometry of 4-OHT-ER-ERE binding at saturation is approximately 50% lower than that of E2-ER binding to all ERE sequences tested.	hydroxytamoxifen	9-27	estrogen receptor 1	Homo sapiens	47-49
8809185-2	1996	These assays revealed identical, high affinity ER-ERE binding, Kd of approximately 0.25 nM, for estradiol-liganded ER (E2-ER), 4-hydroxytamoxifen liganded ER (4-OHT-ER), tamoxifen aziridine liganded ER (TAz-ER), and unliganded dimeric ER, for each ERE in constructs containing up to four tandem EREs.	hydroxytamoxifen	127-145	estrogen receptor 1	Homo sapiens	47-49
8809185-2	1996	These assays revealed identical, high affinity ER-ERE binding, Kd of approximately 0.25 nM, for estradiol-liganded ER (E2-ER), 4-hydroxytamoxifen liganded ER (4-OHT-ER), tamoxifen aziridine liganded ER (TAz-ER), and unliganded dimeric ER, for each ERE in constructs containing up to four tandem EREs.	hydroxytamoxifen	127-145	estrogen receptor 1	Homo sapiens	50-52
8809185-2	1996	These assays revealed identical, high affinity ER-ERE binding, Kd of approximately 0.25 nM, for estradiol-liganded ER (E2-ER), 4-hydroxytamoxifen liganded ER (4-OHT-ER), tamoxifen aziridine liganded ER (TAz-ER), and unliganded dimeric ER, for each ERE in constructs containing up to four tandem EREs.	hydroxytamoxifen	127-145	estrogen receptor 1	Homo sapiens	50-52
8809185-2	1996	These assays revealed identical, high affinity ER-ERE binding, Kd of approximately 0.25 nM, for estradiol-liganded ER (E2-ER), 4-hydroxytamoxifen liganded ER (4-OHT-ER), tamoxifen aziridine liganded ER (TAz-ER), and unliganded dimeric ER, for each ERE in constructs containing up to four tandem EREs.	hydroxytamoxifen	127-145	estrogen receptor 1	Homo sapiens	50-52
8809185-2	1996	These assays revealed identical, high affinity ER-ERE binding, Kd of approximately 0.25 nM, for estradiol-liganded ER (E2-ER), 4-hydroxytamoxifen liganded ER (4-OHT-ER), tamoxifen aziridine liganded ER (TAz-ER), and unliganded dimeric ER, for each ERE in constructs containing up to four tandem EREs.	hydroxytamoxifen	127-145	estrogen receptor 1	Homo sapiens	50-52
8640815-7	1996	Another metabolite of 4-OH-tam, assumed to be 3,4-dihydroxytamoxifen (3,4-di-OH-tam) catechol, was demonstrated by its monomethylation with [3H]S-adenosyl-L-methionine ([3H]SAM) in presence of endogenous catechol-O-methyltransferase.	hydroxytamoxifen	22-30	catechol-O-methyltransferase	Rattus norvegicus	204-232
8593782-9	1996	MCF-7WT and MCF-7D3Res cells exhibit comparable sensitivity to induction of apoptosis and up-regulation of clusterin in response to the antiestrogen 4-hydroxytamoxifen.	hydroxytamoxifen	149-167	clusterin	Homo sapiens	107-116
8593782-11	1996	In both sensitive and resistant cell lines, 1,25-(OH)2D3 up-regulates whereas 4-hydroxytamoxifen down-regulates VDR protein expression, indicating appropriate homologous and heterologous VDR regulation in MCF-7D3Ras cells.	hydroxytamoxifen	78-96	vitamin D receptor	Homo sapiens	112-115
8825558-7	1996	Induction of rPRL and rPRL-Tn5 expression by E2 was reduced by coincubation of cells with the antiestrogen 4-hydroxytamoxifen.	hydroxytamoxifen	107-125	prolactin	Rattus norvegicus	13-17
8825558-7	1996	Induction of rPRL and rPRL-Tn5 expression by E2 was reduced by coincubation of cells with the antiestrogen 4-hydroxytamoxifen.	hydroxytamoxifen	107-125	prolactin	Rattus norvegicus	22-26
8524784-6	1995	Binding also occurs with the glucocorticoid receptor complexed with the antiglucocorticoid RU 38486, with the estrogen receptor complexed with the antiestrogen 4-hydroxytamoxifen or ICI 164,384, and even with receptors not complexed with ligand.	hydroxytamoxifen	160-178	nuclear receptor subfamily 3 group C member 1	Homo sapiens	29-52
7838527-3	1995	Addition of estrogen or the antagonist hydroxytamoxifen to Jurkat T-cells expressing these constructs led to the trans-activation or responsive promoters and upregulation of cell surface markers CD28, CD69 and CD5 but not CD25 (IL2R-alpha subunit) or B7 (ligand for CD28).	hydroxytamoxifen	39-55	CD28 molecule	Homo sapiens	195-199
7649107-6	1995	The PKC-modulating drugs, bryostatin and H-7, and antiestrogens (ICI 164,384 and 4-hydroxytamoxifen) interfere with AR induction by TPA and estrogen, respectively.	hydroxytamoxifen	81-99	amphiregulin	Homo sapiens	116-118
7624356-2	1995	We have established homozygous retinoid X receptor alpha-negative (RXR alpha-/-) F9 embryonal carcinoma cells constitutively expressing Cre-ER and have shown that estradiol or the estrogen agonist/antagonist 4-hydroxytamoxifen efficiently induced the recombinase activity, whereas no activity was detected in the absence of ligand or in the presence of the antiestrogen ICI 164,384.	hydroxytamoxifen	208-226	retinoid X receptor alpha	Homo sapiens	31-56
7760810-6	1995	We demonstrate that the transcriptional activity of GATA-1 is strongly repressed by the estrogen receptor (ER) in a ligand-dependent manner and that this repression is reversible in the presence of 4-hydroxytamoxifen.	hydroxytamoxifen	198-216	GATA binding protein 1	Homo sapiens	52-58
7760810-6	1995	We demonstrate that the transcriptional activity of GATA-1 is strongly repressed by the estrogen receptor (ER) in a ligand-dependent manner and that this repression is reversible in the presence of 4-hydroxytamoxifen.	hydroxytamoxifen	198-216	estrogen receptor 1	Homo sapiens	88-105
7760810-6	1995	We demonstrate that the transcriptional activity of GATA-1 is strongly repressed by the estrogen receptor (ER) in a ligand-dependent manner and that this repression is reversible in the presence of 4-hydroxytamoxifen.	hydroxytamoxifen	198-216	estrogen receptor 1	Homo sapiens	107-109
7784172-7	1995	When the hormone-binding domain of this mutant oestrogen receptor is fused to the C-terminus of the c-Myc protein, Myc-induced proliferation and apoptosis in fibroblasts becomes dependent on 4-hydroxytamoxifen, but remains refractory to 17 beta-oestradiol.	hydroxytamoxifen	191-209	myelocytomatosis oncogene	Mus musculus	102-105
7784172-7	1995	When the hormone-binding domain of this mutant oestrogen receptor is fused to the C-terminus of the c-Myc protein, Myc-induced proliferation and apoptosis in fibroblasts becomes dependent on 4-hydroxytamoxifen, but remains refractory to 17 beta-oestradiol.	hydroxytamoxifen	191-209	myelocytomatosis oncogene	Mus musculus	115-118
7867590-6	1995	This stimulation was mediated by ER, because 1) dose-response curves established with tamoxifen and hydroxytamoxifen were in agreement with their affinity for ER; 2) when present with antiestrogens, estradiol abolished this phenomenon; and 3) this effect was not observed in MDT (ER-negative) cells.	hydroxytamoxifen	100-116	estrogen receptor 1	Homo sapiens	33-35
7867590-6	1995	This stimulation was mediated by ER, because 1) dose-response curves established with tamoxifen and hydroxytamoxifen were in agreement with their affinity for ER; 2) when present with antiestrogens, estradiol abolished this phenomenon; and 3) this effect was not observed in MDT (ER-negative) cells.	hydroxytamoxifen	100-116	estrogen receptor 1	Homo sapiens	159-161
7867590-6	1995	This stimulation was mediated by ER, because 1) dose-response curves established with tamoxifen and hydroxytamoxifen were in agreement with their affinity for ER; 2) when present with antiestrogens, estradiol abolished this phenomenon; and 3) this effect was not observed in MDT (ER-negative) cells.	hydroxytamoxifen	100-116	estrogen receptor 1	Homo sapiens	159-161
7873531-6	1995	Interestingly, when ER was liganded with 4-hydroxytamoxifen (4-OHT), the active metabolite of the widely used therapeutic antiestrogen tamoxifen, the antiestrogen-liganded ER complex (4-OHT-ER) did not bind cooperatively to multiple EREs, regardless of spacing or flanking sequence.	hydroxytamoxifen	41-59	estrogen receptor 1	Homo sapiens	20-22
7873531-6	1995	Interestingly, when ER was liganded with 4-hydroxytamoxifen (4-OHT), the active metabolite of the widely used therapeutic antiestrogen tamoxifen, the antiestrogen-liganded ER complex (4-OHT-ER) did not bind cooperatively to multiple EREs, regardless of spacing or flanking sequence.	hydroxytamoxifen	41-59	estrogen receptor 1	Homo sapiens	172-174
7625716-6	1995	Alternatively, if a "TAF2 function" is supplied by another factor, 4-OH tamoxifen can manifest ER agonist activity.	hydroxytamoxifen	67-81	TATA-box binding protein associated factor 2	Homo sapiens	21-25
8592512-7	1995	Depending on the cell and promoter context and the particular ER form expressed, 4-OH tamoxifen and the related compound, keoxifene, functioned as partial agonists.	hydroxytamoxifen	81-95	estrogen receptor 1	Homo sapiens	62-64
7649348-5	1995	Hydroxy-tamoxifen was shown to increase latent TGF-beta 1 secretion in three of the eight tumor tissue-derived fibroblast cultures.	hydroxytamoxifen	0-17	transforming growth factor beta 1	Homo sapiens	47-57
7721882-6	1995	Our study also demonstrates that, within the context of the whole human estrogen receptor, the same AF-1 activating domains are "induced" by either estradiol or 4-hydroxytamoxifen.	hydroxytamoxifen	161-179	estrogen receptor 1	Homo sapiens	72-89
7721882-6	1995	Our study also demonstrates that, within the context of the whole human estrogen receptor, the same AF-1 activating domains are "induced" by either estradiol or 4-hydroxytamoxifen.	hydroxytamoxifen	161-179	interferon gamma receptor 2	Homo sapiens	100-104
7838527-3	1995	Addition of estrogen or the antagonist hydroxytamoxifen to Jurkat T-cells expressing these constructs led to the trans-activation or responsive promoters and upregulation of cell surface markers CD28, CD69 and CD5 but not CD25 (IL2R-alpha subunit) or B7 (ligand for CD28).	hydroxytamoxifen	39-55	CD69 molecule	Homo sapiens	201-205
7838527-3	1995	Addition of estrogen or the antagonist hydroxytamoxifen to Jurkat T-cells expressing these constructs led to the trans-activation or responsive promoters and upregulation of cell surface markers CD28, CD69 and CD5 but not CD25 (IL2R-alpha subunit) or B7 (ligand for CD28).	hydroxytamoxifen	39-55	CD5 molecule	Homo sapiens	210-213
7838527-3	1995	Addition of estrogen or the antagonist hydroxytamoxifen to Jurkat T-cells expressing these constructs led to the trans-activation or responsive promoters and upregulation of cell surface markers CD28, CD69 and CD5 but not CD25 (IL2R-alpha subunit) or B7 (ligand for CD28).	hydroxytamoxifen	39-55	interleukin 2 receptor subunit alpha	Homo sapiens	222-226
7838527-3	1995	Addition of estrogen or the antagonist hydroxytamoxifen to Jurkat T-cells expressing these constructs led to the trans-activation or responsive promoters and upregulation of cell surface markers CD28, CD69 and CD5 but not CD25 (IL2R-alpha subunit) or B7 (ligand for CD28).	hydroxytamoxifen	39-55	interleukin 2 receptor subunit alpha	Homo sapiens	228-238
7838527-3	1995	Addition of estrogen or the antagonist hydroxytamoxifen to Jurkat T-cells expressing these constructs led to the trans-activation or responsive promoters and upregulation of cell surface markers CD28, CD69 and CD5 but not CD25 (IL2R-alpha subunit) or B7 (ligand for CD28).	hydroxytamoxifen	39-55	CD28 molecule	Homo sapiens	266-270
7961858-2	1994	We have previously identified an intragenic (+698/+723) estrogen-responsive element present in the progesterone receptor gene, which binds the estradiol receptor and mediates estrogen and 4-OH tamoxifen induction.	hydroxytamoxifen	188-202	progesterone receptor	Homo sapiens	99-120
8573710-10	1995	Droloxifene and TAT-59 mimic the metabolite 4-hydroxytamoxifen in having a high affinity for the estrogen receptor (Jordan et al, J Endocrinol 75:305, 1977).	hydroxytamoxifen	44-62	estrogen receptor 1	Homo sapiens	97-114
8001229-9	1994	Cis-4-hydroxytamoxifen was also converted to trans-4-hydroxytamoxifen (range 22-27%).	hydroxytamoxifen	45-69	suppressor of cytokine signaling 6	Homo sapiens	0-5
7961858-3	1994	Progesterone receptor gene expression was equally stimulated by estradiol and 4-OH tamoxifen in the presence of a NH2 terminally deleted estrogen receptor mutant lacking activation function 1, suggesting that activation function 2 was the predominant activation domain.	hydroxytamoxifen	78-92	progesterone receptor	Homo sapiens	0-21
8274405-0	1993	Differential impact of flanking sequences on estradiol- vs 4-hydroxytamoxifen-liganded estrogen receptor binding to estrogen responsive element DNA.	hydroxytamoxifen	59-77	estrogen receptor 1	Homo sapiens	87-104
7914405-5	1994	Antiestrogens such as tamoxifen, metabolites of tamoxifen (4-hydroxytamoxifen and N-desmethyltamoxifen), droloxifen, and toremifene stimulated the Pgp ATPase activity, and the maximum stimulation obtained with these agents equalled the maximal stimulation obtained by the best known MDR chemosensitizer, verapamil.	hydroxytamoxifen	59-77	ATP binding cassette subfamily B member 1	Homo sapiens	147-150
7913604-2	1994	Tamoxifen and its metabolites, N-desmethyltamoxifen and 4-hydroxytamoxifen, were potent inhibitors of [3H]tamoxifen aziridine binding to P-glycoprotein with 4-hydroxytamoxifen > tamoxifen > N-desmethyltamoxifen.	hydroxytamoxifen	56-74	ATP binding cassette subfamily B member 1	Homo sapiens	137-151
8205532-12	1994	The findings reported here raise the possibility that exposure of women undergoing tamoxifen therapy to agents that induce human CYP1A2 or CYPB1/2 analogues may produce increased levels of 4-hydroxytamoxifen and that this may affect the therapeutic potency of tamoxifen.	hydroxytamoxifen	189-207	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	129-135
8293548-10	1994	The major metabolite detected by HPLC was N-desmethyltamoxifen, and 4-hydroxytamoxifen was also detected in cells with cytochrome P450 2E1 and 2D6.	hydroxytamoxifen	68-86	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	119-146
7873531-6	1995	Interestingly, when ER was liganded with 4-hydroxytamoxifen (4-OHT), the active metabolite of the widely used therapeutic antiestrogen tamoxifen, the antiestrogen-liganded ER complex (4-OHT-ER) did not bind cooperatively to multiple EREs, regardless of spacing or flanking sequence.	hydroxytamoxifen	41-59	estrogen receptor 1	Homo sapiens	172-174
8137248-3	1994	All-trans-retinoic acid (RA) and 1,25-dihydroxyvitamin D3 (Vit D3) inhibited estrogen-induced growth of MCF-7 cells and their effect was potentiated by the classical antiestrogen, hydroxytamoxifen.	hydroxytamoxifen	180-196	vitrin	Homo sapiens	59-62
8143893-2	1993	We have evaluated the regulation of TGF beta 1, TGF beta 2, and TGF beta 3 mRNAs by 17 beta-estradiol (E2) and 4-hydroxytamoxifen (MOH) in estrogen receptor-positive (ER(+)) MCF-7 and estrogen receptor-negative (ER(-)) MDA-MB-231 human breast cancer cells.	hydroxytamoxifen	111-129	transforming growth factor beta 1	Homo sapiens	36-46
8143893-2	1993	We have evaluated the regulation of TGF beta 1, TGF beta 2, and TGF beta 3 mRNAs by 17 beta-estradiol (E2) and 4-hydroxytamoxifen (MOH) in estrogen receptor-positive (ER(+)) MCF-7 and estrogen receptor-negative (ER(-)) MDA-MB-231 human breast cancer cells.	hydroxytamoxifen	111-129	transforming growth factor beta 2	Homo sapiens	48-58
8143893-2	1993	We have evaluated the regulation of TGF beta 1, TGF beta 2, and TGF beta 3 mRNAs by 17 beta-estradiol (E2) and 4-hydroxytamoxifen (MOH) in estrogen receptor-positive (ER(+)) MCF-7 and estrogen receptor-negative (ER(-)) MDA-MB-231 human breast cancer cells.	hydroxytamoxifen	111-129	transforming growth factor beta 3	Homo sapiens	64-74
8344199-7	1993	By contrast, 4-hydroxytamoxifen had an agonist effect on cathepsin-D and an additive effect on IGF-I-induced mRNA.	hydroxytamoxifen	13-31	cathepsin D	Homo sapiens	57-68
8402691-7	1993	However, treatment with the antiestrogen hydroxytamoxifen caused growth inhibition, implying that hydroxytamoxifen acts as an agonist of estrogen action in ER-transfected cells.	hydroxytamoxifen	41-57	estrogen receptor 1	Homo sapiens	156-158
8402691-7	1993	However, treatment with the antiestrogen hydroxytamoxifen caused growth inhibition, implying that hydroxytamoxifen acts as an agonist of estrogen action in ER-transfected cells.	hydroxytamoxifen	98-114	estrogen receptor 1	Homo sapiens	156-158
8344199-7	1993	By contrast, 4-hydroxytamoxifen had an agonist effect on cathepsin-D and an additive effect on IGF-I-induced mRNA.	hydroxytamoxifen	13-31	insulin like growth factor 1	Homo sapiens	95-100
8324732-3	1993	A stepwise in vitro selection of the hormone-independent human breast cancer variant MCF-7/LCC1 against 4-hydroxytamoxifen produced a stable resistant population designated MCF7/LCC2.	hydroxytamoxifen	104-122	C-C motif chemokine ligand 16	Homo sapiens	91-95
8357855-1	1993	A highly sensitive and specific assay was developed for the quantitative measurement of 4-hydroxy tamoxifen (4-OH Tam) at the femtomole level in human plasma and mammary tumours.	hydroxytamoxifen	88-107	Myeloproliferative syndrome, transient (transient abnormal myelopoiesis)	Homo sapiens	114-117
8388710-7	1993	ICI 164384 and the tamoxifen metabolite 4-hydroxytamoxifen also blocked 17 beta-hydroxysteroid dehydrogenase at concentrations of 470 and 275 microM, respectively.	hydroxytamoxifen	40-58	hydroxysteroid 17-beta dehydrogenase 7	Homo sapiens	72-108
8388710-8	1993	In human breast tumors, 4-hydroxytamoxifen and desmethyltamoxifen blocked estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase but at higher concentrations than in the rat (i.e. IC50s of 1000-2000 microM).	hydroxytamoxifen	24-42	hydroxysteroid 17-beta dehydrogenase 7	Homo sapiens	96-132
1419885-7	1992	However, the elution profile of the DP-TAT-59-ER complex from a DEAE-Sephadex column was different for both estradiol-and 4-OH-TAM-ER complexes.	hydroxytamoxifen	122-130	estrogen receptor 1	Rattus norvegicus	46-48
8502228-7	1993	The nonsteroidal antiestrogens nafoxidine, Cl-628, and 4-hydroxytamoxifen also induce c-fos expression.	hydroxytamoxifen	55-73	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	86-91
8219251-2	1993	Previous studies have demonstrated that a point mutation in the estrogen receptor (ER) resulted in an alteration of the pharmacology of 4-hydroxytamoxifen, the active metabolite of tamoxifen (Jiang et al, Mol Endocrinol 6:2167-2174, 1992).	hydroxytamoxifen	136-154	estrogen receptor 1	Homo sapiens	64-81
8219251-2	1993	Previous studies have demonstrated that a point mutation in the estrogen receptor (ER) resulted in an alteration of the pharmacology of 4-hydroxytamoxifen, the active metabolite of tamoxifen (Jiang et al, Mol Endocrinol 6:2167-2174, 1992).	hydroxytamoxifen	136-154	estrogen receptor 1	Homo sapiens	83-85
1491696-3	1992	We have studied the effect of a point mutation that leads to the substitution of Val for Gly at codon 400 in the ligand-binding domain of the estrogen receptor (ER) on estrogenic and antiestrogenic activities of 4-hydroxytamoxifen (4-OHT) and its derivatives.	hydroxytamoxifen	212-230	estrogen receptor 1	Homo sapiens	142-159
1491696-3	1992	We have studied the effect of a point mutation that leads to the substitution of Val for Gly at codon 400 in the ligand-binding domain of the estrogen receptor (ER) on estrogenic and antiestrogenic activities of 4-hydroxytamoxifen (4-OHT) and its derivatives.	hydroxytamoxifen	212-230	estrogen receptor 1	Homo sapiens	161-163
8368130-12	1993	4-Hydroxytamoxifen had no effect on the steady-state level of receptor mRNA and effectively blocked the suppression of ER mRNA by estradiol.	hydroxytamoxifen	0-18	estrogen receptor 1	Homo sapiens	119-121
1419885-8	1992	These results suggest that ER forms different complexes with DP-TAT-59 than estradiol or 4-OH-TAM, while the ER binding affinity of these compounds are similar to each other.	hydroxytamoxifen	89-97	estrogen receptor 1	Rattus norvegicus	27-29
1537281-8	1992	While 4-OH-tam frequently decreased the amount of c-erbA beta transcripts, ICI 164 384 did not alter the distribution of alpha and beta cDNA transcripts.	hydroxytamoxifen	6-14	thyroid hormone receptor beta	Homo sapiens	50-61
1632645-3	1992	2, 307-312) were used to find the standard free energy changes that describe the binding of estradiol and 4-hydroxytamoxifen to the estrogen receptor.	hydroxytamoxifen	106-124	estrogen receptor 1	Homo sapiens	132-149
1632645-4	1992	For the binding of estradiol or 4-hydroxytamoxifen to the estrogen receptor the data do not deviate systematically from the best fit to the model.	hydroxytamoxifen	32-50	estrogen receptor 1	Homo sapiens	58-75
1632645-5	1992	The standard free energy change for binding of one molecule of estradiol at one site and one molecule of 4-hydroxytamoxifen at the second site of estrogen receptor indicates that 4-hydroxytamoxifen antagonizes the binding of estradiol to the estrogen receptor.	hydroxytamoxifen	105-123	estrogen receptor 1	Homo sapiens	146-163
1632645-5	1992	The standard free energy change for binding of one molecule of estradiol at one site and one molecule of 4-hydroxytamoxifen at the second site of estrogen receptor indicates that 4-hydroxytamoxifen antagonizes the binding of estradiol to the estrogen receptor.	hydroxytamoxifen	105-123	estrogen receptor 1	Homo sapiens	242-259
1632645-5	1992	The standard free energy change for binding of one molecule of estradiol at one site and one molecule of 4-hydroxytamoxifen at the second site of estrogen receptor indicates that 4-hydroxytamoxifen antagonizes the binding of estradiol to the estrogen receptor.	hydroxytamoxifen	179-197	estrogen receptor 1	Homo sapiens	146-163
1632645-5	1992	The standard free energy change for binding of one molecule of estradiol at one site and one molecule of 4-hydroxytamoxifen at the second site of estrogen receptor indicates that 4-hydroxytamoxifen antagonizes the binding of estradiol to the estrogen receptor.	hydroxytamoxifen	179-197	estrogen receptor 1	Homo sapiens	242-259
1614867-4	1992	We also confirm that the agonistic activity of 4-hydroxytamoxifen (OHT) can be ascribed to the activity of TAF-1.	hydroxytamoxifen	47-65	histone acetyltransferase	Saccharomyces cerevisiae S288C	107-112
1532902-1	1992	We have examined the effects of medroxyprogesterone acetate (MPA) and 4-hydroxytamoxifen (OH-TAM) on the cell proliferation and the expression of TGF-alpha and TGF-beta genes in Ishikawa cells and HEC-50 human endometrial adenocarcinoma cells.	hydroxytamoxifen	70-88	transforming growth factor alpha	Homo sapiens	146-155
1532902-1	1992	We have examined the effects of medroxyprogesterone acetate (MPA) and 4-hydroxytamoxifen (OH-TAM) on the cell proliferation and the expression of TGF-alpha and TGF-beta genes in Ishikawa cells and HEC-50 human endometrial adenocarcinoma cells.	hydroxytamoxifen	70-88	transforming growth factor beta 1	Homo sapiens	160-168
1661135-8	1991	The antiestrogens tamoxifen and 4-hydroxytamoxifen were found to enhance the growth stimulation resulting from Zn2+ induced IGF-II production in MI7 cells.	hydroxytamoxifen	32-50	insulin like growth factor 2	Homo sapiens	124-130
1776859-8	1991	In the same way, the antiestrogen 4-hydroxytamoxifen equally decreased c-myc expression but the reversal effect of E2 after long-term antiestrogen treatment was more pronounced than after short-term treatment.	hydroxytamoxifen	34-52	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	71-76
1930624-3	1991	Production of GCDFP-15 was increased by oestradiol-17 beta, tamoxifen and 4-OH tamoxifen.	hydroxytamoxifen	74-88	prolactin induced protein	Homo sapiens	14-22
1930624-5	1991	Moreover, oestradiol-17 beta and 4-OH tamoxifen acted synergystically in enhancing GCDFP-15 release.	hydroxytamoxifen	33-47	prolactin induced protein	Homo sapiens	83-91
1562525-0	1992	Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment.	hydroxytamoxifen	77-93	estrogen receptor 1	Homo sapiens	38-55
18755852-4	2008	The recent report of the structure of estrogen receptor (ER) beta with a second molecule of 4-hydroxytamoxifen (HT) bound in the coactivator-binding surface of the ligand-binding domain (LBD) represents the first direct example of a second ER ligand-binding site and provides insight into the possible origin of mixed agonist/antagonist activity of type I antiestrogens.	hydroxytamoxifen	92-110	estrogen receptor 1	Homo sapiens	38-55
1834933-8	1991	The inhibitory effect of norethindrone on TGF beta 2 and TGF beta 3 mRNA levels could be blocked by the addition of 10(-7) M 4-hydroxytamoxifen.	hydroxytamoxifen	125-143	transforming growth factor beta 3	Homo sapiens	57-67
1883484-4	1991	PR was significantly increased following treatment with 4-OH tamoxifen, this response being antagonized in the presence of ICI 164,384.	hydroxytamoxifen	56-70	progesterone receptor	Homo sapiens	0-2
2005879-3	1991	This compound, 4-hydroxytamoxifen, is a metabolite of tamoxifen and has a very high binding affinity for ER [J. Endocrinol.	hydroxytamoxifen	15-33	estrogen receptor 1	Homo sapiens	105-107
1826824-0	1991	Distinct effects of gonadotropin-releasing hormone analogs and 4-hydroxytamoxifen on pS2 mRNA expression with respect to cell proliferation in MCF-7 breast cancer cells.	hydroxytamoxifen	63-81	taste 2 receptor member 64 pseudogene	Homo sapiens	85-88
1965340-4	1990	We have found that: 1) cellular proliferation and estrogen or progesterone receptor concentration were mutually dependent, the greatest estradiol binding capacity was obtained in cells in which mitotic activity had been slowed down (G0/G1) by the antiestrogenic action of hydroxytamoxifen added to the culture; 2) the presence of estradiol in the culture medium induced marked changes in the synthesis and catabolism of estrogen and progesterone receptors; and 3) both receptors acted as functional proteins whose intracellular concentrations varied depending on the phases of the mitotic cycle.	hydroxytamoxifen	272-288	progesterone receptor	Homo sapiens	62-83
2144749-6	1990	Secretion of insulin-like growth factor 1 (IGF-1) was not affected by DFMO-induced polyamine depletion but 4-hydroxytamoxifen increased IGF-1, which suggests an estradiol-like effect.	hydroxytamoxifen	107-125	insulin like growth factor 1	Homo sapiens	136-141
1868844-1	1991	The action of diethylpyrocarbonate on lamb uterine estrogen receptor produced an homogeneous population of the receptor (approximately 55%) which still bound triarylethylene antiestrogens such as 4-hydroxytamoxifen with a high affinity but bound classical potent estrogens such as estradiol or diethylstilbestrol with a very low affinity.	hydroxytamoxifen	196-214	estrogen receptor 1	Homo sapiens	51-68
1834933-8	1991	The inhibitory effect of norethindrone on TGF beta 2 and TGF beta 3 mRNA levels could be blocked by the addition of 10(-7) M 4-hydroxytamoxifen.	hydroxytamoxifen	125-143	transforming growth factor beta 2	Homo sapiens	42-52
2257239-4	1990	Another interesting aspect is the response of the antiestrogen 4-hydroxytamoxifen which in isolated cells of very close tissues such as the uterus and vagina is an antagonist for the former and agonist for the latter concerning the progesterone receptor.	hydroxytamoxifen	63-81	LOW QUALITY PROTEIN: progesterone receptor	Cavia porcellus	232-253
2280188-8	1990	Finally, studies using the anti-estrogen drug, hydroxytamoxifen, resulted in blockage of the estrogen-related induction of RBP mRNA in the kidney, suggesting that the induction of RBP mRNA in the kidney by estrogen may be mediated by the nuclear estrogen receptor.	hydroxytamoxifen	47-63	retinol binding protein 4	Rattus norvegicus	123-126
2280188-8	1990	Finally, studies using the anti-estrogen drug, hydroxytamoxifen, resulted in blockage of the estrogen-related induction of RBP mRNA in the kidney, suggesting that the induction of RBP mRNA in the kidney by estrogen may be mediated by the nuclear estrogen receptor.	hydroxytamoxifen	47-63	retinol binding protein 4	Rattus norvegicus	180-183
18755852-4	2008	The recent report of the structure of estrogen receptor (ER) beta with a second molecule of 4-hydroxytamoxifen (HT) bound in the coactivator-binding surface of the ligand-binding domain (LBD) represents the first direct example of a second ER ligand-binding site and provides insight into the possible origin of mixed agonist/antagonist activity of type I antiestrogens.	hydroxytamoxifen	92-110	estrogen receptor 1	Homo sapiens	57-59
34261921-2	2021	Previously, we found that RPS14 was significantly downregulated in estrogen receptor-positive (ER+) breast cancer cells following treatment with 4-hydroxytamoxifen (4-OH-TAM).	hydroxytamoxifen	165-173	ribosomal protein S14	Homo sapiens	26-31
34261921-2	2021	Previously, we found that RPS14 was significantly downregulated in estrogen receptor-positive (ER+) breast cancer cells following treatment with 4-hydroxytamoxifen (4-OH-TAM).	hydroxytamoxifen	165-173	estrogen receptor 1	Homo sapiens	67-84
34261921-2	2021	Previously, we found that RPS14 was significantly downregulated in estrogen receptor-positive (ER+) breast cancer cells following treatment with 4-hydroxytamoxifen (4-OH-TAM).	hydroxytamoxifen	165-173	epiregulin	Homo sapiens	95-97
2608058-4	1989	4-Hydroxytamoxifen had no effect on the steady-state level of receptor mRNA and effectively blocked the suppression of ER mRNA by estradiol.	hydroxytamoxifen	0-18	estrogen receptor 1	Homo sapiens	119-121
2790797-4	1989	In order to gain insight into the molecular mechanism of action of antiestrogens in human breast cancer, we studied the effect of tamoxifen and 4-hydroxytamoxifen on the concentration of ODC mRNA, ODC activity, and the polyamine levels in a hormone-responsive breast cancer cell line, MCF-7.	hydroxytamoxifen	144-162	ornithine decarboxylase 1	Homo sapiens	187-190
2790797-5	1989	ODC mRNA concentration was reduced to 40% of the controls after 6 h of treatment of the cells with 100 nM 4-hydroxytamoxifen, but tamoxifen had no significant effect on ODC mRNA after treating with even 1 microM concentration for 36 h. ODC activity was, however, reduced to 40 and 75% of the controls after 24 h of treatment with 4-hydroxytamoxifen and tamoxifen, respectively.	hydroxytamoxifen	106-124	ornithine decarboxylase 1	Homo sapiens	0-3
2790797-5	1989	ODC mRNA concentration was reduced to 40% of the controls after 6 h of treatment of the cells with 100 nM 4-hydroxytamoxifen, but tamoxifen had no significant effect on ODC mRNA after treating with even 1 microM concentration for 36 h. ODC activity was, however, reduced to 40 and 75% of the controls after 24 h of treatment with 4-hydroxytamoxifen and tamoxifen, respectively.	hydroxytamoxifen	330-348	ornithine decarboxylase 1	Homo sapiens	0-3
2783569-3	1989	This response to EGF was dose dependent; a half-maximal effect was obtained at 10(-10) M. The antiestrogens tamoxifen and 4-hydroxytamoxifen were able to antagonize the stimulatory effect of EGF on progesterone receptor concentrations, but they did not affect its mitogenic effect.	hydroxytamoxifen	122-140	epidermal growth factor	Homo sapiens	17-20
2775256-3	1989	The secretion of Tf by the hormone-responsive cell-line MCF-7 is stimulated by 17 beta-estradiol and reduced by the antiestrogen 4-hydroxy tamoxifen.	hydroxytamoxifen	129-148	transferrin	Homo sapiens	17-19
2720565-3	1989	Addition of the active metabolite of the estrogen-receptor blocker/partial-agonist 4-hydroxytamoxifen had a stimulating effect on the growth rate of the gastric cell lines.	hydroxytamoxifen	83-101	estrogen receptor 1	Homo sapiens	41-58
2736207-4	1989	N-Desmethyltamoxifen and 4-hydroxytamoxifen behaved like tamoxifen except that N-desmethyltamoxifen did not induce the pNR-2 RNA and was only a partial oestrogen for the induction of cathepsin D RNA, and 4-hydroxytamoxifen did not induce the pNR-2 or pNR-25 RNAs.	hydroxytamoxifen	25-43	cathepsin D	Homo sapiens	183-194
2631032-3	1989	Epidermal growth factor (EGF) stimulates both cell proliferation and the progesterone receptor 4-Hydroxytamoxifen, a tamoxifen metabolite and potent anti-oestrogen, completely inhibits the stimulatory effect of EGF on the progesterone receptor but has no effect on the EGF-induced cell growth.	hydroxytamoxifen	95-113	pro-epidermal growth factor	Cavia porcellus	0-23
2631032-3	1989	Epidermal growth factor (EGF) stimulates both cell proliferation and the progesterone receptor 4-Hydroxytamoxifen, a tamoxifen metabolite and potent anti-oestrogen, completely inhibits the stimulatory effect of EGF on the progesterone receptor but has no effect on the EGF-induced cell growth.	hydroxytamoxifen	95-113	pro-epidermal growth factor	Cavia porcellus	25-28
2631032-3	1989	Epidermal growth factor (EGF) stimulates both cell proliferation and the progesterone receptor 4-Hydroxytamoxifen, a tamoxifen metabolite and potent anti-oestrogen, completely inhibits the stimulatory effect of EGF on the progesterone receptor but has no effect on the EGF-induced cell growth.	hydroxytamoxifen	95-113	LOW QUALITY PROTEIN: progesterone receptor	Cavia porcellus	73-94
2631032-3	1989	Epidermal growth factor (EGF) stimulates both cell proliferation and the progesterone receptor 4-Hydroxytamoxifen, a tamoxifen metabolite and potent anti-oestrogen, completely inhibits the stimulatory effect of EGF on the progesterone receptor but has no effect on the EGF-induced cell growth.	hydroxytamoxifen	95-113	pro-epidermal growth factor	Cavia porcellus	211-214
2631032-3	1989	Epidermal growth factor (EGF) stimulates both cell proliferation and the progesterone receptor 4-Hydroxytamoxifen, a tamoxifen metabolite and potent anti-oestrogen, completely inhibits the stimulatory effect of EGF on the progesterone receptor but has no effect on the EGF-induced cell growth.	hydroxytamoxifen	95-113	LOW QUALITY PROTEIN: progesterone receptor	Cavia porcellus	222-243
2631032-3	1989	Epidermal growth factor (EGF) stimulates both cell proliferation and the progesterone receptor 4-Hydroxytamoxifen, a tamoxifen metabolite and potent anti-oestrogen, completely inhibits the stimulatory effect of EGF on the progesterone receptor but has no effect on the EGF-induced cell growth.	hydroxytamoxifen	95-113	pro-epidermal growth factor	Cavia porcellus	211-214
2784313-4	1989	In contrast, when cells are treated with the antiestrogen hydroxytamoxifen, a dose-dependent decrease in EGF-R level occurs.	hydroxytamoxifen	58-74	epidermal growth factor receptor	Homo sapiens	105-110
2783569-3	1989	This response to EGF was dose dependent; a half-maximal effect was obtained at 10(-10) M. The antiestrogens tamoxifen and 4-hydroxytamoxifen were able to antagonize the stimulatory effect of EGF on progesterone receptor concentrations, but they did not affect its mitogenic effect.	hydroxytamoxifen	122-140	epidermal growth factor	Homo sapiens	191-194
2783569-3	1989	This response to EGF was dose dependent; a half-maximal effect was obtained at 10(-10) M. The antiestrogens tamoxifen and 4-hydroxytamoxifen were able to antagonize the stimulatory effect of EGF on progesterone receptor concentrations, but they did not affect its mitogenic effect.	hydroxytamoxifen	122-140	progesterone receptor	Homo sapiens	198-219
2783569-4	1989	The inhibitory effect of 4-hydroxytamoxifen depended on concentration; half-maximal inhibition was observed between 0.5-1 X 10(-9) M. 4-Hydroxytamoxifen could completely inhibit the progesterone receptor increase due to EGF even when added to cells already exposed to the growth factor for 6 days.	hydroxytamoxifen	25-43	progesterone receptor	Homo sapiens	182-203
2783569-4	1989	The inhibitory effect of 4-hydroxytamoxifen depended on concentration; half-maximal inhibition was observed between 0.5-1 X 10(-9) M. 4-Hydroxytamoxifen could completely inhibit the progesterone receptor increase due to EGF even when added to cells already exposed to the growth factor for 6 days.	hydroxytamoxifen	25-43	epidermal growth factor	Homo sapiens	220-223
2783569-4	1989	The inhibitory effect of 4-hydroxytamoxifen depended on concentration; half-maximal inhibition was observed between 0.5-1 X 10(-9) M. 4-Hydroxytamoxifen could completely inhibit the progesterone receptor increase due to EGF even when added to cells already exposed to the growth factor for 6 days.	hydroxytamoxifen	134-152	progesterone receptor	Homo sapiens	182-203
2783569-4	1989	The inhibitory effect of 4-hydroxytamoxifen depended on concentration; half-maximal inhibition was observed between 0.5-1 X 10(-9) M. 4-Hydroxytamoxifen could completely inhibit the progesterone receptor increase due to EGF even when added to cells already exposed to the growth factor for 6 days.	hydroxytamoxifen	134-152	epidermal growth factor	Homo sapiens	220-223
3275538-5	1988	The increase in progesterone receptor depended on the dose of estradiol, with a half-maximal response at about 5 X 10(-11) M. Progesterone receptor concentrations were inhibited to below basal levels by progesterone and R5020 and the nonsteroidal antiestrogens, tamoxifen, and 4-hydroxytamoxifen.	hydroxytamoxifen	277-295	LOW QUALITY PROTEIN: progesterone receptor	Cavia porcellus	16-37
2784101-2	1989	Epidermal growth factor (EGF)-stimulated growth (10(-8) M EGF) was assayed in the MCF-7 breast cancer cell line in the presence of various concentrations (10(-10) to 10(-6) M) of three antiestrogens, 4-hydroxytamoxifen (OH TAM), TAM and ICI 164384.	hydroxytamoxifen	200-218	epidermal growth factor	Homo sapiens	25-28
3050278-4	1988	Both ligands prevented the inactivation of the estrogen receptor by diethylpyrocarbonate, estradiol being more efficient than 4-hydroxytamoxifen.	hydroxytamoxifen	126-144	estrogen receptor 1	Homo sapiens	47-64
3378206-4	1988	This shows that the binding of PKC to immobilized N-didesmethyltamoxifen was not merely due to hydrophobic interactions, since N-didesmethyltamoxifen and 4-hydroxytamoxifen have nearly identical hydrophobicities.	hydroxytamoxifen	154-172	proline rich transmembrane protein 2	Homo sapiens	31-34
2451827-1	1988	Treatment of human breast cancer cytosol with tamoxifen (Tam) or 4-monohydroxytamoxifen (MHT) enhances the immunoreactivity of the estrogen receptor toward monoclonal antibody H222 but not monoclonal antibodies D547 or D75.	hydroxytamoxifen	65-87	estrogen receptor 1	Homo sapiens	131-148
3343247-7	1988	Administration of hydroxytamoxifen abolishes persistent induction of RBP mRNA, suggesting that residual hormone receptor complex plays a role in the persistent induction of RBP gene transcription.	hydroxytamoxifen	18-34	SURP and G-patch domain containing 1 L homeolog	Xenopus laevis	69-72
3343247-7	1988	Administration of hydroxytamoxifen abolishes persistent induction of RBP mRNA, suggesting that residual hormone receptor complex plays a role in the persistent induction of RBP gene transcription.	hydroxytamoxifen	18-34	SURP and G-patch domain containing 1 L homeolog	Xenopus laevis	173-176
3167974-2	1988	Estradiol (E2) or the antiestrogen hydroxytamoxifen is required for ER binding as assayed by gel retardation.	hydroxytamoxifen	35-51	estrogen receptor 1	Homo sapiens	68-70
3275538-5	1988	The increase in progesterone receptor depended on the dose of estradiol, with a half-maximal response at about 5 X 10(-11) M. Progesterone receptor concentrations were inhibited to below basal levels by progesterone and R5020 and the nonsteroidal antiestrogens, tamoxifen, and 4-hydroxytamoxifen.	hydroxytamoxifen	277-295	LOW QUALITY PROTEIN: progesterone receptor	Cavia porcellus	126-147
2824472-0	1987	Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells.	hydroxytamoxifen	25-43	trefoil factor 1	Homo sapiens	61-66
2824472-1	1987	The estrogenic and antiestrogenic activities of tamoxifen and 4-hydroxytamoxifen have been measured on the expression of two estrogen-regulated RNAs (pNR-1 and pNR-2) in the MCF7 human breast cancer cell line cultured in phenol red-free medium.	hydroxytamoxifen	62-80	trefoil factor 1	Homo sapiens	160-165
2824472-3	1987	In contrast, the pNR-2 mRNA was only increased to about 10% of the estradiol-induced level, and its induction by estradiol was antagonized by both tamoxifen and 4-hydroxytamoxifen.	hydroxytamoxifen	161-179	trefoil factor 1	Homo sapiens	17-22
2824472-5	1987	4-Hydroxytamoxifen and estradiol have similar affinities for the estrogen receptor; however, the induction of both RNAs by 4-hydroxytamoxifen required a 10-fold higher concentration than estradiol for maximum agonist activity, and a 500-fold molar excess was required to antagonize the induction by estradiol.	hydroxytamoxifen	0-18	estrogen receptor 1	Homo sapiens	65-82
2824472-5	1987	4-Hydroxytamoxifen and estradiol have similar affinities for the estrogen receptor; however, the induction of both RNAs by 4-hydroxytamoxifen required a 10-fold higher concentration than estradiol for maximum agonist activity, and a 500-fold molar excess was required to antagonize the induction by estradiol.	hydroxytamoxifen	123-141	estrogen receptor 1	Homo sapiens	65-82
3996316-7	1985	Using the 3-day uterine assay in vivo, 4-hydroxytamoxifen partially stimulated progesterone receptor induction in the immature rat, whereas it fully stimulated the same end point in the mature ovariectomized mouse.	hydroxytamoxifen	39-57	progesterone receptor	Rattus norvegicus	79-100
3343247-2	1988	Estrogen induction of RBP mRNA is completely blocked by the anti-estrogen, hydroxytamoxifen.	hydroxytamoxifen	75-91	SURP and G-patch domain containing 1 L homeolog	Xenopus laevis	22-25
3454873-3	1987	Administration of 4-hydroxytamoxifen 24 h before estradiol completely blocked both the suppression of albumin mRNA and the transcriptional activation of the vitellogenin genes.	hydroxytamoxifen	18-36	Albumin A	Xenopus laevis	102-109
3454873-3	1987	Administration of 4-hydroxytamoxifen 24 h before estradiol completely blocked both the suppression of albumin mRNA and the transcriptional activation of the vitellogenin genes.	hydroxytamoxifen	18-36	a1-a	Xenopus laevis	157-169
3743888-4	1986	In similar conditions hydroxytamoxifen-ER complexes apparently do not undergo such a modification.	hydroxytamoxifen	22-38	estrogen receptor 1	Rattus norvegicus	39-41
3743888-7	1986	These data demonstrate that, in vitro, nuclear ER is cleaved into a smaller molecular form and that the receptor fragments can be held together by the triphenylethylene antiestrogen hydroxytamoxifen.	hydroxytamoxifen	182-198	estrogen receptor 1	Rattus norvegicus	47-49
3736040-5	1986	Pre-injection with tamoxifen or 4-hydroxytamoxifen suppressed the estrogen-dependent induction of vitellogenin in serum.	hydroxytamoxifen	32-50	a1-a	Xenopus laevis	98-110
3736040-6	1986	4-Hydroxytamoxifen also inhibited the induction of intracellular vitellogenin and its mRNA by estrogen suggesting that this metabolite of tamoxifen is able to inhibit estrogen-induced transcription of the vitellogenin genes.	hydroxytamoxifen	0-18	a1-a	Xenopus laevis	65-77
3736040-6	1986	4-Hydroxytamoxifen also inhibited the induction of intracellular vitellogenin and its mRNA by estrogen suggesting that this metabolite of tamoxifen is able to inhibit estrogen-induced transcription of the vitellogenin genes.	hydroxytamoxifen	0-18	a1-a	Xenopus laevis	205-217
2820746-7	1987	Tamoxifen (TMX) and its metabolites dihydroxy (di-OH-TMX) and 4-hydroxytamoxifen (4-OH-TMX) inhibited PRL in a dose-dependent manner.	hydroxytamoxifen	62-80	prolactin	Rattus norvegicus	102-105
3497634-4	1987	Furthermore, EGF partially reversed the growth inhibitory effects of several other antiestrogens including tamoxifen, 4-hydroxytamoxifen, and LY 117018.	hydroxytamoxifen	118-136	epidermal growth factor	Homo sapiens	13-16
3579987-4	1987	Its binding affinity for the estrogen receptor was greater than that of tamoxifen but less than that of 4-hydroxytamoxifen, and it possessed a corresponding degree of antitumour activity against the MCF-7 breast cancer cell line.	hydroxytamoxifen	104-122	estrogen receptor 1	Homo sapiens	29-46
3620717-3	1987	The antiestrogen 4-hydroxytamoxifen blocked progesterone receptor induction both by estradiol and by phenolphthalein.	hydroxytamoxifen	17-35	progesterone receptor	Homo sapiens	44-65
3320566-3	1987	Tamoxifen is readily metabolized by liver to 4-hydroxytamoxifen, which binds the liver nuclear estrogen receptor with a Ki of 0.1 nM.	hydroxytamoxifen	45-63	estrogen receptor 1	Gallus gallus	95-112
3320567-5	1987	(3) In the uterus and vagina of newborn guinea-pigs, tamoxifen and its derivatives: 4-hydroxytamoxifen and N-desmethyltamoxifen act as real agonists concerning the uterotrophic and vaginotrophic effects, and also stimulate the amount of DNA per organ, but concerning the progesterone receptor in the uterus, in the short treatment anti-estrogens act as partial agonists but they have no effect in the long treatment.	hydroxytamoxifen	84-102	LOW QUALITY PROTEIN: progesterone receptor	Cavia porcellus	271-292
4066684-15	1985	They also confirm that the conformations of the estrogen receptor differ when bound to estradiol or to 4-hydroxytamoxifen.	hydroxytamoxifen	103-121	estrogen receptor 1	Bos taurus	48-65
6704959-0	1984	Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.	hydroxytamoxifen	84-102	estrogen receptor 1	Homo sapiens	0-17
3987619-4	1985	Within 1-2 h of a sc injection of high affinity ligands (E2, E2B, and 4-OH-TAM), there was decrease in cytosol ER.	hydroxytamoxifen	70-78	estrogen receptor 1	Rattus norvegicus	111-113
4010284-2	1985	Attempts to similarly characterize the isomers of hydroxytamoxifen (which differ greatly in their affinity for the estrogen receptor) are shown to be complicated by their facile isomerization.	hydroxytamoxifen	50-66	estrogen receptor 1	Homo sapiens	115-132
7060530-7	1982	These results confirm that ER directly binds androstanediol, tamoxifen, and hydroxytamoxifen.	hydroxytamoxifen	76-92	estrogen receptor 1	Bos taurus	27-29
6848368-1	1983	As the polynucleotide domain of the estrogen receptor (Re) is a possible site for the modulation of Re activity, the interaction of antiestrogen (4-hydroxytamoxifen and tamoxifen)-receptor complexes (4-OH-Tam-Re and Tam-Re) with polynucleotides (oligodeoxynucleotide-cellulose, DNA-cellulose, and polyribonucleotide-agarose) was investigated and compared with that of the 17 beta-estradiol-receptor complex (E2-Re).	hydroxytamoxifen	146-164	estrogen receptor 1	Homo sapiens	36-53
6371570-5	1984	Tamoxifen and hydroxytamoxifen, estrogen antagonists, were ineffective by themselves, but reversed the E2 facilitation of K+-evoked LH-RH release.	hydroxytamoxifen	14-30	gonadotropin releasing hormone 1	Rattus norvegicus	132-137
6537799-2	1984	Studies were undertaken to examine the biological character (estrogenic-antiestrogenic properties) and estrogen receptor (ER) interaction of the cis- and trans-isomers of tamoxifen and hydroxytamoxifen in MCF-7 human breast cancer cells.	hydroxytamoxifen	185-201	estrogen receptor 1	Homo sapiens	103-120
6537799-4	1984	The relative binding affinities of the compounds cis-tamoxifen, trans-tamoxifen, cis-hydroxytamoxifen, and trans-hydroxytamoxifen for cytosol ER were 0.3, 2.5, 1.8, and 310%, respectively, in which the affinity of estradiol is considered 100%.	hydroxytamoxifen	107-129	estrogen receptor 1	Homo sapiens	142-144
6537799-8	1984	trans-Hydroxytamoxifen had a 100-fold increased affinity for ER and was approximately 100-times more potent than was trans-tamoxifen in suppressing cell growth and plasminogen activator activity.	hydroxytamoxifen	0-22	estrogen receptor 1	Homo sapiens	61-63
6537799-10	1984	This apparently paradoxical behavior of cis-hydroxytamoxifen was shown to be due to the fact that the cis- and trans-hydroxytamoxifens readily undergo isomeric interconversion upon exposure to our cell culture conditions, resulting in substantial accumulation of the higher-affinity trans-hydroxytamoxifen in the nuclear ER fraction of cells.	hydroxytamoxifen	117-134	estrogen receptor 1	Homo sapiens	321-323
6537799-10	1984	This apparently paradoxical behavior of cis-hydroxytamoxifen was shown to be due to the fact that the cis- and trans-hydroxytamoxifens readily undergo isomeric interconversion upon exposure to our cell culture conditions, resulting in substantial accumulation of the higher-affinity trans-hydroxytamoxifen in the nuclear ER fraction of cells.	hydroxytamoxifen	111-133	estrogen receptor 1	Homo sapiens	321-323
6708516-9	1984	ER concentration, estimated by the binding of 4-hydroxytamoxifen (OH-tam) and of estradiol was lower in LB cells than in original tam-sensitive L-929 cells.	hydroxytamoxifen	46-64	estrogen receptor 1 (alpha)	Mus musculus	0-2
6883346-3	1983	Under conditions where autoradiographic controls indicate that most of the estrogen receptor of MCF-7 human breast cancer cells is in the nucleus, we could demonstrate nuclear fluorescence using 10(-9) M concentrations of coumestrol, 12-oxoestradiol, and 4-hydroxytamoxifen.	hydroxytamoxifen	255-273	estrogen receptor 1	Homo sapiens	75-92
6575210-5	1983	In the absence of 17 beta-estradiol, 3-hydroxytamoxifen gave rise to a moderate increase in the progesterone receptor levels, which demonstrates the partially estrogenic character of hydroxytamoxifen.	hydroxytamoxifen	39-55	progesterone receptor	Homo sapiens	96-117
29557271-3	2019	Rigid Docking analysis of DAH at the ligand binding domain (LBD) of ER alpha showed hydrogen bond interactions with Arg394 and Glu353 at the active site, similar to the positive controls 4-Hydroxy Tamoxifen (4-OHT) and Fulvestrant (FUL).	hydroxytamoxifen	187-206	estrogen receptor 1	Homo sapiens	68-76
32085898-4	2020	In MDCK cells expressing a modified Src that can be activated by hydroxytamoxifen, activated Src was transported to late endosomes/lysosomes and secreted via sEVs.	hydroxytamoxifen	65-81	SRC proto-oncogene, non-receptor tyrosine kinase	Canis lupus familiaris	36-39
32085898-4	2020	In MDCK cells expressing a modified Src that can be activated by hydroxytamoxifen, activated Src was transported to late endosomes/lysosomes and secreted via sEVs.	hydroxytamoxifen	65-81	SRC proto-oncogene, non-receptor tyrosine kinase	Canis lupus familiaris	93-96
31826231-2	2019	Methods: Intraperitoneal administration of tamoxifen and (Z)-4-hydroxytamoxifen eyedrops were used to trace the lineage of Myh11-expressing cells with the Myh11-Cre-ERT2-flox-tdTomato mouse model.	hydroxytamoxifen	57-79	myosin, heavy polypeptide 11, smooth muscle	Mus musculus	123-128
31826231-2	2019	Methods: Intraperitoneal administration of tamoxifen and (Z)-4-hydroxytamoxifen eyedrops were used to trace the lineage of Myh11-expressing cells with the Myh11-Cre-ERT2-flox-tdTomato mouse model.	hydroxytamoxifen	57-79	myosin, heavy polypeptide 11, smooth muscle	Mus musculus	155-160
31826231-2	2019	Methods: Intraperitoneal administration of tamoxifen and (Z)-4-hydroxytamoxifen eyedrops were used to trace the lineage of Myh11-expressing cells with the Myh11-Cre-ERT2-flox-tdTomato mouse model.	hydroxytamoxifen	57-79	mitogen-activated protein kinase 3	Mus musculus	165-169
31241994-5	2019	4-hydroxytamoxifen was injected into Sod2lox/lox, SM-CreERT2(ki)Cre/+ mice to activate CreERT2-mediated deletion of Sod2.	hydroxytamoxifen	0-18	lysyl oxidase	Mus musculus	41-44
31241994-5	2019	4-hydroxytamoxifen was injected into Sod2lox/lox, SM-CreERT2(ki)Cre/+ mice to activate CreERT2-mediated deletion of Sod2.	hydroxytamoxifen	0-18	superoxide dismutase 2, mitochondrial	Mus musculus	37-41
30987380-5	2019	Our transcriptomics analysis showed that 4-Hydroxytamoxifen (4-OHT), SEL alone or their combination induced differential Akt signaling- and metabolism-associated gene expression profiles.	hydroxytamoxifen	41-59	AKT serine/threonine kinase 1	Homo sapiens	121-124
7317574-2	1981	4-Hydroxytamoxifen binds to the estrogen receptor with affinity equal to estradiol, and with 25-50 times higher affinity than does tamoxifen.	hydroxytamoxifen	0-18	estrogen receptor 1	Homo sapiens	32-49
7451477-2	1981	4-Hydroxytamoxifen and M2, another hydroxylated metabolite of tamoxifen, were the major tritiated compounds of the cytosol and the KCl-nuclear extract of target tissues and appeared to occupy the estrogen receptor sites since their accumulation in these fractions was saturable, resistant to charcoal, and prevented by estradiol.	hydroxytamoxifen	0-18	estrogen receptor 1	Rattus norvegicus	196-213
7451477-7	1981	4-Hydroxytamoxifen formed in vitro was able to bind selectively to estrogen receptor with a high affinity and with a low dissociation rate similar to estradiol.	hydroxytamoxifen	0-18	estrogen receptor 1	Rattus norvegicus	67-84
7451477-8	1981	These results demonstrate that 4-hydroxytamoxifen is formed in vivo and retained on estrogen receptor in target tissues, due to its high affinity.	hydroxytamoxifen	31-49	estrogen receptor 1	Rattus norvegicus	84-101
31916635-2	2020	TAM is activated by endogenous CYP450 enzymes to the more biologically active metabolites 4-hydroxytamoxifen and endoxifen mainly via CYP2D6 and CYP3A4/5.	hydroxytamoxifen	90-108	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	134-140
31916635-2	2020	TAM is activated by endogenous CYP450 enzymes to the more biologically active metabolites 4-hydroxytamoxifen and endoxifen mainly via CYP2D6 and CYP3A4/5.	hydroxytamoxifen	90-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	145-151
31141164-5	2019	Inhibition of NAMPT by FK866 inhibited cell viability and aggravated apoptosis in cancer cells treated with 4-hydroxytamoxifen.	hydroxytamoxifen	108-126	nicotinamide phosphoribosyltransferase	Mus musculus	14-19
31398422-0	2019	Corrigendum to "Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol" [Toxicology and Applied Pharmacology, 378 (2019) 114619].	hydroxytamoxifen	37-55	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	66-71
31263129-9	2019	Transient overexpression of HNRNPA2/B1 reduced MCF-7 sensitivity to 4-hydroxytamoxifen and fulvestrant, suggesting a role for HNRNPA2/B1 in endocrine-resistance.	hydroxytamoxifen	68-86	heterogeneous nuclear ribonucleoprotein A2/B1	Homo sapiens	28-38
30937657-14	2019	4-OH-TAM sensitized ERalpha-positive breast cancer cells to docetaxel in a ZNF423 SNP-dependent manner.	hydroxytamoxifen	0-8	estrogen receptor 1	Homo sapiens	20-27
30937657-14	2019	4-OH-TAM sensitized ERalpha-positive breast cancer cells to docetaxel in a ZNF423 SNP-dependent manner.	hydroxytamoxifen	0-8	zinc finger protein 423	Homo sapiens	75-81
30901604-5	2019	In the present study, the effects of c-Myc activation in UW228-MycER MB cell line were investigated using 4-hydroxytamoxifen (4-OHT) induction system.	hydroxytamoxifen	106-124	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	37-42
30707122-2	2019	WHAT THIS ARTICLE TELLS US THAT IS NEW: In a tamoxifen-activated astrocyte-specific Ndufs4(KO) mouse, the induction EC50s for tail clamp in both isoflurane and halothane were similar between the control and astrocyte-specific Ndufs4(KO) mice at 3 weeks after 4-hydroxy tamoxifen injection.	hydroxytamoxifen	259-278	NADH:ubiquinone oxidoreductase core subunit S4	Mus musculus	84-90
30423024-7	2019	An in vitro model of CDH1 mutated ER-positive breast cancer demonstrates that NF1 knockdown confers a growth advantage in the presence of 4-hydroxy tamoxifen.	hydroxytamoxifen	138-157	cadherin 1	Homo sapiens	21-25
30782165-12	2019	Importantly, MTA1 knockout sensitized hormone receptor negative cells to 4-hydroxy tamoxifen treatment, which could be reversed by the addition of MTA1-exosomes.	hydroxytamoxifen	73-92	metastasis associated 1	Homo sapiens	13-17
30782165-12	2019	Importantly, MTA1 knockout sensitized hormone receptor negative cells to 4-hydroxy tamoxifen treatment, which could be reversed by the addition of MTA1-exosomes.	hydroxytamoxifen	73-92	metastasis associated 1	Homo sapiens	147-151
30416150-8	2019	An in vitro spermatogonia culture model (germline stem cells) revealed that hydroxytamoxifen-induced deletion of PTBP1 from germline stem cells caused severe proliferation arrest accompanied by an increase of apoptotic cell death.	hydroxytamoxifen	76-92	polypyrimidine tract binding protein 1	Mus musculus	113-118
30180270-9	2019	Nlrp3L351P CreT HSCs also showed elevated mRNA and protein expression of fibrotic markers 24 hours after inflammasome activation induced with 4-hydroxytamoxifen (4OHT).	hydroxytamoxifen	142-160	NLR family, pyrin domain containing 3	Mus musculus	0-5
30180270-9	2019	Nlrp3L351P CreT HSCs also showed elevated mRNA and protein expression of fibrotic markers 24 hours after inflammasome activation induced with 4-hydroxytamoxifen (4OHT).	hydroxytamoxifen	142-160	ret proto-oncogene	Mus musculus	11-15
30423024-7	2019	An in vitro model of CDH1 mutated ER-positive breast cancer demonstrates that NF1 knockdown confers a growth advantage in the presence of 4-hydroxy tamoxifen.	hydroxytamoxifen	138-157	neurofibromin 1	Homo sapiens	78-81
30312845-3	2018	Here, we engrafted the CRISPR/Cas9 system with a mutated human estrogen receptor (ERT2), which renders it 4-hydroxytamoxifen (4-OHT) inducible for the access of genome, and a nuclear export signal (NES), which lowers the background activity.	hydroxytamoxifen	106-124	mitogen-activated protein kinase 3	Homo sapiens	82-86
29899353-4	2018	Using the qPLEX-RIME method, we delineate the temporal changes of the Estrogen Receptor alpha (ERalpha) interactome in breast cancer cells treated with 4-hydroxytamoxifen.	hydroxytamoxifen	152-170	estrogen receptor 1	Homo sapiens	70-93
30208932-6	2018	METHODS: Tamoxifen-resistant ERalpha-positive MCF-7 and T47D breast cancer cell lines were established by culturing with gradually increased concentration of 4-hydroxytamoxifen (4-OHT).	hydroxytamoxifen	158-176	estrogen receptor 1	Homo sapiens	29-36
29964089-4	2018	Here, we treated pregnant Abcg2 Cre/Cre RosaLSL-YFP mice with a single injection of 4-hydroxytamoxifen at embryonic day 7.5.	hydroxytamoxifen	84-102	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
29890199-11	2018	These effects of glyphosate and E2 were abolished by the ER antagonist, 4-hydroxytamoxifen and U0126, a MEK inhibitor.	hydroxytamoxifen	72-90	mitogen-activated protein kinase kinase 7	Homo sapiens	104-107
29899353-4	2018	Using the qPLEX-RIME method, we delineate the temporal changes of the Estrogen Receptor alpha (ERalpha) interactome in breast cancer cells treated with 4-hydroxytamoxifen.	hydroxytamoxifen	152-170	estrogen receptor 1	Homo sapiens	95-102
29632071-9	2018	4-Hydroxytamoxifen (4OHT)-mediated transcriptional activity of mouse-human F domain-swapped ERalphas was the inverse of the WT ERalpha activities but not estradiol-mediated transcriptional activities.	hydroxytamoxifen	0-18	estrogen receptor 1	Homo sapiens	92-99
29718959-9	2018	Treatment in vitro of CD4+ splenocytes from GIMAP6fl/flERT2Cre mice with 4-hydroxytamoxifen resulted in the disappearance of GIMAP6 within five days.	hydroxytamoxifen	73-91	CD4 antigen	Mus musculus	22-25
29545311-4	2018	SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor alpha (ERalpha) ligand 4-hydroxytamoxifen by a PEG linker, and we have previously reported that this SNIPER efficiently degrades the ERalpha protein.	hydroxytamoxifen	158-176	magnesium transporter 1	Homo sapiens	29-59
29545311-4	2018	SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor alpha (ERalpha) ligand 4-hydroxytamoxifen by a PEG linker, and we have previously reported that this SNIPER efficiently degrades the ERalpha protein.	hydroxytamoxifen	158-176	magnesium transporter 1	Homo sapiens	61-64
29545311-4	2018	SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor alpha (ERalpha) ligand 4-hydroxytamoxifen by a PEG linker, and we have previously reported that this SNIPER efficiently degrades the ERalpha protein.	hydroxytamoxifen	158-176	estrogen receptor 1	Homo sapiens	117-140
29545311-4	2018	SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor alpha (ERalpha) ligand 4-hydroxytamoxifen by a PEG linker, and we have previously reported that this SNIPER efficiently degrades the ERalpha protein.	hydroxytamoxifen	158-176	estrogen receptor 1	Homo sapiens	142-149
29545311-4	2018	SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor alpha (ERalpha) ligand 4-hydroxytamoxifen by a PEG linker, and we have previously reported that this SNIPER efficiently degrades the ERalpha protein.	hydroxytamoxifen	158-176	estrogen receptor 1	Homo sapiens	268-275
29718959-9	2018	Treatment in vitro of CD4+ splenocytes from GIMAP6fl/flERT2Cre mice with 4-hydroxytamoxifen resulted in the disappearance of GIMAP6 within five days.	hydroxytamoxifen	73-91	GTPase, IMAP family member 6	Mus musculus	44-50
29385237-1	2018	Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug.	hydroxytamoxifen	41-59	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	31-37
29718959-9	2018	Treatment in vitro of CD4+ splenocytes from GIMAP6fl/flERT2Cre mice with 4-hydroxytamoxifen resulted in the disappearance of GIMAP6 within five days.	hydroxytamoxifen	73-91	GTPase, IMAP family member 6	Mus musculus	125-131
29176980-7	2017	In this system, the RAG1 protein is constitutively expressed and functional, while the RAG2 protein, coupled to the estrogen receptor, becomes functionally active upon 4-hydroxytamoxifen (TAM) administration.	hydroxytamoxifen	168-186	recombination activating gene 2	Mus musculus	87-91
29237052-3	2018	Here, we designed and vigorously optimized a series of Hybrid drug Inducible CRISPR/Cas9 Technologies (HIT) for transcriptional activation by grafting a mutated human estrogen receptor (ERT2) to multiple CRISPR/Cas9 systems, which renders them 4-hydroxytamoxifen (4-OHT) inducible for the access of genome.	hydroxytamoxifen	244-262	estrogen receptor 1	Homo sapiens	167-184
29237052-3	2018	Here, we designed and vigorously optimized a series of Hybrid drug Inducible CRISPR/Cas9 Technologies (HIT) for transcriptional activation by grafting a mutated human estrogen receptor (ERT2) to multiple CRISPR/Cas9 systems, which renders them 4-hydroxytamoxifen (4-OHT) inducible for the access of genome.	hydroxytamoxifen	244-262	mitogen-activated protein kinase 3	Homo sapiens	186-190
29285606-9	2018	Regarding phase II metabolism, UGT2B7, 1A8 and 1A3 showed highest activity in glucuronidation of tamoxifen bisphenol and metabolite E. Anti-estrogenic metabolites (Z)-4-hydroxytamoxifen, (Z)-endoxifen and (Z)-norendoxifen inhibited the activity of CYP2C enzymes while tamoxifen bisphenol consistently induced CYPs similar to rifampicin and phenobarbital.	hydroxytamoxifen	163-185	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	31-37
29285606-10	2018	On the transcript level, highest induction up to 5.6-fold was observed for CYP3A4 by tamoxifen, (Z)-4-hydroxytamoxifen, tamoxifen bisphenol and (E)-metabolite E. Estrogen-like tamoxifen metabolites are formed in CYP-dependent reactions and are further metabolized by glucuronidation.	hydroxytamoxifen	96-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
29436156-4	2018	Only the CYP2D6 variation was significantly associated with concentrations of endoxifen (P = 0.0008) and 4-hydroxytamoxifen (P = 0.0074), tamoxifen"s principal active metabolites, as well as key metabolic ratios.	hydroxytamoxifen	105-123	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	9-15
29140506-7	2018	Six days of exposure to 17beta-estradiol or the selective ER modulator 4-hydroxytamoxifen respectively increased or decreased MCF7 organoid CSA (p < .01), consistent with the role of estrogen signaling in ER-positive mammary epithelial cell proliferation.	hydroxytamoxifen	71-89	estrogen receptor 1	Homo sapiens	58-60
29140506-7	2018	Six days of exposure to 17beta-estradiol or the selective ER modulator 4-hydroxytamoxifen respectively increased or decreased MCF7 organoid CSA (p < .01), consistent with the role of estrogen signaling in ER-positive mammary epithelial cell proliferation.	hydroxytamoxifen	71-89	estrogen receptor 1	Homo sapiens	208-210
29389973-7	2018	In addition, leptin, IL-6 and TNFalpha, at concentrations reflecting plasma concentrations in obese patients, decreased the anti-proliferative efficacy of 4-hydroxytamoxifen (a major active metabolite of Tx).	hydroxytamoxifen	155-173	leptin	Homo sapiens	13-19
29389973-7	2018	In addition, leptin, IL-6 and TNFalpha, at concentrations reflecting plasma concentrations in obese patients, decreased the anti-proliferative efficacy of 4-hydroxytamoxifen (a major active metabolite of Tx).	hydroxytamoxifen	155-173	interleukin 6	Homo sapiens	21-25
29389973-7	2018	In addition, leptin, IL-6 and TNFalpha, at concentrations reflecting plasma concentrations in obese patients, decreased the anti-proliferative efficacy of 4-hydroxytamoxifen (a major active metabolite of Tx).	hydroxytamoxifen	155-173	tumor necrosis factor	Homo sapiens	30-38
27890927-8	2017	Moreover, 4-hydroxytamoxifen-induced activation of a JunB-ER fusion protein protected dexamethasone-sensitive MM cells against dexamethasone- and bortezomib-induced cytotoxicity.	hydroxytamoxifen	10-28	jun B proto-oncogene	Mus musculus	53-57
29416786-3	2018	MCF-7 cell growth was inhibited by 4-OH-TAM dose-dependently with IC50 of 29 muM.	hydroxytamoxifen	35-43	latexin	Homo sapiens	77-80
29416786-8	2018	These genes, except PGR and CCND1 which were down-regulated, were also up-regulated in ER+ MCF-7 cells by 4-OH-TAM.	hydroxytamoxifen	106-114	progesterone receptor	Homo sapiens	20-23
29416786-8	2018	These genes, except PGR and CCND1 which were down-regulated, were also up-regulated in ER+ MCF-7 cells by 4-OH-TAM.	hydroxytamoxifen	106-114	cyclin D1	Homo sapiens	28-33
28892037-6	2017	At postnatal day 1 (P1), we used 4-hydroxytamoxifen (4HT) to activate Cre recombinase activity from the Cdh5-CreErt2 transgene to cleave the floxed allele of Ccm2.	hydroxytamoxifen	33-51	cadherin 5	Mus musculus	104-108
28892037-6	2017	At postnatal day 1 (P1), we used 4-hydroxytamoxifen (4HT) to activate Cre recombinase activity from the Cdh5-CreErt2 transgene to cleave the floxed allele of Ccm2.	hydroxytamoxifen	33-51	cerebral cavernous malformation 2	Mus musculus	158-162
29245979-8	2017	CYP2D6 AS was the only variable that showed associations with both metabolite concentration and ratio: endoxifen (P < 0.001), NDM (P < 0.001), endoxifen/NDM (P < 0.001), NDM/tamoxifen (P < 0.001), and 4-OH tamoxifen/tamoxifen (P = 0.005).	hydroxytamoxifen	213-227	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
28459113-4	2017	There is also evidence that some AhR-active pharmaceuticals, including tranilast, flutamide, hydroxytamoxifen and omeprazole or their derivatives, may be effective AhR-dependent anticancer agents for single or combination cancer chemotherapies for treatment of breast and pancreatic cancers.	hydroxytamoxifen	93-109	aryl hydrocarbon receptor	Homo sapiens	33-36
28276606-9	2017	Furthermore, 4-hydroxytamoxifen-mediated deletion of Smarca5 in the ex vivo cultures confirmed its requirement for erythroid cell proliferation.	hydroxytamoxifen	13-31	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5	Homo sapiens	53-60
27991921-1	2017	To study ROCK2 activation in carcinogenesis, mice expressing 4-hydroxytamoxifen (4HT)-activated ROCK2 (K14.ROCKer) were crossed with mice expressing epidermal-activated rasHa (HK1.ras1205).	hydroxytamoxifen	61-79	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	96-101
28075498-2	2017	In this work we demonstrate for the first time that the commonly prescribed breast cancer therapeutic tamoxifen and its major metabolites, 4-hydroxytamoxifen and endoxifen, inhibit DAT function.	hydroxytamoxifen	139-157	solute carrier family 6 member 3	Homo sapiens	181-184
28656802-4	2017	Western blot results also showed that 4-hydroxytamoxifen induced the activity of pro-apoptotic protein Caspase-3 in MCF-7 and SKBR3 cells, as evidenced by the cleavage of mammalian sterile 20-like kinase 1 substrate in a dose-dependent manner.	hydroxytamoxifen	38-56	caspase 3	Homo sapiens	103-112
28137615-3	2017	We observed that 4-hydroxytamoxifen (4-OHT) increased pri-miR-29b-1 and pri-miR-29a transcription in CHO-K1 cells by activating endogenous estrogen receptor alpha (ERalpha).	hydroxytamoxifen	17-35	microRNA 29b	Cricetulus griseus	58-65
28137615-3	2017	We observed that 4-hydroxytamoxifen (4-OHT) increased pri-miR-29b-1 and pri-miR-29a transcription in CHO-K1 cells by activating endogenous estrogen receptor alpha (ERalpha).	hydroxytamoxifen	17-35	microRNA 29a	Cricetulus griseus	76-83
28137615-3	2017	We observed that 4-hydroxytamoxifen (4-OHT) increased pri-miR-29b-1 and pri-miR-29a transcription in CHO-K1 cells by activating endogenous estrogen receptor alpha (ERalpha).	hydroxytamoxifen	17-35	estrogen receptor	Cricetulus griseus	139-162
28166815-6	2017	ESR2-dependent regulation of SMR3A was supported by induced expression after stimulation with estradiol (E2), which was impaired by co-treatment with 4-Hydroxytamoxifen (TAM) or Fulvestrant, respectively.	hydroxytamoxifen	150-168	estrogen receptor 2	Homo sapiens	0-4
28166815-6	2017	ESR2-dependent regulation of SMR3A was supported by induced expression after stimulation with estradiol (E2), which was impaired by co-treatment with 4-Hydroxytamoxifen (TAM) or Fulvestrant, respectively.	hydroxytamoxifen	150-168	submaxillary gland androgen regulated protein 3A	Homo sapiens	29-34
28459113-4	2017	There is also evidence that some AhR-active pharmaceuticals, including tranilast, flutamide, hydroxytamoxifen and omeprazole or their derivatives, may be effective AhR-dependent anticancer agents for single or combination cancer chemotherapies for treatment of breast and pancreatic cancers.	hydroxytamoxifen	93-109	aryl hydrocarbon receptor	Homo sapiens	164-167
27805390-0	2016	Insights of a Lead Optimization Study and Biological Evaluation of Novel 4-Hydroxytamoxifen Analogs as Estrogen-Related Receptor gamma (ERRgamma) Inverse Agonists.	hydroxytamoxifen	73-91	estrogen related receptor gamma	Homo sapiens	103-134
29599800-5	2017	Estrogen receptor- (ER-) positive T47D breast cancer cells are less sensitive to 4-hydroxytamoxifen (4-HT) treatment when cultured on the 3D porous scaffolds than in 2D cultures.	hydroxytamoxifen	81-99	estrogen receptor 1	Homo sapiens	0-17
28849994-3	2017	The aim of the present study was to characterize single and combined antiestrogenic effects of the aryl hydrocarbon receptor (AhR)-agonist beta-naphthoflavone (BNF) and ER-antagonist 4-hydroxytamoxifen (OHT) on vitellogenin (Vtg) protein using primary rainbow trout (Oncorhynchus mykiss) hepatocytes.	hydroxytamoxifen	183-201	estrogen receptor	Oncorhynchus mykiss	169-171
28849994-3	2017	The aim of the present study was to characterize single and combined antiestrogenic effects of the aryl hydrocarbon receptor (AhR)-agonist beta-naphthoflavone (BNF) and ER-antagonist 4-hydroxytamoxifen (OHT) on vitellogenin (Vtg) protein using primary rainbow trout (Oncorhynchus mykiss) hepatocytes.	hydroxytamoxifen	183-201	LOC100136735	Oncorhynchus mykiss	211-223
27924574-5	2017	These cells are then seeded in the absence or presence of 4-Hydroxytamoxifen (4-OHT), which activates the resident CreERT2 alleles resulting in elimination of the conditional K-Ras alleles and ultimately generating Rasless cells.	hydroxytamoxifen	58-76	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	175-180
27882656-0	2016	Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen.	hydroxytamoxifen	81-99	lysine demethylase 1A	Homo sapiens	44-48
27519631-5	2016	In vitro 4-hydroxytamoxifen (OHT) induced cell proliferation and cell cycle promotion in type I and type II endometrial cancer cell lines, and this proliferation was blocked by GPER silencing.	hydroxytamoxifen	9-27	G protein-coupled estrogen receptor 1	Homo sapiens	177-181
27264933-10	2017	4-OH tamoxifen also induced ERalpha homodimers but the subcellular localization of these ERalpha homodimers was predominant in cytoplasm instead of the nuclei induced by E2 treatment.	hydroxytamoxifen	0-14	estrogen receptor 1	Homo sapiens	28-35
27264933-10	2017	4-OH tamoxifen also induced ERalpha homodimers but the subcellular localization of these ERalpha homodimers was predominant in cytoplasm instead of the nuclei induced by E2 treatment.	hydroxytamoxifen	0-14	estrogen receptor 1	Homo sapiens	89-96
27157612-1	2016	Using a 4-hydroxytamoxifen (4OHT)-inducible, conditional Sos1-null mutation, we analyzed wild-type (WT), single Sos1-KO, Sos2-KO and double Sos1/2 KO primary mouse embryonic fibroblasts (MEF) with an aim at evaluating the functional specificity or redundancy of the Sos1 and Sos2 alleles at the cellular level.	hydroxytamoxifen	8-26	SOS Ras/Rac guanine nucleotide exchange factor 1	Mus musculus	57-61
27775859-4	2016	This two-stage system of regulation allows for tissue-selective expression of the ROCK2:ER fusion protein, which then requires administration of estrogen analogues such as tamoxifen or 4-hydroxytamoxifen to elicit kinase activity.	hydroxytamoxifen	185-203	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	82-87
27198207-1	2016	Tamoxifen is metabolically activated to 4-hydroxytamoxifen and endoxifen by cytochrome P450 (CYP).	hydroxytamoxifen	40-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-96
27198207-9	2016	Lower concentrations of endoxifen and endoxifen/4-hydroxytamoxifen ratios were seen with impaired CYP2C9 (P = .05 and P = .03, respectively) if patients had the same CYP2D6 phenotype and were not taking a CYP2D6 or CYP2C19 inhibitor.	hydroxytamoxifen	48-66	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	98-104
27198207-9	2016	Lower concentrations of endoxifen and endoxifen/4-hydroxytamoxifen ratios were seen with impaired CYP2C9 (P = .05 and P = .03, respectively) if patients had the same CYP2D6 phenotype and were not taking a CYP2D6 or CYP2C19 inhibitor.	hydroxytamoxifen	48-66	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	166-172
27198207-9	2016	Lower concentrations of endoxifen and endoxifen/4-hydroxytamoxifen ratios were seen with impaired CYP2C9 (P = .05 and P = .03, respectively) if patients had the same CYP2D6 phenotype and were not taking a CYP2D6 or CYP2C19 inhibitor.	hydroxytamoxifen	48-66	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	205-211
27198207-9	2016	Lower concentrations of endoxifen and endoxifen/4-hydroxytamoxifen ratios were seen with impaired CYP2C9 (P = .05 and P = .03, respectively) if patients had the same CYP2D6 phenotype and were not taking a CYP2D6 or CYP2C19 inhibitor.	hydroxytamoxifen	48-66	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	215-222
27198207-10	2016	Lower concentrations of 4-hydroxytamoxifen were seen for impaired CYP2C19 when ABCB1 SNP3435 was nonvariant (P = .04).	hydroxytamoxifen	24-42	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	66-73
27198207-10	2016	Lower concentrations of 4-hydroxytamoxifen were seen for impaired CYP2C19 when ABCB1 SNP3435 was nonvariant (P = .04).	hydroxytamoxifen	24-42	ATP binding cassette subfamily B member 1	Homo sapiens	79-84
27805390-0	2016	Insights of a Lead Optimization Study and Biological Evaluation of Novel 4-Hydroxytamoxifen Analogs as Estrogen-Related Receptor gamma (ERRgamma) Inverse Agonists.	hydroxytamoxifen	73-91	estrogen related receptor gamma	Homo sapiens	136-144
27618190-3	2016	Here we report the development of a Cas9 variant whose activity can be switched on and off in human cells with 4-hydroxytamoxifen (4-HT) by fusing the Cas9 enzyme with the hormone-binding domain of the estrogen receptor (ERT2).	hydroxytamoxifen	111-129	estrogen receptor 1	Homo sapiens	202-219
27618190-3	2016	Here we report the development of a Cas9 variant whose activity can be switched on and off in human cells with 4-hydroxytamoxifen (4-HT) by fusing the Cas9 enzyme with the hormone-binding domain of the estrogen receptor (ERT2).	hydroxytamoxifen	111-129	mitogen-activated protein kinase 3	Homo sapiens	221-225
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	hydroxytamoxifen	38-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
27580485-1	2016	Molecular dynamics (MD) simulations have been used to model dynamic fluctuations in the structure of estrogen receptor-alpha (ER-alpha) upon binding to the natural agonist 17beta-estradiol (E2) and to the active metabolite of the breast cancer drug and antagonist, 4-hydroxytamoxifen (OHT).	hydroxytamoxifen	265-283	estrogen receptor 1	Homo sapiens	101-124
27580485-1	2016	Molecular dynamics (MD) simulations have been used to model dynamic fluctuations in the structure of estrogen receptor-alpha (ER-alpha) upon binding to the natural agonist 17beta-estradiol (E2) and to the active metabolite of the breast cancer drug and antagonist, 4-hydroxytamoxifen (OHT).	hydroxytamoxifen	265-283	estrogen receptor 1	Homo sapiens	126-134
27236015-0	2016	Synthesis and biological evaluation of novel 4-hydroxytamoxifen analogs as estrogen-related receptor gamma inverse agonists.	hydroxytamoxifen	45-63	estrogen related receptor gamma	Homo sapiens	75-106
27484880-7	2016	The IGF-I decrease correlated with endoxifen (P = 0.002) and 4-hydroxytamoxifen levels, demonstrating steeper decreases at higher metabolite levels (P = 0.001).	hydroxytamoxifen	61-79	insulin like growth factor 1	Homo sapiens	4-9
26645832-8	2016	Treatment with either 4-Hydroxytamoxifen (OHT) or fulvestrant reduced hPYGO2 mRNA 10-fold and protein 5-10-fold within 4 h. Promoter analysis indicated an ER/SP1 binding site at nt -225 to -531 of hPYGO2.	hydroxytamoxifen	22-40	pygopus family PHD finger 2	Homo sapiens	70-76
26645832-8	2016	Treatment with either 4-Hydroxytamoxifen (OHT) or fulvestrant reduced hPYGO2 mRNA 10-fold and protein 5-10-fold within 4 h. Promoter analysis indicated an ER/SP1 binding site at nt -225 to -531 of hPYGO2.	hydroxytamoxifen	22-40	pygopus family PHD finger 2	Homo sapiens	197-203
27159275-9	2016	Moreover, reactivation of ERalpha expression by resveratrol combined with pterostilbene was found to sensitize ERalpha-dependent response to 17beta-estradiol (E2)-mediated cellular proliferation and antagonist 4-hydroxytamoxifen (4-OHT)-mediated inhibition of cellular proliferation in ERalpha-negative breast cancer cells.	hydroxytamoxifen	210-228	estrogen receptor 1	Homo sapiens	26-33
27159275-9	2016	Moreover, reactivation of ERalpha expression by resveratrol combined with pterostilbene was found to sensitize ERalpha-dependent response to 17beta-estradiol (E2)-mediated cellular proliferation and antagonist 4-hydroxytamoxifen (4-OHT)-mediated inhibition of cellular proliferation in ERalpha-negative breast cancer cells.	hydroxytamoxifen	210-228	estrogen receptor 1	Homo sapiens	111-118
27159275-9	2016	Moreover, reactivation of ERalpha expression by resveratrol combined with pterostilbene was found to sensitize ERalpha-dependent response to 17beta-estradiol (E2)-mediated cellular proliferation and antagonist 4-hydroxytamoxifen (4-OHT)-mediated inhibition of cellular proliferation in ERalpha-negative breast cancer cells.	hydroxytamoxifen	210-228	estrogen receptor 1	Homo sapiens	111-118
27012210-0	2016	Curcumin suppresses 4-hydroxytamoxifen resistance in breast cancer cells by targeting SLUG/Hexokinase 2 pathway.	hydroxytamoxifen	20-38	snail family transcriptional repressor 2	Homo sapiens	86-90
27012210-0	2016	Curcumin suppresses 4-hydroxytamoxifen resistance in breast cancer cells by targeting SLUG/Hexokinase 2 pathway.	hydroxytamoxifen	20-38	hexokinase 2	Homo sapiens	91-103
27012210-3	2016	4-hydroxytamoxifen (4-OHT) promoted SLUG expression, which was blocked by curcumin.	hydroxytamoxifen	0-18	snail family transcriptional repressor 2	Homo sapiens	36-40
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	hydroxytamoxifen	38-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	hydroxytamoxifen	38-56	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	114-120
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	hydroxytamoxifen	38-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
26896706-2	2016	TAM is metabolized to the more active 4-hydroxytamoxifen (4-OH-TAM) and endoxifen by cytochrome P450 (CYP) mainly CYP2D6 and CYP3A4 enzymes.	hydroxytamoxifen	58-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
27053216-4	2016	The QKI proteins were also required for adult myelin maintenance, because their ablation using PLP-CreERT resulted in hindlimb paralysis with immobility at ~30 d after 4-hydroxytamoxifen injection.	hydroxytamoxifen	168-186	quaking, KH domain containing RNA binding	Mus musculus	4-7
26692764-8	2015	ERalpha36, a splice variant from the ER1 locus, governs nongenomic membrane signaling pathways triggered by estrogen and confers 4-hydroxytamoxifen resistance in BC therapy.	hydroxytamoxifen	129-147	MIER1 transcriptional regulator	Homo sapiens	37-40
26898104-1	2016	BACKGROUND: Tamoxifen (TAM) is metabolized to the more active 4-hydroxytamoxifen by CYP2D6 enzyme.	hydroxytamoxifen	62-80	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	84-90
27443928-6	2016	We will then outline in detail practical experimental steps for efficient transgenesis toward the creation of single-insertion transgenes and will introduce protocols for 4-hydroxytamoxifen-mediated CreERT2 induction to perform spatiotemporal lox transgene regulation experiments in zebrafish embryos.	hydroxytamoxifen	171-189	lysyl oxidase a	Danio rerio	243-246
26014809-0	2016	Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants.	hydroxytamoxifen	72-90	estrogen receptor 1	Homo sapiens	17-34
26418898-9	2016	Additionally, miR-146b overexpression inhibited cell proliferation and reversed chemoresistance to 4-hydroxytamoxifen in TAMR-MCF-7 cells.	hydroxytamoxifen	99-117	microRNA 146b	Homo sapiens	14-22
26708273-7	2016	Interestingly, 4-hydroxytamoxifen-resistant cells had significantly increased FOXA1 gene expression levels.	hydroxytamoxifen	15-33	forkhead box A1	Homo sapiens	78-83
26446141-10	2016	The ratio of endoxifen to N-desmethyltamoxifen and the ratio of 4-hydroxytamoxifen to tamoxifen increased by 3.3- and ~1.5-fold, reflecting increased CYP2D6 activity.	hydroxytamoxifen	64-82	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	150-156
27468577-10	2016	Further study showed that overexpres- sion of miR-124-3p could partially reverse 4-hydroxytamoxifen (4-OHT)-induced autophagy in breast cancer cells.	hydroxytamoxifen	81-99	microRNA 124-3	Homo sapiens	46-56
26712520-6	2016	Furthermore, treatment with 4-hydroxytamoxifen (4-OHT) resulted in a dose-dependent decrease in PRP4K protein expression in MCF7 cells.	hydroxytamoxifen	28-46	pre-mRNA processing factor 4B	Homo sapiens	96-101
26304202-5	2015	Mouse embryonic fibroblasts (MEFs) were isolated from RAB6A(loxP/loxP) Rosa26-CreERT2 and incubated with 4-hydroxy tamoxifen, resulting in the efficient depletion of Rab6A and Rab6A".	hydroxytamoxifen	105-124	RAB6A, member RAS oncogene family	Mus musculus	54-59
26304202-5	2015	Mouse embryonic fibroblasts (MEFs) were isolated from RAB6A(loxP/loxP) Rosa26-CreERT2 and incubated with 4-hydroxy tamoxifen, resulting in the efficient depletion of Rab6A and Rab6A".	hydroxytamoxifen	105-124	gene trap ROSA 26, Philippe Soriano	Mus musculus	71-77
26304202-5	2015	Mouse embryonic fibroblasts (MEFs) were isolated from RAB6A(loxP/loxP) Rosa26-CreERT2 and incubated with 4-hydroxy tamoxifen, resulting in the efficient depletion of Rab6A and Rab6A".	hydroxytamoxifen	105-124	RAB6A, member RAS oncogene family	Mus musculus	166-171
26304202-5	2015	Mouse embryonic fibroblasts (MEFs) were isolated from RAB6A(loxP/loxP) Rosa26-CreERT2 and incubated with 4-hydroxy tamoxifen, resulting in the efficient depletion of Rab6A and Rab6A".	hydroxytamoxifen	105-124	RAB6A, member RAS oncogene family	Mus musculus	176-182
26299756-7	2015	Our studies also show that the gammaSyn protected conformation of ERalpha36 can effectively bind with both estradiol (E2) and 4-hydroxy tamoxifen (4-OHT).	hydroxytamoxifen	126-145	synuclein gamma	Homo sapiens	31-39
26071758-1	2015	As a prodrug, tamoxifen is activated by the P450 enzyme CYP2D6 that is responsible for converting it to the active metabolites, 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	128-146	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	56-62
25896350-5	2015	Organoids grown ex vivo from intestinal crypts of Vil-Scap(-) mice are readily killed when Scap is deleted by 4-hydroxytamoxifen.	hydroxytamoxifen	110-128	villin 1	Mus musculus	50-53
25896350-5	2015	Organoids grown ex vivo from intestinal crypts of Vil-Scap(-) mice are readily killed when Scap is deleted by 4-hydroxytamoxifen.	hydroxytamoxifen	110-128	SREBF chaperone	Mus musculus	54-58
26238412-4	2015	To investigate HER4 expression and localization in response to estradiol (E2) and 4-hydroxytamoxifen (4-OHT) exposure, we also performed in vitro studies.	hydroxytamoxifen	82-100	erb-b2 receptor tyrosine kinase 4	Homo sapiens	15-19
25819444-4	2015	Our results indicated that endoxifen, N-desmethyltamoxifen (N-desTAM), 4-hydroxytamoxifen (4-OHTAM), and tamoxifen-N-oxide were weak inhibitors of hSULT1E1 with Ki values ranging from 10 muM to 38 muM (i.e., over 1000 times higher than the 8.1 nM Km value for estradiol as substrate for the enzyme).	hydroxytamoxifen	71-89	sulfotransferase family 1E member 1	Homo sapiens	147-155
25795461-0	2015	Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.	hydroxytamoxifen	108-126	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	13-45
25819444-4	2015	Our results indicated that endoxifen, N-desmethyltamoxifen (N-desTAM), 4-hydroxytamoxifen (4-OHTAM), and tamoxifen-N-oxide were weak inhibitors of hSULT1E1 with Ki values ranging from 10 muM to 38 muM (i.e., over 1000 times higher than the 8.1 nM Km value for estradiol as substrate for the enzyme).	hydroxytamoxifen	71-89	latexin	Homo sapiens	187-190
25819444-4	2015	Our results indicated that endoxifen, N-desmethyltamoxifen (N-desTAM), 4-hydroxytamoxifen (4-OHTAM), and tamoxifen-N-oxide were weak inhibitors of hSULT1E1 with Ki values ranging from 10 muM to 38 muM (i.e., over 1000 times higher than the 8.1 nM Km value for estradiol as substrate for the enzyme).	hydroxytamoxifen	71-89	latexin	Homo sapiens	197-200
26022099-12	2015	Treatment of MCF-7 cells with 4-OH tamoxifen or siRNA silencing of estrogen receptor-alpha largely prevented 17beta-estradiol-induced SCD-1 expression.	hydroxytamoxifen	30-44	stearoyl-CoA desaturase	Homo sapiens	134-139
25900183-4	2015	TFF3 was induced by oestrogen, and its induction was inhibited by antioestrogens, tamoxifen, 4-hydroxytamoxifen and fulvestrant in oestrogen-responsive breast cancer cells.	hydroxytamoxifen	93-111	trefoil factor 3	Homo sapiens	0-4
25499232-7	2015	We transduced these lines with an E47/estrogen receptor fusion construct that could be forced to homodimerize with 4-hydroxytamoxifen.	hydroxytamoxifen	115-133	transcription factor 3	Homo sapiens	34-37
25091503-4	2015	CYP2C19 and CYP2C9 correlated with norendoxifen and (Z)-4-hydroxytamoxifen concentrations, respectively (P<0.001).	hydroxytamoxifen	52-74	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	0-7
25091503-4	2015	CYP2C19 and CYP2C9 correlated with norendoxifen and (Z)-4-hydroxytamoxifen concentrations, respectively (P<0.001).	hydroxytamoxifen	52-74	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	12-18
25734062-6	2015	Compared to the wild-type HBD, ER(TAM) has 1000-fold lower affinity for estrogen, yet remains responsive to activation by the synthetic steroid 4-hydroxytamoxifen (4-OHT).	hydroxytamoxifen	144-162	estrogen receptor 1 (alpha)	Mus musculus	31-33
25279503-2	2015	The goal of the present study was to determine how oestradiol (E2) and 4-hydroxytamoxifen (4-OHT) affect cellular bioenergetic function in MCF-7 and T47D ERalpha+ breast cancer cells in serum-replete compared with dextran-coated charcoal (DCC)-stripped foetal bovine serum (FBS)-containing medium ("serum-starved").	hydroxytamoxifen	71-89	estrogen receptor 1	Homo sapiens	154-161
25893704-0	2015	CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen.	hydroxytamoxifen	51-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
25893704-1	2015	AIM: To evaluate the impact of CYP3A4*22 in the formation of endoxifen (EDF) and hydroxytamoxifen (HTF), under different CYP2D6 genotypic backgrounds.	hydroxytamoxifen	81-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
25893704-1	2015	AIM: To evaluate the impact of CYP3A4*22 in the formation of endoxifen (EDF) and hydroxytamoxifen (HTF), under different CYP2D6 genotypic backgrounds.	hydroxytamoxifen	99-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
25893704-5	2015	HTF and TAM levels were respectively 47 and 53% higher in CYP3A4*22 carriers compared with *1/*1 patients in the whole group.	hydroxytamoxifen	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64
25073551-1	2014	BACKGROUND AND PURPOSE: Tamoxifen is a prodrug that is metabolically activated by 4-hydroxylation to the potent primary metabolite 4-hydroxytamoxifen (4OHT) or via another primary metabolite N-desmethyltamoxifen (NDMTAM) to a biologically active secondary metabolite endoxifen through a cytochrome P450 2D6 variant system (CYP2D6).	hydroxytamoxifen	131-149	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	287-306
25073551-1	2014	BACKGROUND AND PURPOSE: Tamoxifen is a prodrug that is metabolically activated by 4-hydroxylation to the potent primary metabolite 4-hydroxytamoxifen (4OHT) or via another primary metabolite N-desmethyltamoxifen (NDMTAM) to a biologically active secondary metabolite endoxifen through a cytochrome P450 2D6 variant system (CYP2D6).	hydroxytamoxifen	131-149	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	323-329
25100862-4	2014	Notable in this regard is the observation here and in other studies that expression of anterior gradient homology 2 (AGR2), a known proto-oncogene and disulfide isomerase, was induced by both estrogen (17beta-estradiol, E2) and 4-hydroxytamoxifen (4OHT) in breast cancer cells.	hydroxytamoxifen	228-246	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	87-115
25100862-4	2014	Notable in this regard is the observation here and in other studies that expression of anterior gradient homology 2 (AGR2), a known proto-oncogene and disulfide isomerase, was induced by both estrogen (17beta-estradiol, E2) and 4-hydroxytamoxifen (4OHT) in breast cancer cells.	hydroxytamoxifen	228-246	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	117-121
25157097-7	2014	In the hSULT2A1-catalyzed sulfation of PREG, 4-hydroxytamoxifen (4-OHTAM) and N-desmethyltamoxifen (N-desTAM) exhibited Ki values of 12.7 and 9.8 muM, respectively, whereas corresponding Ki values of 19.4 and 17.2 muM were observed with DHEA as substrate.	hydroxytamoxifen	45-63	sulfotransferase family 2A member 1	Homo sapiens	7-15
25157097-7	2014	In the hSULT2A1-catalyzed sulfation of PREG, 4-hydroxytamoxifen (4-OHTAM) and N-desmethyltamoxifen (N-desTAM) exhibited Ki values of 12.7 and 9.8 muM, respectively, whereas corresponding Ki values of 19.4 and 17.2 muM were observed with DHEA as substrate.	hydroxytamoxifen	45-63	latexin	Homo sapiens	146-149
25157097-7	2014	In the hSULT2A1-catalyzed sulfation of PREG, 4-hydroxytamoxifen (4-OHTAM) and N-desmethyltamoxifen (N-desTAM) exhibited Ki values of 12.7 and 9.8 muM, respectively, whereas corresponding Ki values of 19.4 and 17.2 muM were observed with DHEA as substrate.	hydroxytamoxifen	45-63	latexin	Homo sapiens	214-217
25258390-1	2014	BACKGROUND: Tamoxifen is metabolically activated via a CYP2D6 enzyme system to the more potent hydroxylated derivatives 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	120-138	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
25135431-6	2014	4-Hydroxytamoxifen (4-OHT) was given to label Lgr5-positive cells with RFP, for comparison to GFP-positive Lgr5-negative cells.	hydroxytamoxifen	0-18	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	46-50
25135431-6	2014	4-Hydroxytamoxifen (4-OHT) was given to label Lgr5-positive cells with RFP, for comparison to GFP-positive Lgr5-negative cells.	hydroxytamoxifen	0-18	tripartite motif containing 27	Homo sapiens	71-74
24881593-5	2014	The steady-state plasma concentrations of TAM and its active metabolites EDX and 4-hydroxytamoxifen (OHTAM) in patients taking TAM are highly variable, reflecting genetic variants of CYP2D6 involved in TAM metabolism.	hydroxytamoxifen	81-99	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	183-189
24482362-3	2014	In comparison with known bis-arylidene drugs, these compounds are at least three orders of magnitude more toxic than tamoxifen and 1.5-4-fold more toxic than 4-hydroxytamoxifen in ER+ MCF-7 cancer cells.	hydroxytamoxifen	158-176	estrogen receptor 1	Homo sapiens	180-182
24590896-6	2014	Moreover, hydroxytamoxifen activation of an Akt-estrogen receptor construct blocked an increase in Mirk mRNA and protein.	hydroxytamoxifen	10-26	AKT serine/threonine kinase 1	Homo sapiens	44-47
24590896-6	2014	Moreover, hydroxytamoxifen activation of an Akt-estrogen receptor construct blocked an increase in Mirk mRNA and protein.	hydroxytamoxifen	10-26	dual specificity tyrosine phosphorylation regulated kinase 1B	Homo sapiens	99-103
24066662-9	2014	However, application of 4-hydroxytamoxifen results in translocation of the fusion protein to the nucleus, where it binds to the Atoh1 enhancer, upregulates transcription and translation of endogenous ATOH1 and activates downstream Atoh1 signaling such as upregulation of the hair cell protein MYOSIN 7A.	hydroxytamoxifen	24-42	atonal bHLH transcription factor 1	Homo sapiens	128-133
24701358-9	2014	4-Hydroxytamoxifen, alone or associated with triiodothyronine, modulated gene expression of TNFRSF9, BMP-6, and THRA, similar to triiodothyronine treatment.	hydroxytamoxifen	0-18	TNF receptor superfamily member 9	Homo sapiens	92-99
24701358-9	2014	4-Hydroxytamoxifen, alone or associated with triiodothyronine, modulated gene expression of TNFRSF9, BMP-6, and THRA, similar to triiodothyronine treatment.	hydroxytamoxifen	0-18	bone morphogenetic protein 6	Homo sapiens	101-106
24701358-9	2014	4-Hydroxytamoxifen, alone or associated with triiodothyronine, modulated gene expression of TNFRSF9, BMP-6, and THRA, similar to triiodothyronine treatment.	hydroxytamoxifen	0-18	thyroid hormone receptor alpha	Homo sapiens	112-116
24066662-9	2014	However, application of 4-hydroxytamoxifen results in translocation of the fusion protein to the nucleus, where it binds to the Atoh1 enhancer, upregulates transcription and translation of endogenous ATOH1 and activates downstream Atoh1 signaling such as upregulation of the hair cell protein MYOSIN 7A.	hydroxytamoxifen	24-42	atonal bHLH transcription factor 1	Homo sapiens	200-205
24066662-9	2014	However, application of 4-hydroxytamoxifen results in translocation of the fusion protein to the nucleus, where it binds to the Atoh1 enhancer, upregulates transcription and translation of endogenous ATOH1 and activates downstream Atoh1 signaling such as upregulation of the hair cell protein MYOSIN 7A.	hydroxytamoxifen	24-42	atonal bHLH transcription factor 1	Homo sapiens	231-236
24434530-2	2014	Tamoxifen is a mainly inactive prodrug, necessitating metabolism by the cytochrome P450 (CYP450) pathway, predominantly the Cytochrome P450 2D6 (CYP2D6), into the active metabolites 4-hydroxytamoxifen and, in particular, endoxifen to achieve its therapeutic effect.	hydroxytamoxifen	182-200	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	124-143
24434530-2	2014	Tamoxifen is a mainly inactive prodrug, necessitating metabolism by the cytochrome P450 (CYP450) pathway, predominantly the Cytochrome P450 2D6 (CYP2D6), into the active metabolites 4-hydroxytamoxifen and, in particular, endoxifen to achieve its therapeutic effect.	hydroxytamoxifen	182-200	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	145-151
23790951-5	2013	These results showed that the level of CCNE2 protein expression was specifically inhibited in luteolin-treated (5muM) TAM-R cells, either in the presence or absence of 4-OH-TAM (100nM).	hydroxytamoxifen	168-176	cyclin E2	Homo sapiens	39-44
23881388-6	2013	Additionally, the effects of fulvestrant, 4-hydroxytamoxifen, or estrogen on estrogen receptor expression were not associated with TIMP1 levels.	hydroxytamoxifen	42-60	estrogen receptor 1	Homo sapiens	77-94
23892277-2	2013	We reported that estradiol (E2) and 4-hydroxytamoxifen (4-OHT) stimulate NRF-1 transcription in an estrogen receptor alpha (ERalpha)- and ERbeta-dependent manner in human breast cancer cells.	hydroxytamoxifen	36-54	estrogen receptor 2	Homo sapiens	138-144
23870655-5	2013	METHODS: K14-Raf:ER transgenic mice, in which the 4-hydroxytamoxifen (4OHT)-responsive mutant estrogen receptor ligand binding domain-Raf fusion gene is expressed under control of the keratin 14 promoter, were mated with epidermis-specific Stat3 null mice (K5-Cre.Stat3(flox/flox)).	hydroxytamoxifen	50-68	zinc fingers and homeoboxes 2	Mus musculus	13-16
23870655-5	2013	METHODS: K14-Raf:ER transgenic mice, in which the 4-hydroxytamoxifen (4OHT)-responsive mutant estrogen receptor ligand binding domain-Raf fusion gene is expressed under control of the keratin 14 promoter, were mated with epidermis-specific Stat3 null mice (K5-Cre.Stat3(flox/flox)).	hydroxytamoxifen	50-68	zinc fingers and homeoboxes 2	Mus musculus	134-137
23805908-4	2013	We initially observed that tamoxifen inhibited macrophage/foam cell formation, but the inhibition was attenuated when FABP4 expression was selectively inhibited by siRNA.We then observed that tamoxifen and 4-hydroxytamoxifen inhibited FABP4 protein expression in primary macrophages isolated from both the male and female wild-type mice, suggesting that the inhibition is sex-independent.	hydroxytamoxifen	206-224	fatty acid binding protein 4, adipocyte	Mus musculus	118-123
23805908-4	2013	We initially observed that tamoxifen inhibited macrophage/foam cell formation, but the inhibition was attenuated when FABP4 expression was selectively inhibited by siRNA.We then observed that tamoxifen and 4-hydroxytamoxifen inhibited FABP4 protein expression in primary macrophages isolated from both the male and female wild-type mice, suggesting that the inhibition is sex-independent.	hydroxytamoxifen	206-224	fatty acid binding protein 4, adipocyte	Mus musculus	235-240
23805908-5	2013	Tamoxifen and 4-hydroxytamoxifen inhibited macrophage FABP4 protein expression induced either by activation of GR (glucocorticoid receptor) or PPARgamma (peroxisome-proliferator-activated receptor gamma).	hydroxytamoxifen	14-32	fatty acid binding protein 4, adipocyte	Mus musculus	54-59
23805908-5	2013	Tamoxifen and 4-hydroxytamoxifen inhibited macrophage FABP4 protein expression induced either by activation of GR (glucocorticoid receptor) or PPARgamma (peroxisome-proliferator-activated receptor gamma).	hydroxytamoxifen	14-32	nuclear receptor subfamily 3, group C, member 1	Mus musculus	111-113
23805908-5	2013	Tamoxifen and 4-hydroxytamoxifen inhibited macrophage FABP4 protein expression induced either by activation of GR (glucocorticoid receptor) or PPARgamma (peroxisome-proliferator-activated receptor gamma).	hydroxytamoxifen	14-32	nuclear receptor subfamily 3, group C, member 1	Mus musculus	115-138
23805908-5	2013	Tamoxifen and 4-hydroxytamoxifen inhibited macrophage FABP4 protein expression induced either by activation of GR (glucocorticoid receptor) or PPARgamma (peroxisome-proliferator-activated receptor gamma).	hydroxytamoxifen	14-32	peroxisome proliferator activated receptor gamma	Mus musculus	143-152
23805908-5	2013	Tamoxifen and 4-hydroxytamoxifen inhibited macrophage FABP4 protein expression induced either by activation of GR (glucocorticoid receptor) or PPARgamma (peroxisome-proliferator-activated receptor gamma).	hydroxytamoxifen	14-32	peroxisome proliferator activated receptor gamma	Mus musculus	154-202
23805908-6	2013	Associated with the decreased protein expression, Fabp4 mRNA expression and promoter activity were also inhibited by tamoxifen and 4-hydroxytamoxifen, indicating transcriptional regulation.	hydroxytamoxifen	131-149	fatty acid binding protein 4, adipocyte	Mus musculus	50-55
23805908-7	2013	Analysis of promoter activity and EMSA/ChIP assays indicated that tamoxifen and 4-hydroxytamoxifen activated the nGRE (negative glucocorticoid regulatory element), but inhibited the PPRE (PPARgamma regulatory element) in the Fabp4 gene.	hydroxytamoxifen	80-98	peroxisome proliferator activated receptor gamma	Mus musculus	188-197
23805908-7	2013	Analysis of promoter activity and EMSA/ChIP assays indicated that tamoxifen and 4-hydroxytamoxifen activated the nGRE (negative glucocorticoid regulatory element), but inhibited the PPRE (PPARgamma regulatory element) in the Fabp4 gene.	hydroxytamoxifen	80-98	fatty acid binding protein 4, adipocyte	Mus musculus	225-230
23892277-2	2013	We reported that estradiol (E2) and 4-hydroxytamoxifen (4-OHT) stimulate NRF-1 transcription in an estrogen receptor alpha (ERalpha)- and ERbeta-dependent manner in human breast cancer cells.	hydroxytamoxifen	36-54	nuclear respiratory factor 1	Homo sapiens	73-78
23892277-2	2013	We reported that estradiol (E2) and 4-hydroxytamoxifen (4-OHT) stimulate NRF-1 transcription in an estrogen receptor alpha (ERalpha)- and ERbeta-dependent manner in human breast cancer cells.	hydroxytamoxifen	36-54	estrogen receptor 1	Homo sapiens	99-122
23892277-2	2013	We reported that estradiol (E2) and 4-hydroxytamoxifen (4-OHT) stimulate NRF-1 transcription in an estrogen receptor alpha (ERalpha)- and ERbeta-dependent manner in human breast cancer cells.	hydroxytamoxifen	36-54	estrogen receptor 1	Homo sapiens	124-131
23991038-9	2013	Furthermore, 4-hydroxytamoxifen had different modes of action in breast cancer cell lines with high or low ZNF703 expression.	hydroxytamoxifen	13-31	zinc finger protein 703	Homo sapiens	107-113
23874882-5	2013	Notch1 was conditionally deleted in adult Notch1(flox/flox), K14-Cre-ERT(+/-) mice using hydroxy-tamoxifen.	hydroxytamoxifen	89-106	notch 1	Mus musculus	0-6
23811274-6	2013	Correspondingly, cells overexpressing CITED2 demonstrated reduced sensitivity to the growth inhibitory effects of the selective estrogen receptor modulator, 4-hydroxytamoxifen.	hydroxytamoxifen	157-175	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2	Homo sapiens	38-44
23811274-6	2013	Correspondingly, cells overexpressing CITED2 demonstrated reduced sensitivity to the growth inhibitory effects of the selective estrogen receptor modulator, 4-hydroxytamoxifen.	hydroxytamoxifen	157-175	estrogen receptor 1	Homo sapiens	128-145
23770613-8	2013	Therefore, mice were fed a vitamin E-depleted diet for 6 weeks before endothelial deletion of Gpx4 was induced by 4-hydroxytamoxifen.	hydroxytamoxifen	114-132	glutathione peroxidase 4	Mus musculus	94-98
23722551-0	2013	4-Hydroxytamoxifen induces autophagic death through K-Ras degradation.	hydroxytamoxifen	0-18	KRAS proto-oncogene, GTPase	Homo sapiens	52-57
23624423-0	2013	4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.	hydroxytamoxifen	0-18	G protein-coupled estrogen receptor 1	Homo sapiens	69-98
23704208-5	2013	E2 elevated phosphorylation of c-Src, which was blocked by 4-hydroxytamoxifen (4-OHT), suggesting that E2 activated c-Src through the ER.	hydroxytamoxifen	59-77	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	31-36
23704208-5	2013	E2 elevated phosphorylation of c-Src, which was blocked by 4-hydroxytamoxifen (4-OHT), suggesting that E2 activated c-Src through the ER.	hydroxytamoxifen	59-77	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	116-121
23704208-5	2013	E2 elevated phosphorylation of c-Src, which was blocked by 4-hydroxytamoxifen (4-OHT), suggesting that E2 activated c-Src through the ER.	hydroxytamoxifen	59-77	estrogen receptor 1	Homo sapiens	134-136
23624423-0	2013	4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.	hydroxytamoxifen	0-18	G protein-coupled estrogen receptor 1	Homo sapiens	100-105
23760924-11	2013	Here, the ablation of Cx43 was achieved by the injection of 4-hydroxytamoxifen (4-OHT; Cx43(Cre-ER(T)/fl) + 4-OHT).	hydroxytamoxifen	60-78	gap junction protein, alpha 1	Mus musculus	22-26
23760924-11	2013	Here, the ablation of Cx43 was achieved by the injection of 4-hydroxytamoxifen (4-OHT; Cx43(Cre-ER(T)/fl) + 4-OHT).	hydroxytamoxifen	60-78	gap junction protein, alpha 1	Mus musculus	87-91
23781139-9	2013	CONCLUSION: CYP2D6*4/*4 genotype was inversely associated with 4-hydroxy tamoxifen and endoxifen levels.	hydroxytamoxifen	63-82	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	12-18
23478097-6	2013	A pulmonary endothelial cell line in which the Bmpr2 gene deletion can be induced by 4-hydroxy tamoxifen was established.	hydroxytamoxifen	85-104	bone morphogenetic protein receptor, type II (serine/threonine kinase)	Mus musculus	47-52
23595215-3	2013	To answer this question we used Cx43(Cre-ER(T)/fl) mice, in which Cx43 expression is abolished after 4-hydroxytamoxifen (4-OHT) administration.	hydroxytamoxifen	101-119	gap junction protein, alpha 1	Mus musculus	32-36
22658320-9	2012	However, blocking c-Src recovered ER expression and down-regulated HER2 which made Sk-Br-3 cells regain responsiveness to 4-hydroxytamoxifen.	hydroxytamoxifen	122-140	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	18-23
23384448-7	2013	However, MPT was prevented by ANT ligands ATP, ADP, tamoxifen and 4-hydroxytamoxifen, implying that the MPT induction by acitretin is mediated by the ANT.	hydroxytamoxifen	66-84	solute carrier family 25 member 6	Homo sapiens	150-153
23593342-2	2013	In contrast to the Selective Estrogen Receptor Modulators (SERMs) such as 4-hydroxytamoxifen that bind to estrogen receptor alpha (ERalpha) as antagonists or partial agonists, fulvestrant causes proteasomal degradation of ERalpha protein, shutting down the estrogen signaling to induce proliferation arrest and apoptosis of estrogen-dependent breast cancer cells.	hydroxytamoxifen	74-92	estrogen receptor 1	Homo sapiens	106-129
23593342-2	2013	In contrast to the Selective Estrogen Receptor Modulators (SERMs) such as 4-hydroxytamoxifen that bind to estrogen receptor alpha (ERalpha) as antagonists or partial agonists, fulvestrant causes proteasomal degradation of ERalpha protein, shutting down the estrogen signaling to induce proliferation arrest and apoptosis of estrogen-dependent breast cancer cells.	hydroxytamoxifen	74-92	estrogen receptor 1	Homo sapiens	131-138
23299318-6	2013	When mDPCET cells were treated with 4-hydroxytamoxifen, (ERT2)Cre(ERT2) translocated from the cytoplasm to the nucleus and caused the excision of SV40Tag-TK, which led to the reversion of mDPCETs.	hydroxytamoxifen	36-54	mitogen-activated protein kinase 3	Mus musculus	57-61
23299318-6	2013	When mDPCET cells were treated with 4-hydroxytamoxifen, (ERT2)Cre(ERT2) translocated from the cytoplasm to the nucleus and caused the excision of SV40Tag-TK, which led to the reversion of mDPCETs.	hydroxytamoxifen	36-54	mitogen-activated protein kinase 3	Mus musculus	66-70
22658320-9	2012	However, blocking c-Src recovered ER expression and down-regulated HER2 which made Sk-Br-3 cells regain responsiveness to 4-hydroxytamoxifen.	hydroxytamoxifen	122-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
23074235-11	2012	The estrogen antagonist, hydroxytamoxifen, the active metabolite of tamoxifen, reduced IGF1R protein levels and both E2- and IGF-II-induced cell proliferation.	hydroxytamoxifen	25-41	insulin like growth factor 1 receptor	Homo sapiens	87-92
23074235-11	2012	The estrogen antagonist, hydroxytamoxifen, the active metabolite of tamoxifen, reduced IGF1R protein levels and both E2- and IGF-II-induced cell proliferation.	hydroxytamoxifen	25-41	cystatin 12, pseudogene	Homo sapiens	117-131
22476979-4	2012	The estrogen-induced FOXA1 upregulation was repressed by 4-hydroxytamoxifen treatment.	hydroxytamoxifen	57-75	forkhead box A1	Homo sapiens	21-26
23024189-9	2012	In cultured cells, significantly increased numbers of genes with modified expression were detected after 48 h, compared to 24-h treatments with DPN or 4-hydroxytamoxifen, including the parathyroid-related genes CASR, VDR, JUN, CALR, and ORAI2.	hydroxytamoxifen	151-169	calcium sensing receptor	Homo sapiens	211-215
23024189-9	2012	In cultured cells, significantly increased numbers of genes with modified expression were detected after 48 h, compared to 24-h treatments with DPN or 4-hydroxytamoxifen, including the parathyroid-related genes CASR, VDR, JUN, CALR, and ORAI2.	hydroxytamoxifen	151-169	vitamin D receptor	Homo sapiens	217-220
23024189-9	2012	In cultured cells, significantly increased numbers of genes with modified expression were detected after 48 h, compared to 24-h treatments with DPN or 4-hydroxytamoxifen, including the parathyroid-related genes CASR, VDR, JUN, CALR, and ORAI2.	hydroxytamoxifen	151-169	calreticulin	Homo sapiens	227-231
23024189-9	2012	In cultured cells, significantly increased numbers of genes with modified expression were detected after 48 h, compared to 24-h treatments with DPN or 4-hydroxytamoxifen, including the parathyroid-related genes CASR, VDR, JUN, CALR, and ORAI2.	hydroxytamoxifen	151-169	ORAI calcium release-activated calcium modulator 2	Homo sapiens	237-242
22158035-9	2012	Importantly, 4-OH tamoxifen (4-OHT), when used in combination with overexpressed CDK10 or Raf-1 inhibitor, increased cleaved PARP and DNA fragmentation to inhibit cologenic growth of MCF7 cells and Tamoxifen-resistant MCF7 cells, respectively.	hydroxytamoxifen	13-27	cyclin dependent kinase 10	Homo sapiens	81-86
22158035-9	2012	Importantly, 4-OH tamoxifen (4-OHT), when used in combination with overexpressed CDK10 or Raf-1 inhibitor, increased cleaved PARP and DNA fragmentation to inhibit cologenic growth of MCF7 cells and Tamoxifen-resistant MCF7 cells, respectively.	hydroxytamoxifen	13-27	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	90-95
22158035-9	2012	Importantly, 4-OH tamoxifen (4-OHT), when used in combination with overexpressed CDK10 or Raf-1 inhibitor, increased cleaved PARP and DNA fragmentation to inhibit cologenic growth of MCF7 cells and Tamoxifen-resistant MCF7 cells, respectively.	hydroxytamoxifen	13-27	collagen type XI alpha 2 chain	Homo sapiens	125-129
22158035-9	2012	Importantly, 4-OH tamoxifen (4-OHT), when used in combination with overexpressed CDK10 or Raf-1 inhibitor, increased cleaved PARP and DNA fragmentation to inhibit cologenic growth of MCF7 cells and Tamoxifen-resistant MCF7 cells, respectively.	hydroxytamoxifen	29-34	cyclin dependent kinase 10	Homo sapiens	81-86
22158035-9	2012	Importantly, 4-OH tamoxifen (4-OHT), when used in combination with overexpressed CDK10 or Raf-1 inhibitor, increased cleaved PARP and DNA fragmentation to inhibit cologenic growth of MCF7 cells and Tamoxifen-resistant MCF7 cells, respectively.	hydroxytamoxifen	29-34	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	90-95
22158035-9	2012	Importantly, 4-OH tamoxifen (4-OHT), when used in combination with overexpressed CDK10 or Raf-1 inhibitor, increased cleaved PARP and DNA fragmentation to inhibit cologenic growth of MCF7 cells and Tamoxifen-resistant MCF7 cells, respectively.	hydroxytamoxifen	29-34	collagen type XI alpha 2 chain	Homo sapiens	125-129
22879383-1	2012	Leflunomide, flutamide, nimodipine, mexiletine, sulindac, tranilast, 4-hydroxytamoxifen, and omeprazole are pharmaceuticals previously characterized as aryl hydrocarbon receptor (AHR) agonists in various cell lines and animal models.	hydroxytamoxifen	69-87	aryl hydrocarbon receptor	Homo sapiens	152-177
22879383-1	2012	Leflunomide, flutamide, nimodipine, mexiletine, sulindac, tranilast, 4-hydroxytamoxifen, and omeprazole are pharmaceuticals previously characterized as aryl hydrocarbon receptor (AHR) agonists in various cell lines and animal models.	hydroxytamoxifen	69-87	aryl hydrocarbon receptor	Homo sapiens	179-182
22332638-4	2012	This study reports a destabilizing domain system based on the ligand binding domain of the estrogen receptor that can be regulated by one of two synthetic ligands, CMP8 or 4-hydroxytamoxifen.	hydroxytamoxifen	172-190	estrogen receptor 1	Homo sapiens	91-108
22281313-6	2012	Hydroxytamoxifen, an antagonist of both estrogen-related receptor gamma (ERRgamma) and estrogen receptors (ERalpha/ERbeta), blocked the BPA-induced enhancement of the spine density.	hydroxytamoxifen	0-16	estrogen receptor 1	Rattus norvegicus	107-114
22281313-6	2012	Hydroxytamoxifen, an antagonist of both estrogen-related receptor gamma (ERRgamma) and estrogen receptors (ERalpha/ERbeta), blocked the BPA-induced enhancement of the spine density.	hydroxytamoxifen	0-16	estrogen receptor 2	Rattus norvegicus	115-121
22290080-16	2012	Transactivation of the EGF-receptor was similarly increased in both cell lines by 17beta-estradiol and 4-hydroxytamoxifen.	hydroxytamoxifen	103-121	epidermal growth factor receptor	Homo sapiens	23-35
22708928-1	2012	BACKGROUND: Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM).	hydroxytamoxifen	99-107	sulfotransferase family 1A member 1	Homo sapiens	12-32
22708928-1	2012	BACKGROUND: Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM).	hydroxytamoxifen	99-107	sulfotransferase family 1A member 1	Homo sapiens	34-41
22425989-0	2012	The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells.	hydroxytamoxifen	96-112	G protein-coupled estrogen receptor 1	Homo sapiens	31-36
22105178-4	2012	We report that 17beta-estradiol (E(2)), 4-hydroxytamoxifen (4-OHT), and raloxifene increased NRF-1 transcription in HUVECs in an ER-dependent manner.	hydroxytamoxifen	40-58	nuclear respiratory factor 1	Homo sapiens	93-98
22429491-6	2012	RESULTS: IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the antiprogestin MIF.	hydroxytamoxifen	105-123	insulin like growth factor 1	Homo sapiens	9-14
22059479-3	2012	Upon 4-hydroxytamoxifen treatment, the ER(T2) fusion proteins with IL-1 receptor-associated kinase (IRAK)1 and IRAK4 elicited specific activation of a reporter gene for the post-transcriptional regulation of IkappaB-zeta.	hydroxytamoxifen	5-23	interleukin 1 receptor associated kinase 1	Homo sapiens	67-106
22611478-6	2012	MCF-7 breast cancer cells treated with UpHT showed decreased proliferation upon co-incubation with RNase 1, consistent with the release of the active drug-4-hydroxytamoxifen.	hydroxytamoxifen	155-173	ribonuclease A family member 1, pancreatic	Homo sapiens	99-106
21947681-1	2012	CYP2D6 is a key enzyme responsible for the metabolism of tamoxifen to active metabolites, endoxifen, and 4-hydroxytamoxifen.	hydroxytamoxifen	105-123	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
21947681-2	2012	The breast cancer patients who are heterozygous and homozygous for decreased-function and null alleles of CYP2D6 showed lower plasma concentrations of endoxifen and 4-hydroxytamoxifen compared to patients with homozygous-wild-type allele, resulting in worse clinical outcome in tamoxifen therapy.	hydroxytamoxifen	165-183	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	106-112
21947681-9	2012	Plasma 4-hydroxytamoxifen concentrations in the patients with CYP2D6*1/*10 and CYP2D6*10/*10 were also significantly increased to the similar levels of the CYP2D6*1/*1 patients according to the increasing tamoxifen dosages (P < 0.001).	hydroxytamoxifen	7-25	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	62-68
21947681-9	2012	Plasma 4-hydroxytamoxifen concentrations in the patients with CYP2D6*1/*10 and CYP2D6*10/*10 were also significantly increased to the similar levels of the CYP2D6*1/*1 patients according to the increasing tamoxifen dosages (P < 0.001).	hydroxytamoxifen	7-25	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-85
21947681-9	2012	Plasma 4-hydroxytamoxifen concentrations in the patients with CYP2D6*1/*10 and CYP2D6*10/*10 were also significantly increased to the similar levels of the CYP2D6*1/*1 patients according to the increasing tamoxifen dosages (P < 0.001).	hydroxytamoxifen	7-25	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-85
22041137-2	2012	Tamoxifen requires metabolic activation by cytochrome P450 (CYP) enzymes for formation of active metabolites, 4-hydroxytamoxifen and endoxifen, which have 30- to 100-fold greater affinity to the estrogen receptor and the potency to suppress estrogen-dependent breast cancer cell proliferation.	hydroxytamoxifen	110-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-58
22041137-2	2012	Tamoxifen requires metabolic activation by cytochrome P450 (CYP) enzymes for formation of active metabolites, 4-hydroxytamoxifen and endoxifen, which have 30- to 100-fold greater affinity to the estrogen receptor and the potency to suppress estrogen-dependent breast cancer cell proliferation.	hydroxytamoxifen	110-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
22059479-3	2012	Upon 4-hydroxytamoxifen treatment, the ER(T2) fusion proteins with IL-1 receptor-associated kinase (IRAK)1 and IRAK4 elicited specific activation of a reporter gene for the post-transcriptional regulation of IkappaB-zeta.	hydroxytamoxifen	5-23	interleukin 1 receptor associated kinase 4	Homo sapiens	111-116
22059479-3	2012	Upon 4-hydroxytamoxifen treatment, the ER(T2) fusion proteins with IL-1 receptor-associated kinase (IRAK)1 and IRAK4 elicited specific activation of a reporter gene for the post-transcriptional regulation of IkappaB-zeta.	hydroxytamoxifen	5-23	NFKB inhibitor zeta	Homo sapiens	208-220
23056320-3	2012	To explore the mechanisms underpinning KLF1 action at the gene loci regulating the first 3 steps in this process, we have exploited the K1-ERp erythroid cell line, in which KLF1 translocates rapidly to the nucleus in response to treatment with 4-OH-Tamoxifen (4-OHT).	hydroxytamoxifen	260-265	Kruppel like factor 1	Homo sapiens	39-43
23251571-2	2012	In these cells, the ER-E2F1 fusion protein is expressed in the cytosol; the addition of 4-hydroxytamoxifen (OHT) induces its translocation to the nucleus and activation of E2F1target genes.	hydroxytamoxifen	88-106	E2F transcription factor 1	Homo sapiens	23-27
21777996-0	2011	Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.	hydroxytamoxifen	71-89	albumin	Homo sapiens	114-127
22295107-5	2012	The treatment with estradiol (E2), anti-estrogenic agents 4-hydroxytamoxifen and ICI 182780, ERbeta specific ligand DPN and GPR30 agonist G1 led to a rapid activation of p-ERK1/2, suggesting the involvement of ERalpha36, ERbeta and GPR30 in the non-genomic signaling pathway in these cells.	hydroxytamoxifen	58-76	mitogen-activated protein kinase 3	Homo sapiens	172-178
22295107-5	2012	The treatment with estradiol (E2), anti-estrogenic agents 4-hydroxytamoxifen and ICI 182780, ERbeta specific ligand DPN and GPR30 agonist G1 led to a rapid activation of p-ERK1/2, suggesting the involvement of ERalpha36, ERbeta and GPR30 in the non-genomic signaling pathway in these cells.	hydroxytamoxifen	58-76	estrogen receptor 2	Homo sapiens	221-227
22295107-5	2012	The treatment with estradiol (E2), anti-estrogenic agents 4-hydroxytamoxifen and ICI 182780, ERbeta specific ligand DPN and GPR30 agonist G1 led to a rapid activation of p-ERK1/2, suggesting the involvement of ERalpha36, ERbeta and GPR30 in the non-genomic signaling pathway in these cells.	hydroxytamoxifen	58-76	G protein-coupled estrogen receptor 1	Homo sapiens	232-237
21840388-6	2011	RESULTS: In ERalpha-positive MCF-7 cells, annonacin (half-effective dose ED(50) = 0.31 muM) and 4-hydroxytamoxifen (ED(50) = 1.13 muM) decreased cell survival whereas annonacin (0.5-1 muM) increased cell death at 48 h. Annonacin and 4-hydroxytamoxifen were additive in inhibiting cell survival.	hydroxytamoxifen	96-114	latexin	Homo sapiens	130-133
21840388-6	2011	RESULTS: In ERalpha-positive MCF-7 cells, annonacin (half-effective dose ED(50) = 0.31 muM) and 4-hydroxytamoxifen (ED(50) = 1.13 muM) decreased cell survival whereas annonacin (0.5-1 muM) increased cell death at 48 h. Annonacin and 4-hydroxytamoxifen were additive in inhibiting cell survival.	hydroxytamoxifen	96-114	latexin	Homo sapiens	130-133
21820658-0	2011	Induction of macrophage scavenger receptor type BI expression by tamoxifen and 4-hydroxytamoxifen.	hydroxytamoxifen	79-97	scavenger receptor class B, member 1	Mus musculus	24-50
21820658-5	2011	METHODS AND RESULTS: In this study, we investigated the effect of tamoxifen and 4-hydroxytamoxifen on macrophage SR-BI expression.	hydroxytamoxifen	80-98	scavenger receptor class B, member 1	Mus musculus	113-118
21820658-6	2011	Macrophage cell lines and peritoneal macrophages isolated from wild-type mice were used to determine changes in SR-BI mRNA and protein expression in response to tamoxifen and 4-hydroxytamoxifen.	hydroxytamoxifen	175-193	scavenger receptor class B, member 1	Mus musculus	112-117
21820658-7	2011	We observed that tamoxifen and 4-hydroxytamoxifen increased SR-BI protein expression in a macrophage cell line derived from female mice (J774 cells) but not in a line derived from male mice (RAW cells).	hydroxytamoxifen	31-49	scavenger receptor class B, member 1	Mus musculus	60-65
21820658-9	2011	Thus, the induction of macrophage SR-BI expression by tamoxifen and 4-hydroxytamoxifen is sex-dependent.	hydroxytamoxifen	68-86	scavenger receptor class B, member 1	Mus musculus	34-39
21820658-14	2011	CONCLUSION: Our study demonstrates that tamoxifen and 4-hydroxytamoxifen induce macrophage SR-BI protein expression via a post-transcriptional mechanism.	hydroxytamoxifen	54-72	scavenger receptor class B, member 1	Mus musculus	91-96
21900890-1	2011	Tamoxifen (Tam), the major drug for estrogen receptor (ER)-positive breast cancer, is converted to its active metabolites, Z- and Z"-endoxifen and 4-OH-Tam isomers, primarily by cytochrome P450 CYP2D6.	hydroxytamoxifen	147-155	estrogen receptor 1	Homo sapiens	36-53
21900890-1	2011	Tamoxifen (Tam), the major drug for estrogen receptor (ER)-positive breast cancer, is converted to its active metabolites, Z- and Z"-endoxifen and 4-OH-Tam isomers, primarily by cytochrome P450 CYP2D6.	hydroxytamoxifen	147-155	estrogen receptor 1	Homo sapiens	55-57
21898684-6	2011	Based on this rationale, we screened only 17 small molecules in reprogramming assays and discovered that the nonsteroidal anti-inflammatory drug Nabumetone and the anticancer drug 4-hydroxytamoxifen can generate iPSCs without Sox2.	hydroxytamoxifen	180-198	SRY (sex determining region Y)-box 2	Mus musculus	226-230
21870861-0	2011	A mechanistic hypothesis for the cytochrome P450-catalyzed cis-trans isomerization of 4-hydroxytamoxifen: an unusual redox reaction.	hydroxytamoxifen	86-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-48
21870861-1	2011	We provide a detailed description of the cis-trans isomerization of 4-hydroxytamoxifen/endoxifen catalyzed by several isoforms from the cytochrome P450 (CYP) superfamily, including CYP1B1, CYP2B6, and CYP2C19.	hydroxytamoxifen	68-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-151
21870861-1	2011	We provide a detailed description of the cis-trans isomerization of 4-hydroxytamoxifen/endoxifen catalyzed by several isoforms from the cytochrome P450 (CYP) superfamily, including CYP1B1, CYP2B6, and CYP2C19.	hydroxytamoxifen	68-86	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-156
21870861-1	2011	We provide a detailed description of the cis-trans isomerization of 4-hydroxytamoxifen/endoxifen catalyzed by several isoforms from the cytochrome P450 (CYP) superfamily, including CYP1B1, CYP2B6, and CYP2C19.	hydroxytamoxifen	68-86	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	181-187
21870861-1	2011	We provide a detailed description of the cis-trans isomerization of 4-hydroxytamoxifen/endoxifen catalyzed by several isoforms from the cytochrome P450 (CYP) superfamily, including CYP1B1, CYP2B6, and CYP2C19.	hydroxytamoxifen	68-86	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	189-195
21870861-1	2011	We provide a detailed description of the cis-trans isomerization of 4-hydroxytamoxifen/endoxifen catalyzed by several isoforms from the cytochrome P450 (CYP) superfamily, including CYP1B1, CYP2B6, and CYP2C19.	hydroxytamoxifen	68-86	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	201-208
21789304-3	2011	These 2-phenylquinoline hybrids effectively and selectively photo-degraded the target transcription factor, ER-alpha, which has a high affinity for estradiol and 4-hydroxytamoxifen.	hydroxytamoxifen	162-180	estrogen receptor 1	Homo sapiens	108-116
21789304-6	2011	In contrast, 2-phenylquinoline-4-hydroxytamoxifen hybrid 3 inhibited growth of MCF-7 cells in the absence of photo-irradiation due to the antagonist effect of the 4-hydroxytamoxifen moiety against ER-alpha, and upon photo-irradiation significantly inhibited cell growth due to the dual antagonist effect of the 4-hydroxytamoxifen moiety and photo-degradation of ER-alpha.	hydroxytamoxifen	31-49	estrogen receptor 1	Homo sapiens	197-205
21789304-6	2011	In contrast, 2-phenylquinoline-4-hydroxytamoxifen hybrid 3 inhibited growth of MCF-7 cells in the absence of photo-irradiation due to the antagonist effect of the 4-hydroxytamoxifen moiety against ER-alpha, and upon photo-irradiation significantly inhibited cell growth due to the dual antagonist effect of the 4-hydroxytamoxifen moiety and photo-degradation of ER-alpha.	hydroxytamoxifen	31-49	estrogen receptor 1	Homo sapiens	362-370
21789304-6	2011	In contrast, 2-phenylquinoline-4-hydroxytamoxifen hybrid 3 inhibited growth of MCF-7 cells in the absence of photo-irradiation due to the antagonist effect of the 4-hydroxytamoxifen moiety against ER-alpha, and upon photo-irradiation significantly inhibited cell growth due to the dual antagonist effect of the 4-hydroxytamoxifen moiety and photo-degradation of ER-alpha.	hydroxytamoxifen	163-181	estrogen receptor 1	Homo sapiens	197-205
21789304-6	2011	In contrast, 2-phenylquinoline-4-hydroxytamoxifen hybrid 3 inhibited growth of MCF-7 cells in the absence of photo-irradiation due to the antagonist effect of the 4-hydroxytamoxifen moiety against ER-alpha, and upon photo-irradiation significantly inhibited cell growth due to the dual antagonist effect of the 4-hydroxytamoxifen moiety and photo-degradation of ER-alpha.	hydroxytamoxifen	163-181	estrogen receptor 1	Homo sapiens	362-370
21906315-0	2011	Upstream molecular signaling pathways of p27(Kip1) expression in human breast cancer cells in vitro: differential effects of 4-hydroxytamoxifen and deficiency of either D-(+)-glucose or L-leucine.	hydroxytamoxifen	125-143	cyclin dependent kinase inhibitor 1B	Homo sapiens	45-49
21906315-4	2011	We found that 4-hydroxytamoxifen - but not tamoxifen - up-regulated the expression of p27 using pathway #1 which consisted mainly of receptor tyrosine kinases and mTORC1.	hydroxytamoxifen	14-32	dynactin subunit 6	Homo sapiens	86-89
21906315-4	2011	We found that 4-hydroxytamoxifen - but not tamoxifen - up-regulated the expression of p27 using pathway #1 which consisted mainly of receptor tyrosine kinases and mTORC1.	hydroxytamoxifen	14-32	CREB regulated transcription coactivator 1	Mus musculus	163-169
21906315-8	2011	Furthermore, the results indicated that, although 4-hydroxytamoxifen used primarily pathway #1 to down-regulate the phosphorylation of 4E-BP1 and up-regulate the expression of p27, it also secondarily down-regulated the phosphorylation of S6K1.	hydroxytamoxifen	50-68	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	135-141
21906315-8	2011	Furthermore, the results indicated that, although 4-hydroxytamoxifen used primarily pathway #1 to down-regulate the phosphorylation of 4E-BP1 and up-regulate the expression of p27, it also secondarily down-regulated the phosphorylation of S6K1.	hydroxytamoxifen	50-68	dynactin subunit 6	Homo sapiens	176-179
21906315-8	2011	Furthermore, the results indicated that, although 4-hydroxytamoxifen used primarily pathway #1 to down-regulate the phosphorylation of 4E-BP1 and up-regulate the expression of p27, it also secondarily down-regulated the phosphorylation of S6K1.	hydroxytamoxifen	50-68	ribosomal protein S6 kinase B1	Homo sapiens	239-243
21777996-2	2011	We located the binding sites of tamoxifen, 4-hydroxytamoxifen and endoxifen on bovine serum albumin (BSA).	hydroxytamoxifen	43-61	albumin	Homo sapiens	86-99
21906462-4	2011	TAM is known to be metabolised to its active metabolites N-desmethyl TAM and 4-hydroxytamoxifen by a number of CYP450 enzymes, including CYP2D6, CYP3A4, CYP2C9, CYP2C19 and CYP2B6.	hydroxytamoxifen	77-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	137-143
30780881-9	2011	This study found that cells harboring p53 mutations were more resistant to the cytotoxic effects of 4-hydroxytamoxifen than their p53 wild-type counterparts.	hydroxytamoxifen	100-118	tumor protein p53	Homo sapiens	38-41
30780881-10	2011	Furthermore, mutant p53 cells were actually stimulated by low concentrations of 4-hydroxytamoxifen, with evidence that this may be mediated through enhanced growth factor signaling.	hydroxytamoxifen	80-98	tumor protein p53	Homo sapiens	20-23
21906462-4	2011	TAM is known to be metabolised to its active metabolites N-desmethyl TAM and 4-hydroxytamoxifen by a number of CYP450 enzymes, including CYP2D6, CYP3A4, CYP2C9, CYP2C19 and CYP2B6.	hydroxytamoxifen	77-95	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	153-159
21906462-4	2011	TAM is known to be metabolised to its active metabolites N-desmethyl TAM and 4-hydroxytamoxifen by a number of CYP450 enzymes, including CYP2D6, CYP3A4, CYP2C9, CYP2C19 and CYP2B6.	hydroxytamoxifen	77-95	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	161-168
21906462-4	2011	TAM is known to be metabolised to its active metabolites N-desmethyl TAM and 4-hydroxytamoxifen by a number of CYP450 enzymes, including CYP2D6, CYP3A4, CYP2C9, CYP2C19 and CYP2B6.	hydroxytamoxifen	77-95	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	173-179
21056929-8	2011	The inhibitory effects of E(2), genistein and daidzein on CRE-mediated transcription activity were enhanced by estrogen receptor (ER) alpha overexpression in MG-63 cells, which could be blocked by nonselective ER antagonists ICI182780, 4-OH tamoxifen and specific ERalpha antagonist MPP.	hydroxytamoxifen	236-250	estrogen receptor 1	Homo sapiens	111-139
21056929-9	2011	Genistein and daidzein, but not E(2) treatment, caused a significant decrease in CRE-mediated transcription activity in ERbeta-transfected MG-63 cells, which could be blocked by ICI182780, 4-OH tamoxifen and the selective ERbeta antagonist (R,R)-5,11-diethyl-5.6,11,12-tetradro-2,8-chrysenediol.	hydroxytamoxifen	189-203	estrogen receptor 2	Homo sapiens	120-126
21378205-0	2011	P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.	hydroxytamoxifen	89-107	phosphoglycolate phosphatase	Mus musculus	0-14
21744342-5	2011	Here we establish an inducible oncogenic zebrafish cell model, in which oncogenic human Raf-1(DeltaRaf1) can be post-transcriptionally activated in zebrafish liver cells by administration of 4-hydroxytamoxifen (4HT).	hydroxytamoxifen	191-209	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	88-103
21727187-3	2011	We generated a conditional zebrafish model of T-ALL in which 4-hydroxytamoxifen (4HT) treatment induces MYC activation and disease, and withdrawal of 4HT results in T-ALL apoptosis and tumor regression.	hydroxytamoxifen	61-79	MYC proto-oncogene, bHLH transcription factor a	Danio rerio	104-107
21840388-10	2011	The combination of annonacin (0.1 muM) and 4-hydroxytamoxifen (1 muM) decreased Bcl-2 protein expression and ERalpha transcriptional activity more than annonacin (0.1 muM) did alone.	hydroxytamoxifen	43-61	latexin	Homo sapiens	65-68
21840388-10	2011	The combination of annonacin (0.1 muM) and 4-hydroxytamoxifen (1 muM) decreased Bcl-2 protein expression and ERalpha transcriptional activity more than annonacin (0.1 muM) did alone.	hydroxytamoxifen	43-61	BCL2 apoptosis regulator	Homo sapiens	80-85
21840388-10	2011	The combination of annonacin (0.1 muM) and 4-hydroxytamoxifen (1 muM) decreased Bcl-2 protein expression and ERalpha transcriptional activity more than annonacin (0.1 muM) did alone.	hydroxytamoxifen	43-61	estrogen receptor 1	Homo sapiens	109-116
21840388-10	2011	The combination of annonacin (0.1 muM) and 4-hydroxytamoxifen (1 muM) decreased Bcl-2 protein expression and ERalpha transcriptional activity more than annonacin (0.1 muM) did alone.	hydroxytamoxifen	43-61	latexin	Homo sapiens	65-68
21840388-16	2011	Annonacin and 4-hydroxytamoxifen were additive in inhibiting cell survival and ERalpha transcriptional activity.	hydroxytamoxifen	14-32	estrogen receptor 1	Homo sapiens	79-86
21525417-4	2011	On the administration of 4-hydroxytamoxifen (4-OHT), the Dppa3-MCM strains recombined the sequence flanked by the loxP elements (the floxed sequence) specifically in primordial germ cells as early as Embryonic Day (E) 7.0, and this recombination became robust after E9.5.	hydroxytamoxifen	25-43	developmental pluripotency-associated 3	Mus musculus	57-62
21525417-4	2011	On the administration of 4-hydroxytamoxifen (4-OHT), the Dppa3-MCM strains recombined the sequence flanked by the loxP elements (the floxed sequence) specifically in primordial germ cells as early as Embryonic Day (E) 7.0, and this recombination became robust after E9.5.	hydroxytamoxifen	25-43	APOBEC1 complementation factor	Mus musculus	63-66
21439346-0	2011	Binding of antitumor tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen to human serum albumin.	hydroxytamoxifen	51-69	albumin	Homo sapiens	93-106
21439346-2	2011	The aim of this study was to examine the interaction of human serum albumin (HSA) with tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen at physiological conditions, using constant protein concentration and various drug contents.	hydroxytamoxifen	117-135	albumin	Homo sapiens	62-75
21378205-0	2011	P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.	hydroxytamoxifen	89-107	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-21
21087932-0	2011	Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells.	hydroxytamoxifen	77-95	prolylcarboxypeptidase	Homo sapiens	0-22
21167227-4	2011	The Cre-ER protein could be induced to translocate from the cytoplasm to the nucleus by 4-hydroxytamoxifen to make SV40LTAg, hTERT and the Cre-ER gene itself excise without a secondary gene transfer.	hydroxytamoxifen	88-106	telomerase reverse transcriptase	Homo sapiens	125-130
21451508-4	2011	CYP2D6 genotypes explained 39 and 9% of the variability of steady-state concentrations of (Z)-endoxifen and (Z)-4-hydroxytamoxifen, respectively.	hydroxytamoxifen	108-130	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
21372145-5	2011	ER antagonists, ICI 182,780 and 4-hydroxytamoxifen, prevent estradiol-induced stimulation of the endogenously expressed HSD17B7, suggesting that these inhibitors not only block estradiol action but also its production.	hydroxytamoxifen	32-50	hydroxysteroid 17-beta dehydrogenase 7	Homo sapiens	120-127
21233487-3	2011	Here we report that 4-hydroxytamoxifen (4-OHT), with an EC(50) of ~1.7 nM, increases NRF-1 expression by recruiting ERbeta, cJun, cFos, CBP, and RNA polymerase II to and dismissing NCoR from the NRF1 promoter.	hydroxytamoxifen	20-38	nuclear respiratory factor 1	Homo sapiens	85-90
21233487-3	2011	Here we report that 4-hydroxytamoxifen (4-OHT), with an EC(50) of ~1.7 nM, increases NRF-1 expression by recruiting ERbeta, cJun, cFos, CBP, and RNA polymerase II to and dismissing NCoR from the NRF1 promoter.	hydroxytamoxifen	20-38	estrogen receptor 2	Homo sapiens	116-122
21233487-3	2011	Here we report that 4-hydroxytamoxifen (4-OHT), with an EC(50) of ~1.7 nM, increases NRF-1 expression by recruiting ERbeta, cJun, cFos, CBP, and RNA polymerase II to and dismissing NCoR from the NRF1 promoter.	hydroxytamoxifen	20-38	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	124-128
21233487-3	2011	Here we report that 4-hydroxytamoxifen (4-OHT), with an EC(50) of ~1.7 nM, increases NRF-1 expression by recruiting ERbeta, cJun, cFos, CBP, and RNA polymerase II to and dismissing NCoR from the NRF1 promoter.	hydroxytamoxifen	20-38	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	130-134
21233487-3	2011	Here we report that 4-hydroxytamoxifen (4-OHT), with an EC(50) of ~1.7 nM, increases NRF-1 expression by recruiting ERbeta, cJun, cFos, CBP, and RNA polymerase II to and dismissing NCoR from the NRF1 promoter.	hydroxytamoxifen	20-38	CREB binding protein	Homo sapiens	136-139
21233487-3	2011	Here we report that 4-hydroxytamoxifen (4-OHT), with an EC(50) of ~1.7 nM, increases NRF-1 expression by recruiting ERbeta, cJun, cFos, CBP, and RNA polymerase II to and dismissing NCoR from the NRF1 promoter.	hydroxytamoxifen	20-38	nuclear receptor corepressor 1	Homo sapiens	181-185
21233487-3	2011	Here we report that 4-hydroxytamoxifen (4-OHT), with an EC(50) of ~1.7 nM, increases NRF-1 expression by recruiting ERbeta, cJun, cFos, CBP, and RNA polymerase II to and dismissing NCoR from the NRF1 promoter.	hydroxytamoxifen	20-38	nuclear respiratory factor 1	Homo sapiens	195-199
21121684-0	2011	Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve eta1-N, eta2-N,O, eta1-O, and eta6 bonding modes, via a novel N-pi rearrangement; relative binding affinities and computer docking studies of cis and trans-eta6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERalpha and ERbeta receptors, and growth inhibition to breast cancer cells.	hydroxytamoxifen	46-68	secreted phosphoprotein 1	Homo sapiens	129-133
21113150-7	2011	To this end, we engineered a knock-in allele encoding a 4-hydroxytamoxifen (4-OHT)-inducible telomerase reverse transcriptase-oestrogen receptor (TERT-ER) under transcriptional control of the endogenous TERT promoter.	hydroxytamoxifen	56-74	telomerase reverse transcriptase	Mus musculus	146-150
21113150-7	2011	To this end, we engineered a knock-in allele encoding a 4-hydroxytamoxifen (4-OHT)-inducible telomerase reverse transcriptase-oestrogen receptor (TERT-ER) under transcriptional control of the endogenous TERT promoter.	hydroxytamoxifen	56-74	telomerase reverse transcriptase	Mus musculus	203-207
21121684-0	2011	Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve eta1-N, eta2-N,O, eta1-O, and eta6 bonding modes, via a novel N-pi rearrangement; relative binding affinities and computer docking studies of cis and trans-eta6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERalpha and ERbeta receptors, and growth inhibition to breast cancer cells.	hydroxytamoxifen	46-68	DNA polymerase iota	Homo sapiens	137-141
21121684-0	2011	Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve eta1-N, eta2-N,O, eta1-O, and eta6 bonding modes, via a novel N-pi rearrangement; relative binding affinities and computer docking studies of cis and trans-eta6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERalpha and ERbeta receptors, and growth inhibition to breast cancer cells.	hydroxytamoxifen	46-68	secreted phosphoprotein 1	Homo sapiens	147-151
21121684-0	2011	Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve eta1-N, eta2-N,O, eta1-O, and eta6 bonding modes, via a novel N-pi rearrangement; relative binding affinities and computer docking studies of cis and trans-eta6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERalpha and ERbeta receptors, and growth inhibition to breast cancer cells.	hydroxytamoxifen	46-68	estrogen receptor 1	Homo sapiens	340-347
21121684-0	2011	Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve eta1-N, eta2-N,O, eta1-O, and eta6 bonding modes, via a novel N-pi rearrangement; relative binding affinities and computer docking studies of cis and trans-eta6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERalpha and ERbeta receptors, and growth inhibition to breast cancer cells.	hydroxytamoxifen	46-68	estrogen receptor 2	Homo sapiens	352-358
21121684-0	2011	Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve eta1-N, eta2-N,O, eta1-O, and eta6 bonding modes, via a novel N-pi rearrangement; relative binding affinities and computer docking studies of cis and trans-eta6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERalpha and ERbeta receptors, and growth inhibition to breast cancer cells.	hydroxytamoxifen	52-68	secreted phosphoprotein 1	Homo sapiens	129-133
21121684-0	2011	Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve eta1-N, eta2-N,O, eta1-O, and eta6 bonding modes, via a novel N-pi rearrangement; relative binding affinities and computer docking studies of cis and trans-eta6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERalpha and ERbeta receptors, and growth inhibition to breast cancer cells.	hydroxytamoxifen	52-68	DNA polymerase iota	Homo sapiens	137-141
21121684-0	2011	Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve eta1-N, eta2-N,O, eta1-O, and eta6 bonding modes, via a novel N-pi rearrangement; relative binding affinities and computer docking studies of cis and trans-eta6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERalpha and ERbeta receptors, and growth inhibition to breast cancer cells.	hydroxytamoxifen	52-68	secreted phosphoprotein 1	Homo sapiens	147-151
21121684-0	2011	Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve eta1-N, eta2-N,O, eta1-O, and eta6 bonding modes, via a novel N-pi rearrangement; relative binding affinities and computer docking studies of cis and trans-eta6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERalpha and ERbeta receptors, and growth inhibition to breast cancer cells.	hydroxytamoxifen	52-68	estrogen receptor 1	Homo sapiens	340-347
21121684-0	2011	Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve eta1-N, eta2-N,O, eta1-O, and eta6 bonding modes, via a novel N-pi rearrangement; relative binding affinities and computer docking studies of cis and trans-eta6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERalpha and ERbeta receptors, and growth inhibition to breast cancer cells.	hydroxytamoxifen	52-68	estrogen receptor 2	Homo sapiens	352-358
21056663-2	2011	The synthetic estrogen receptor ligands 4-hydroxytamoxifen and diethylstilbestrol have, however, been shown to bind to and abolish the constitutive transcriptional activity of ERRgamma.	hydroxytamoxifen	40-58	estrogen related receptor gamma	Homo sapiens	176-184
21138979-4	2011	We further generated transgenic zebrafish that express ubiquitous 4-hydroxytamoxifen-controlled Cre recombinase activity from a ubi:cre(ERt2) transgene, as well as ubi:loxP-EGFP-loxP-mCherry (ubi:Switch) transgenics and show their use as a constitutive fluorescent lineage tracing reagent.	hydroxytamoxifen	66-84	ubiquitin B	Danio rerio	55-58
21138979-4	2011	We further generated transgenic zebrafish that express ubiquitous 4-hydroxytamoxifen-controlled Cre recombinase activity from a ubi:cre(ERt2) transgene, as well as ubi:loxP-EGFP-loxP-mCherry (ubi:Switch) transgenics and show their use as a constitutive fluorescent lineage tracing reagent.	hydroxytamoxifen	66-84	ubiquitin B	Danio rerio	128-131
21138979-4	2011	We further generated transgenic zebrafish that express ubiquitous 4-hydroxytamoxifen-controlled Cre recombinase activity from a ubi:cre(ERt2) transgene, as well as ubi:loxP-EGFP-loxP-mCherry (ubi:Switch) transgenics and show their use as a constitutive fluorescent lineage tracing reagent.	hydroxytamoxifen	66-84	ubiquitin B	Danio rerio	128-131
20951138-3	2011	METHODS: We investigated the effects of decreased sumoylation in adult mammals by generating mice with an inducible knockout (by injection of 4-hydroxytamoxifen) of the E2 enzyme Ubc9 (Ubc9fl/-/ROSA26-CreERT2 mice).	hydroxytamoxifen	142-160	ubiquitin-conjugating enzyme E2I	Mus musculus	179-183
20951138-6	2011	Ubc9fl/-/ROSA26-CreERT2 mice died within 6 days of 4-hydroxytamoxifen injection, losing 20% or less of their body weight and developing severe diarrhea on the second day after injection.	hydroxytamoxifen	51-69	ubiquitin-conjugating enzyme E2I	Mus musculus	0-4
21924163-6	2011	Lastly, we will introduce protocols for 4-hydroxytamoxifen-mediated CreER(T2) induction to perform spatio-temporal lox transgene regulation experiments in zebrafish embryos.	hydroxytamoxifen	40-58	lysyl oxidase a	Danio rerio	115-118
20543998-2	2010	Among the compounds, the diisopropyl and piperidinyl derivatives were found to be more active than 4-hydroxytamoxifen (HO-Tam), the active metabolite of tamoxifen based upon IC(50) values.	hydroxytamoxifen	99-117	Myeloproliferative syndrome, transient (transient abnormal myelopoiesis)	Homo sapiens	122-125
21041310-6	2010	TPSF also inhibits ERalpha-dependent growth in three cellular models for tamoxifen resistance; that is, 4-hydroxytamoxifen-stimulated MCF7ERalphaHA cells that overexpress ERalpha, fully tamoxifen-resistant BT474 cells that have amplified HER-2 and AIB1, and partially tamoxifen-resistant ZR-75 cells.	hydroxytamoxifen	104-122	estrogen receptor 1	Homo sapiens	138-145
21086978-1	2010	Tamoxifen (Tam), the antiestrogen used to treat estrogen receptor-positive breast cancer is a pro-drug that is converted to its major active metabolites, endoxifen and 4-hydroxy-tamoxifen (4-OH-Tam) by various biotransformation enzymes of which cytochrome P450-2D6 (CYP2D6) is key.	hydroxytamoxifen	189-197	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	245-264
21086978-1	2010	Tamoxifen (Tam), the antiestrogen used to treat estrogen receptor-positive breast cancer is a pro-drug that is converted to its major active metabolites, endoxifen and 4-hydroxy-tamoxifen (4-OH-Tam) by various biotransformation enzymes of which cytochrome P450-2D6 (CYP2D6) is key.	hydroxytamoxifen	189-197	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	266-272
20926391-2	2010	Using a cell line in which deletion of the O-GlcNAc transferase (OGT; the enzyme that adds O-GlcNAc) can be induced by 4-hydroxytamoxifen, we screened the expression of 84 HSPs using quantitative reverse transcriptase PCR.	hydroxytamoxifen	119-137	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	43-63
20926391-2	2010	Using a cell line in which deletion of the O-GlcNAc transferase (OGT; the enzyme that adds O-GlcNAc) can be induced by 4-hydroxytamoxifen, we screened the expression of 84 HSPs using quantitative reverse transcriptase PCR.	hydroxytamoxifen	119-137	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	65-68
20808831-8	2010	Using MDA-MB-231 cells, in which FOXO3a activity can be induced by 4-hydroxytamoxifen, we showed that FOXO3a induction up-regulates PI3K-Akt activity and enhanced doxorubicin resistance.	hydroxytamoxifen	67-85	forkhead box O3	Homo sapiens	33-39
20808831-8	2010	Using MDA-MB-231 cells, in which FOXO3a activity can be induced by 4-hydroxytamoxifen, we showed that FOXO3a induction up-regulates PI3K-Akt activity and enhanced doxorubicin resistance.	hydroxytamoxifen	67-85	forkhead box O3	Homo sapiens	102-108
20808831-8	2010	Using MDA-MB-231 cells, in which FOXO3a activity can be induced by 4-hydroxytamoxifen, we showed that FOXO3a induction up-regulates PI3K-Akt activity and enhanced doxorubicin resistance.	hydroxytamoxifen	67-85	AKT serine/threonine kinase 1	Homo sapiens	137-140
20542892-0	2010	Distinction of the binding modes for human nuclear receptor ERRgamma between bisphenol A and 4-hydroxytamoxifen.	hydroxytamoxifen	93-111	estrogen related receptor gamma	Homo sapiens	60-68
20542892-3	2010	BPA functions as an inverse-type antagonist of ERRgamma to retain its high basal constitutive activity by inhibiting the deactivating inverse agonist activity of 4-hydroxytamoxifen (4-OHT).	hydroxytamoxifen	162-180	estrogen related receptor gamma	Homo sapiens	47-55
20578288-7	2010	METHODS: K14-Raf:ER transgenic mice, in which the 4-hydroxytamoxifen (4OHT)-responsive mutant estrogen receptor (ER) ligand binding domain-Raf fusion gene was expressed under control of the keratin 14 promoter, were used to characterize inflammatory reactions induced by Raf expression in the epidermis.	hydroxytamoxifen	50-68	estrogen receptor 1 (alpha)	Mus musculus	94-111
20578288-7	2010	METHODS: K14-Raf:ER transgenic mice, in which the 4-hydroxytamoxifen (4OHT)-responsive mutant estrogen receptor (ER) ligand binding domain-Raf fusion gene was expressed under control of the keratin 14 promoter, were used to characterize inflammatory reactions induced by Raf expression in the epidermis.	hydroxytamoxifen	50-68	estrogen receptor 1 (alpha)	Mus musculus	113-115
20348541-6	2010	Differences in ERalpha complex composition with the ER ligands 17beta-estradiol, 4-hydroxytamoxifen, and ICI-182,780 could also be observed.	hydroxytamoxifen	81-99	estrogen receptor 1	Homo sapiens	15-22
21143970-4	2010	We combined digitonin-based cell fractionation analyses with fluorescence and immuno-electron microscopy to determine the intracellular distribution of ligand-bound ERalpha and/or GFP-ERalpha.Using fluorescence- and electron microscopy we demonstrate that both endogenous ERalpha and GFP-ERalpha form numerous nuclear focal accumulations upon addition of agonist, 17beta-estradiol (E2), and pure antagonists (selective estrogen regulator disruptor; SERD), ICI 182,780 or RU58,668, while in the presence of partial antagonists (selective estrogen regulator modulator; SERM), 4-hydroxytamoxifen (OHT) or RU39,411, diffuse nuclear staining persisted.Digitonin based cell fractionation analyses confirmed that endogenous ERalpha and GFP-ERalpha predominantly reside in the nuclear fraction.	hydroxytamoxifen	574-592	estrogen receptor 1	Homo sapiens	165-172
20479004-9	2010	Importantly, 4-hydroxy tamoxifen, when used in combination with silencing of Pin1 or LC-3, increased cleaved poly(ADP-ribose) polymerase and DNA fragmentation to inhibit cologenic growth of MCF7 cells.	hydroxytamoxifen	13-32	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	77-81
20479004-9	2010	Importantly, 4-hydroxy tamoxifen, when used in combination with silencing of Pin1 or LC-3, increased cleaved poly(ADP-ribose) polymerase and DNA fragmentation to inhibit cologenic growth of MCF7 cells.	hydroxytamoxifen	13-32	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	85-89
20479004-9	2010	Importantly, 4-hydroxy tamoxifen, when used in combination with silencing of Pin1 or LC-3, increased cleaved poly(ADP-ribose) polymerase and DNA fragmentation to inhibit cologenic growth of MCF7 cells.	hydroxytamoxifen	13-32	poly(ADP-ribose) polymerase 1	Homo sapiens	109-136
20387803-2	2010	Binding affinities of tethered full length human estrogen receptor alpha (ERalpha) with 17beta-estradiol, diethylstilbestrol, raloxifene, 4-hydroxytamoxifen, tamoxifen, and genistein were measured to be 100 (as reference), 100, 35, 21, 8, and 1.5, respectively.	hydroxytamoxifen	138-156	estrogen receptor 1	Homo sapiens	49-72
20387803-2	2010	Binding affinities of tethered full length human estrogen receptor alpha (ERalpha) with 17beta-estradiol, diethylstilbestrol, raloxifene, 4-hydroxytamoxifen, tamoxifen, and genistein were measured to be 100 (as reference), 100, 35, 21, 8, and 1.5, respectively.	hydroxytamoxifen	138-156	estrogen receptor 1	Homo sapiens	74-81
20026264-4	2010	In previous reports, 2.3-kb Col1a1-CreERT2 mice that expressed a Cre recombinase that is transiently inducible by 4-hydroxytamoxifen (4-OHT) were intercrossed with Rosa26R (R26R) reporter mice, which resulted in the production of Cre-expressing osteoblasts that were detected upon X-gal staining.	hydroxytamoxifen	114-132	collagen, type I, alpha 1	Mus musculus	28-34
19427779-3	2010	Genistein- and equol-induced cell proliferation and S-phase entry were blocked by the ERalpha antagonists 4-hydroxytamoxifen and ICI 182,780 and by the mitogen-activated protein kinase 1/2 inhibitor U0126.	hydroxytamoxifen	106-124	estrogen receptor 1	Homo sapiens	86-93
20116857-0	2010	A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen receptor-independent mechanism of action in breast cancer cell lines.	hydroxytamoxifen	27-43	estrogen receptor 1	Homo sapiens	55-72
20179196-5	2010	FGFR1-amplified cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1, suggesting that FGFR1 overexpression also promotes endocrine therapy resistance.	hydroxytamoxifen	46-64	fibroblast growth factor receptor 1	Homo sapiens	0-5
19526339-2	2010	We used a novel approach to detect changes in the hormone-binding domain of ERalpha, based on the evidence that antiestrogens, such as 4-hydroxytamoxifen (ZOHT) and ICI 182,780, block the function of ERalpha by binding and folding the AF-2 transcriptional domain in a way that inhibits its association with coactivator proteins.	hydroxytamoxifen	135-153	estrogen receptor 1	Homo sapiens	76-83
19526339-2	2010	We used a novel approach to detect changes in the hormone-binding domain of ERalpha, based on the evidence that antiestrogens, such as 4-hydroxytamoxifen (ZOHT) and ICI 182,780, block the function of ERalpha by binding and folding the AF-2 transcriptional domain in a way that inhibits its association with coactivator proteins.	hydroxytamoxifen	135-153	estrogen receptor 1	Homo sapiens	200-207
20188517-5	2010	METHODS: K14-Raf:ER transgenic mice, in which the 4-hydroxytamoxifen (4OHT)-responsive mutant estrogen receptor (ER) ligand binding domain-Raf fusion gene was expressed under control of the keratin 14 promoter, were used to characterize inflammatory reactions induced by Raf expression in the epidermis.	hydroxytamoxifen	50-68	estrogen receptor 1 (alpha)	Mus musculus	94-111
20188517-5	2010	METHODS: K14-Raf:ER transgenic mice, in which the 4-hydroxytamoxifen (4OHT)-responsive mutant estrogen receptor (ER) ligand binding domain-Raf fusion gene was expressed under control of the keratin 14 promoter, were used to characterize inflammatory reactions induced by Raf expression in the epidermis.	hydroxytamoxifen	50-68	estrogen receptor 1 (alpha)	Mus musculus	113-115
20376192-3	2010	METHODOLOGY/PRINCIPAL FINDINGS: Using a virtual screening approach, 4-hydroxytamoxifen, the active metabolite of the anti-estrogen drug tamoxifen, was identified as a putative Hsp90 ligand.	hydroxytamoxifen	68-86	heat shock protein 90 alpha family class A member 1	Homo sapiens	176-181
20376192-4	2010	Surprisingly, while all drugs targeting Hsp90 inhibit the chaperone ATPase activity, it was found experimentally that 4-hydroxytamoxifen and tamoxifen enhance rather than inhibit Hsp90 ATPase.	hydroxytamoxifen	118-136	heat shock protein 90 alpha family class A member 1	Homo sapiens	179-184
20376192-4	2010	Surprisingly, while all drugs targeting Hsp90 inhibit the chaperone ATPase activity, it was found experimentally that 4-hydroxytamoxifen and tamoxifen enhance rather than inhibit Hsp90 ATPase.	hydroxytamoxifen	118-136	dynein axonemal heavy chain 8	Homo sapiens	185-191
20544555-4	2010	It was found that some of the PBDE compounds with antiestrogenic activity extended into the channel of the estrogen receptor (ER), which is usually occupied by the alkylamine side chain of the ER antagonists raloxifene (RAL) and 4-hydroxytamoxifen (OHT), while most PBDE compounds without antiestrogenic activity adopted binding modes similar to that of ER agonist 17beta-estradiol (E2), located in the binding cavity and which did not protrude into the channel.	hydroxytamoxifen	229-247	estrogen receptor 1	Homo sapiens	107-124
20544555-4	2010	It was found that some of the PBDE compounds with antiestrogenic activity extended into the channel of the estrogen receptor (ER), which is usually occupied by the alkylamine side chain of the ER antagonists raloxifene (RAL) and 4-hydroxytamoxifen (OHT), while most PBDE compounds without antiestrogenic activity adopted binding modes similar to that of ER agonist 17beta-estradiol (E2), located in the binding cavity and which did not protrude into the channel.	hydroxytamoxifen	229-247	estrogen receptor 1	Homo sapiens	126-128
20124171-10	2010	CYP2D6 variants were associated with lower plasma levels of endoxifen and 4-hydroxytamoxifen (P = .0000043 and .00052), whereas no significant difference was found among ABCC2 genotype groups.	hydroxytamoxifen	74-92	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
20018866-5	2010	Here, we established a dual-regulatable FL5.12 pre-B cell line in which myristoylated Akt is expressed under the control of doxycycline, and c-Myc, fused to the hormone-binding domain of the human estrogen receptor, is activated by 4-hydroxytamoxifen.	hydroxytamoxifen	232-250	thymoma viral proto-oncogene 1	Mus musculus	86-89
20018866-5	2010	Here, we established a dual-regulatable FL5.12 pre-B cell line in which myristoylated Akt is expressed under the control of doxycycline, and c-Myc, fused to the hormone-binding domain of the human estrogen receptor, is activated by 4-hydroxytamoxifen.	hydroxytamoxifen	232-250	estrogen receptor 1	Homo sapiens	197-214
20179196-5	2010	FGFR1-amplified cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1, suggesting that FGFR1 overexpression also promotes endocrine therapy resistance.	hydroxytamoxifen	46-64	fibroblast growth factor receptor 1	Homo sapiens	122-127
20179196-5	2010	FGFR1-amplified cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1, suggesting that FGFR1 overexpression also promotes endocrine therapy resistance.	hydroxytamoxifen	46-64	fibroblast growth factor receptor 1	Homo sapiens	122-127
20170512-0	2010	Upstream molecular signaling pathways of p27(Kip1) expression: effects of 4-hydroxytamoxifen, dexamethasone, and retinoic acids.	hydroxytamoxifen	74-92	cyclin dependent kinase inhibitor 1B	Homo sapiens	45-49
20170512-6	2010	1) The evidence indicated that 4-hydroxytamoxifen, dexamethasone, and various retinoic acids up-regulated expression of p27 in both estrogen receptor-positive and negative human breast cancer cells in vitro.	hydroxytamoxifen	31-49	interferon alpha inducible protein 27	Homo sapiens	120-123
20170512-12	2010	CONCLUSIONS: 4-Hydroxytamoxifen and dexamethasone up-regulated translation initiation of p27 by down-regulating 4E-BP1 phosphorylated at Ser65 and this down-regulation seemed to be mediated by upstream RTKs/PI3K/Akt/AMPK/mTOR protein kinase signaling pathways.	hydroxytamoxifen	13-31	interferon alpha inducible protein 27	Homo sapiens	89-92
20170512-12	2010	CONCLUSIONS: 4-Hydroxytamoxifen and dexamethasone up-regulated translation initiation of p27 by down-regulating 4E-BP1 phosphorylated at Ser65 and this down-regulation seemed to be mediated by upstream RTKs/PI3K/Akt/AMPK/mTOR protein kinase signaling pathways.	hydroxytamoxifen	13-31	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	112-118
20170512-12	2010	CONCLUSIONS: 4-Hydroxytamoxifen and dexamethasone up-regulated translation initiation of p27 by down-regulating 4E-BP1 phosphorylated at Ser65 and this down-regulation seemed to be mediated by upstream RTKs/PI3K/Akt/AMPK/mTOR protein kinase signaling pathways.	hydroxytamoxifen	13-31	AKT serine/threonine kinase 1	Homo sapiens	212-215
19935718-0	2010	c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells.	hydroxytamoxifen	33-51	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-5
20170512-12	2010	CONCLUSIONS: 4-Hydroxytamoxifen and dexamethasone up-regulated translation initiation of p27 by down-regulating 4E-BP1 phosphorylated at Ser65 and this down-regulation seemed to be mediated by upstream RTKs/PI3K/Akt/AMPK/mTOR protein kinase signaling pathways.	hydroxytamoxifen	13-31	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	216-220
19935718-4	2010	We show that before DNA fragmentation and caspase 3/7 activation, cytotoxic concentrations of 4-hydroxytamoxifen (OHT) induced JNK-dependent phosphorylation of c-Jun at JNK sites earlier shown to regulate c-Jun-mediated apoptosis.	hydroxytamoxifen	94-112	mitogen-activated protein kinase 8	Homo sapiens	127-130
19935718-4	2010	We show that before DNA fragmentation and caspase 3/7 activation, cytotoxic concentrations of 4-hydroxytamoxifen (OHT) induced JNK-dependent phosphorylation of c-Jun at JNK sites earlier shown to regulate c-Jun-mediated apoptosis.	hydroxytamoxifen	94-112	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	160-165
20170512-12	2010	CONCLUSIONS: 4-Hydroxytamoxifen and dexamethasone up-regulated translation initiation of p27 by down-regulating 4E-BP1 phosphorylated at Ser65 and this down-regulation seemed to be mediated by upstream RTKs/PI3K/Akt/AMPK/mTOR protein kinase signaling pathways.	hydroxytamoxifen	13-31	mechanistic target of rapamycin kinase	Homo sapiens	221-225
19935718-4	2010	We show that before DNA fragmentation and caspase 3/7 activation, cytotoxic concentrations of 4-hydroxytamoxifen (OHT) induced JNK-dependent phosphorylation of c-Jun at JNK sites earlier shown to regulate c-Jun-mediated apoptosis.	hydroxytamoxifen	94-112	mitogen-activated protein kinase 8	Homo sapiens	169-172
19935718-4	2010	We show that before DNA fragmentation and caspase 3/7 activation, cytotoxic concentrations of 4-hydroxytamoxifen (OHT) induced JNK-dependent phosphorylation of c-Jun at JNK sites earlier shown to regulate c-Jun-mediated apoptosis.	hydroxytamoxifen	94-112	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	205-210
20086172-6	2010	In Ca(2+) mobilization studies, GPR30, but not ERalpha, mediated E(2)-induced Ca(2+) responses because E(2), 4-hydroxytamoxifen (activates GPR30), and G-1, but not DES, elicited cytosolic Ca(2+) increases not only in MCF-7 cells but also in ER-negative SKBr3 cells.	hydroxytamoxifen	109-127	G protein-coupled estrogen receptor 1	Homo sapiens	139-144
21537383-0	2010	Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis.	hydroxytamoxifen	100-118	sulfotransferase family 1A member 1	Homo sapiens	14-42
21537383-0	2010	Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis.	hydroxytamoxifen	100-118	sulfotransferase family 1A member 1	Homo sapiens	44-51
21537383-1	2010	Previously, we reported a strong association of the high activity SULT1A1*1 allele and overall survival of patients receiving tamoxifen therapy, indicating that sulfation of 4-hydroxytamoxifen (4-OHT) via SULT1A1 may contribute to the therapeutic efficacy of tamoxifen treatment.	hydroxytamoxifen	174-192	sulfotransferase family 1A member 1	Homo sapiens	66-73
21537383-1	2010	Previously, we reported a strong association of the high activity SULT1A1*1 allele and overall survival of patients receiving tamoxifen therapy, indicating that sulfation of 4-hydroxytamoxifen (4-OHT) via SULT1A1 may contribute to the therapeutic efficacy of tamoxifen treatment.	hydroxytamoxifen	174-192	sulfotransferase family 1A member 1	Homo sapiens	205-212
19654266-11	2009	Pretreatment with PIP(2) significantly decreased the inhibition induced by tamoxifen, 4-hydroxytamoxifen, and raloxifene on Kir2.3 channels.	hydroxytamoxifen	86-104	potassium inwardly rectifying channel subfamily J member 4	Homo sapiens	124-130
20086172-6	2010	In Ca(2+) mobilization studies, GPR30, but not ERalpha, mediated E(2)-induced Ca(2+) responses because E(2), 4-hydroxytamoxifen (activates GPR30), and G-1, but not DES, elicited cytosolic Ca(2+) increases not only in MCF-7 cells but also in ER-negative SKBr3 cells.	hydroxytamoxifen	109-127	G protein-coupled estrogen receptor 1	Homo sapiens	32-37
19455332-3	2010	METHODS: Concurrent treatment with 4-OH-TAM and paclitaxel (Ptx) was investigated in estrogen receptor (ER)-positive breast cancer cells.	hydroxytamoxifen	35-43	estrogen receptor 1	Homo sapiens	85-102
19455332-3	2010	METHODS: Concurrent treatment with 4-OH-TAM and paclitaxel (Ptx) was investigated in estrogen receptor (ER)-positive breast cancer cells.	hydroxytamoxifen	35-43	estrogen receptor 1	Homo sapiens	104-106
19455332-5	2010	RESULTS: Concurrent treatment with 4-OH-TAM and Ptx yielded less than additive antitumor effects in ER-positive breast cancer cells, as observed with Dox in our previous study.	hydroxytamoxifen	35-43	estrogen receptor 1	Homo sapiens	100-102
19455332-9	2010	Estrogen depletion down-regulated the level of expression of one of the molecules related to 5-FU resistance, thymidylate synthase, as observed with 4-OH-TAM in our previous study.	hydroxytamoxifen	149-157	thymidylate synthetase	Homo sapiens	110-130
19635455-0	2009	Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen.	hydroxytamoxifen	93-107	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	15-46
19809024-1	2009	CONTEXT: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	160-178	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-103
19635455-6	2009	siRNA experiments showed that PTP1B, but not TC-PTP, is necessary for resistance to 4-OH tamoxifen.	hydroxytamoxifen	84-98	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	30-35
19706837-4	2009	Tamoxifen-resistant (TamR) MCF-7 cells selected by prolonged exposure to 4-hydroxytamoxifen, exhibited higher levels in SphK1 expression and activity, compared with the control cells.	hydroxytamoxifen	73-91	sphingosine kinase 1	Homo sapiens	120-125
19574470-2	2009	CONTENT: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	122-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
19574470-2	2009	CONTENT: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	122-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
19553561-2	2009	To study mechanisms mediating effects of FoxO proteins on muscle wasting, FoxO1-estrogen receptor fusion proteins that are activated by treatment with 4-hydroxytamoxifen (4-OH-T) were stably transfected in C(2)C(12) skeletal myoblasts using the pBABE retroviral system and grown into multinucleated skeletal myotubes.	hydroxytamoxifen	151-169	forkhead box O1	Homo sapiens	74-79
19661335-6	2009	To determine that the resistance to 4-OH-Tam-inducing cell killing after the KGF treatment was due to the inactivation of the apoptotic pathway, low molecular weight DNA was isolated from cells of different treatments and inter-nucleosomal DNA fragmentation was investigated.	hydroxytamoxifen	36-44	fibroblast growth factor 7	Homo sapiens	77-80
20641702-6	2004	Active metabolites such as 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen have 30-100 times more affinity with the ER than TAM itself.	hydroxytamoxifen	27-45	Myeloproliferative syndrome, transient (transient abnormal myelopoiesis)	Homo sapiens	130-133
19830888-2	2009	The purpose of this study was to investigate whether modulation of Src activity in endocrine-sensitive and endocrine-resistant breast cancer cells directly affected their phenotype and sensitivity to 4-hydroxy Tamoxifen (tamoxifen) and to determine whether Src activity in breast cancer tissue affected patient outcome.	hydroxytamoxifen	200-219	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	67-70
19549820-6	2009	Fusion of EBF and Pax5 with the ligand-binding domain of ERalpha allowed for 4-hydroxytamoxifen-dependent, synergistic activation of mb-1 transcription in plasmacytoma cells.	hydroxytamoxifen	77-95	EBF transcription factor 1	Homo sapiens	10-13
19549820-6	2009	Fusion of EBF and Pax5 with the ligand-binding domain of ERalpha allowed for 4-hydroxytamoxifen-dependent, synergistic activation of mb-1 transcription in plasmacytoma cells.	hydroxytamoxifen	77-95	paired box 5	Homo sapiens	18-22
19549820-6	2009	Fusion of EBF and Pax5 with the ligand-binding domain of ERalpha allowed for 4-hydroxytamoxifen-dependent, synergistic activation of mb-1 transcription in plasmacytoma cells.	hydroxytamoxifen	77-95	estrogen receptor 1	Homo sapiens	57-64
19391117-2	2009	We generated mice expressing 4-hydroxytamoxifen (4HT)-regulated human ROCK II (ROCKII:mER) under the transcriptional control of the cytokeratin14 (K14) promoter.	hydroxytamoxifen	29-47	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	70-77
19391117-2	2009	We generated mice expressing 4-hydroxytamoxifen (4HT)-regulated human ROCK II (ROCKII:mER) under the transcriptional control of the cytokeratin14 (K14) promoter.	hydroxytamoxifen	29-47	keratin 14	Homo sapiens	132-145
19391117-2	2009	We generated mice expressing 4-hydroxytamoxifen (4HT)-regulated human ROCK II (ROCKII:mER) under the transcriptional control of the cytokeratin14 (K14) promoter.	hydroxytamoxifen	29-47	keratin 14	Homo sapiens	147-150
19347870-1	2009	In previous studies on HeLa cells we demonstrated estrogen-responsiveness of the epidermal growth factor receptor (EGFR) gene, as 17beta-estradiol (E(2)) and selective estrogen receptor modulators (SERMs) genistein (G), daidzein (D), and 4-hydroxytamoxifen (4OH-T) modulated its transcription in a ligand- and estrogen receptor (ER) isoform-specific way.	hydroxytamoxifen	238-256	epidermal growth factor receptor	Homo sapiens	81-113
19347870-1	2009	In previous studies on HeLa cells we demonstrated estrogen-responsiveness of the epidermal growth factor receptor (EGFR) gene, as 17beta-estradiol (E(2)) and selective estrogen receptor modulators (SERMs) genistein (G), daidzein (D), and 4-hydroxytamoxifen (4OH-T) modulated its transcription in a ligand- and estrogen receptor (ER) isoform-specific way.	hydroxytamoxifen	238-256	epidermal growth factor receptor	Homo sapiens	115-119
19244109-2	2009	A major mode of metabolism of the major active metabolites of TAM, 4-OH-TAM and endoxifen, is by glucuronidation via the UDP-glucuronosyltransferase (UGT) family of enzymes.	hydroxytamoxifen	67-75	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	121-148
19661335-12	2009	In the cell proliferation assay, KGF maintained MCF-7 cell survival in the presence of 4-OH-Tam which could be blocked by LY.	hydroxytamoxifen	87-95	fibroblast growth factor 7	Homo sapiens	33-36
19289494-5	2009	We show using a 4-hydroxytamoxifen-inducible Cre that the loss of PRMT1 in MEFs leads to a higher incidence of chromosome losses, gains, structural rearrangements, and polyploidy, as documented by spectral karyotyping.	hydroxytamoxifen	16-34	protein arginine N-methyltransferase 1	Mus musculus	66-71
19179445-5	2009	MCF-7 cells exposed to PM but not Pre-M conditions exhibited up-regulation of basal epidermal growth factor (EGF) receptor (EGFR) levels, an effect exaggerated in cells exposed to 4-hydroxytamoxifen.	hydroxytamoxifen	180-198	epidermal growth factor receptor	Homo sapiens	84-122
19179445-5	2009	MCF-7 cells exposed to PM but not Pre-M conditions exhibited up-regulation of basal epidermal growth factor (EGF) receptor (EGFR) levels, an effect exaggerated in cells exposed to 4-hydroxytamoxifen.	hydroxytamoxifen	180-198	epidermal growth factor receptor	Homo sapiens	124-128
19179445-7	2009	Long-term treatment with both 4-hydroxytamoxifen and ICI182,780 increased EGFR levels, but this was not seen in response to TAM.	hydroxytamoxifen	30-48	epidermal growth factor receptor	Homo sapiens	74-78
19264808-4	2009	The E(2)-induced reduction in miR-21 was inhibited by 4-hydroxytamoxifen (4-OHT), ICI 182 780 (Faslodex), and siRNA ER alpha indicating that the suppression is ER alpha-mediated.	hydroxytamoxifen	54-72	microRNA 21	Homo sapiens	30-36
19221464-6	2009	Under conditions of compromised autophagy, including treatments with pharmacological inhibitors and RNAi targeting of the beclin 1 gene, the cytotoxicity (death-inducing effects) of the antiestrogen 4-hydroxytamoxifen (4-OHT) was significantly increased.	hydroxytamoxifen	199-217	beclin 1	Homo sapiens	122-130
19153601-3	2009	We show here for ER-negative human breast cancer cells that the activation of GPR30 signalling by oestrogen or by hydroxytamoxifen (OHT), an ER antagonist but GPR30 agonist, induces a transcription factor network, which resembles that induced by serum in fibroblasts.	hydroxytamoxifen	114-130	G protein-coupled estrogen receptor 1	Homo sapiens	78-83
19153601-3	2009	We show here for ER-negative human breast cancer cells that the activation of GPR30 signalling by oestrogen or by hydroxytamoxifen (OHT), an ER antagonist but GPR30 agonist, induces a transcription factor network, which resembles that induced by serum in fibroblasts.	hydroxytamoxifen	114-130	G protein-coupled estrogen receptor 1	Homo sapiens	159-164
19244109-6	2009	For active hepatic UGTs, the UGT2B7(268Tyr) variant exhibited significant (P < 0.01) 2- and 5-fold decreases in activity against the trans isomers of 4-OH-TAM and endoxifen, respectively, compared with wild-type UGT2B7(268His).	hydroxytamoxifen	153-161	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	29-35
19244109-6	2009	For active hepatic UGTs, the UGT2B7(268Tyr) variant exhibited significant (P < 0.01) 2- and 5-fold decreases in activity against the trans isomers of 4-OH-TAM and endoxifen, respectively, compared with wild-type UGT2B7(268His).	hydroxytamoxifen	153-161	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	215-221
19244109-2	2009	A major mode of metabolism of the major active metabolites of TAM, 4-OH-TAM and endoxifen, is by glucuronidation via the UDP-glucuronosyltransferase (UGT) family of enzymes.	hydroxytamoxifen	67-75	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	150-153
18974135-6	2008	Selection for resistance to 4-hydroxytamoxifen led to the development of the SUM44/LCCTam cell line, which exhibits decreased expression of ERalpha and increased expression of the estrogen-related receptor gamma (ERRgamma).	hydroxytamoxifen	28-46	estrogen receptor 1	Homo sapiens	140-147
19212635-2	2009	In addition, using proteolysis assays, we tested the conformational changes induced in ERalpha and ERbeta by CH4893237, fulvestrant, and 4-OH tamoxifen (4OHT).	hydroxytamoxifen	137-151	estrogen receptor 1	Homo sapiens	87-94
19212635-2	2009	In addition, using proteolysis assays, we tested the conformational changes induced in ERalpha and ERbeta by CH4893237, fulvestrant, and 4-OH tamoxifen (4OHT).	hydroxytamoxifen	137-151	estrogen receptor 2	Homo sapiens	99-105
19202055-6	2009	We found that AID-ER, but not JP8Bdel-ER, caused a CSR to IgA from the addition of 4-hydroxy tamoxifen.	hydroxytamoxifen	83-102	activation induced cytidine deaminase	Homo sapiens	14-17
18822397-9	2009	In addition, the ERR antagonists 4-hydroxytamoxifen and diethylstilbestrol inhibited the Hr-ERR-mediated transactivation, whereas Hr-ERR activity on ERE was further induced by genistein, an ERRalpha agonist.	hydroxytamoxifen	33-51	solute carrier family 7 member 1	Homo sapiens	17-20
18822397-9	2009	In addition, the ERR antagonists 4-hydroxytamoxifen and diethylstilbestrol inhibited the Hr-ERR-mediated transactivation, whereas Hr-ERR activity on ERE was further induced by genistein, an ERRalpha agonist.	hydroxytamoxifen	33-51	solute carrier family 7 member 1	Homo sapiens	92-95
18822397-9	2009	In addition, the ERR antagonists 4-hydroxytamoxifen and diethylstilbestrol inhibited the Hr-ERR-mediated transactivation, whereas Hr-ERR activity on ERE was further induced by genistein, an ERRalpha agonist.	hydroxytamoxifen	33-51	solute carrier family 7 member 1	Homo sapiens	92-95
18822397-9	2009	In addition, the ERR antagonists 4-hydroxytamoxifen and diethylstilbestrol inhibited the Hr-ERR-mediated transactivation, whereas Hr-ERR activity on ERE was further induced by genistein, an ERRalpha agonist.	hydroxytamoxifen	33-51	estrogen related receptor alpha	Homo sapiens	190-198
19197145-4	2009	In cultured cells, activation of a conditional, KLF4-estrogen receptor fusion protein by 4-hydroxytamoxifen resulted in rapid upregulation of transcripts for nuclear receptors including RARgamma and RXRalpha.	hydroxytamoxifen	89-107	Kruppel-like factor 4 (gut)	Mus musculus	48-52
19197145-4	2009	In cultured cells, activation of a conditional, KLF4-estrogen receptor fusion protein by 4-hydroxytamoxifen resulted in rapid upregulation of transcripts for nuclear receptors including RARgamma and RXRalpha.	hydroxytamoxifen	89-107	retinoic acid receptor, gamma	Mus musculus	186-194
19197145-4	2009	In cultured cells, activation of a conditional, KLF4-estrogen receptor fusion protein by 4-hydroxytamoxifen resulted in rapid upregulation of transcripts for nuclear receptors including RARgamma and RXRalpha.	hydroxytamoxifen	89-107	retinoid X receptor alpha	Mus musculus	199-207
18974135-6	2008	Selection for resistance to 4-hydroxytamoxifen led to the development of the SUM44/LCCTam cell line, which exhibits decreased expression of ERalpha and increased expression of the estrogen-related receptor gamma (ERRgamma).	hydroxytamoxifen	28-46	estrogen related receptor gamma	Homo sapiens	213-221
18974135-6	2008	Selection for resistance to 4-hydroxytamoxifen led to the development of the SUM44/LCCTam cell line, which exhibits decreased expression of ERalpha and increased expression of the estrogen-related receptor gamma (ERRgamma).	hydroxytamoxifen	28-46	estrogen related receptor gamma	Homo sapiens	180-211
19016759-4	2008	The ERalpha-positive human breast adenocarcinoma derived-MCF-7 cells used in this study have acquired both cross-resistance to hydroxy-tamoxifen (OH-Tam) and to fulvestrant and strong activation of the Akt/mTOR pathway.	hydroxytamoxifen	127-144	estrogen receptor 1	Homo sapiens	4-11
18922978-0	2008	An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.	hydroxytamoxifen	70-88	vascular endothelial growth factor A	Homo sapiens	13-17
18922978-0	2008	An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.	hydroxytamoxifen	70-88	kinase insert domain receptor	Homo sapiens	18-24
18922978-0	2008	An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.	hydroxytamoxifen	70-88	mitogen-activated protein kinase 14	Homo sapiens	29-32
18678925-9	2008	The 3ERT PDB crystal structure has the estrogen receptor bound to the cancer drug 4-hydroxytamoxifen.	hydroxytamoxifen	82-100	estrogen receptor 1	Homo sapiens	39-56
18782222-5	2008	First, we employed an embryonic forelimb organ culture of transgenic mice expressing an Akt-Mer (a ligand-binding domain of a mutated estrogen receptor) fusion protein whose kinase activity was conditionally activated by treatment with 4-hydroxytamoxifen (4OHT).	hydroxytamoxifen	236-254	AKT serine/threonine kinase 1	Homo sapiens	88-91
18499701-6	2008	However, treatment with 4-hydroxytamoxifen (4-OHT), an antiestrogen, abrogates the ERalpha-mediated suppression in cancer cells.	hydroxytamoxifen	24-42	estrogen receptor 1	Homo sapiens	83-90
18790785-6	2008	4-hydroxytamoxifen (TAM; 10(-7) mol/L) alone resulted in cell cycle arrest but no apoptosis, whereas MSA alone (10 micromol/L) induced apoptosis in tamoxifen-sensitive cells.	hydroxytamoxifen	0-18	Myeloproliferative syndrome, transient (transient abnormal myelopoiesis)	Homo sapiens	20-23
18264725-11	2008	Cell cycle analysis showed AZA + TSA treated cells showed S phase arrest, which was partially attenuated by addition of estradiol (E2); furthermore, the effect of E2 on stimulation of cell cycle could be reversed by 4-OHT in the treated cells with induced ER alpha.	hydroxytamoxifen	216-221	estrogen receptor 1	Homo sapiens	256-264
18508261-7	2008	We show that ICI-182780, raloxifene, 4-hydroxytamoxifen and estradiol all exhibit differential agonistic activities on the MMP1 promoter by suppressing activity by 20-80%.	hydroxytamoxifen	37-55	matrix metallopeptidase 1	Homo sapiens	123-127
18338336-7	2008	This could have been because the contribution of CYP3A to the formation of 4-hydroxytamoxifen is not considerable in rats.	hydroxytamoxifen	75-93	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	49-54
18337247-7	2008	In tamoxifen-resistant breast cancer cells that overexpress ERalpha, TPBM inhibited 17beta-estradiol (E(2))-ERalpha (IC(50) 9 microm) and 4-hydroxytamoxifen-ERalpha-mediated gene expression.	hydroxytamoxifen	138-156	estrogen receptor 1	Homo sapiens	60-67
18294285-1	2008	The clinical outcomes of breast cancer patients treated with tamoxifen may be influenced by the activity of cytochrome P450 2D6 (CYP2D6) enzyme because tamixifen is metabolized by CYP2D6 to its active forms of antiestrogenic metabolite, 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	237-255	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	108-127
18299335-0	2008	Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells.	hydroxytamoxifen	52-70	nuclear receptor subfamily 1 group I member 2	Homo sapiens	14-33
18299335-0	2008	Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells.	hydroxytamoxifen	52-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
18299335-1	2008	Previously we observed that the antiestrogens tamoxifen and 4-hydroxytamoxifen (4OHT) induce CYP3A4 in primary human hepatocytes and activate human pregnane X receptor (PXR) in cell-based reporter assays.	hydroxytamoxifen	60-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
18299335-1	2008	Previously we observed that the antiestrogens tamoxifen and 4-hydroxytamoxifen (4OHT) induce CYP3A4 in primary human hepatocytes and activate human pregnane X receptor (PXR) in cell-based reporter assays.	hydroxytamoxifen	60-78	nuclear receptor subfamily 1 group I member 2	Homo sapiens	148-167
18299335-1	2008	Previously we observed that the antiestrogens tamoxifen and 4-hydroxytamoxifen (4OHT) induce CYP3A4 in primary human hepatocytes and activate human pregnane X receptor (PXR) in cell-based reporter assays.	hydroxytamoxifen	60-78	nuclear receptor subfamily 1 group I member 2	Homo sapiens	169-172
18294285-1	2008	The clinical outcomes of breast cancer patients treated with tamoxifen may be influenced by the activity of cytochrome P450 2D6 (CYP2D6) enzyme because tamixifen is metabolized by CYP2D6 to its active forms of antiestrogenic metabolite, 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	237-255	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	129-135
18294285-1	2008	The clinical outcomes of breast cancer patients treated with tamoxifen may be influenced by the activity of cytochrome P450 2D6 (CYP2D6) enzyme because tamixifen is metabolized by CYP2D6 to its active forms of antiestrogenic metabolite, 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	237-255	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	180-186
18006630-3	2008	This activation was blocked by treatment with estrogen receptor (ER) antagonists 4-hydroxytamoxifen and ICI-182,780.	hydroxytamoxifen	81-99	estrogen receptor 1	Homo sapiens	46-63
21479421-4	2008	Transient expression of p72, AIB1 and erbB-2 in human embryonic kidney 293T cells led to a synergistic promotion of the transactivation function of ERalpha in the presence of 17alpha-estradiol or 4-hydroxytamoxifen, an ERalpha AF-1 agonist/AF-2 antagonist, as a ligand.	hydroxytamoxifen	196-214	DEAD-box helicase 17	Homo sapiens	24-27
21479421-4	2008	Transient expression of p72, AIB1 and erbB-2 in human embryonic kidney 293T cells led to a synergistic promotion of the transactivation function of ERalpha in the presence of 17alpha-estradiol or 4-hydroxytamoxifen, an ERalpha AF-1 agonist/AF-2 antagonist, as a ligand.	hydroxytamoxifen	196-214	ANIB1	Homo sapiens	29-33
21479421-4	2008	Transient expression of p72, AIB1 and erbB-2 in human embryonic kidney 293T cells led to a synergistic promotion of the transactivation function of ERalpha in the presence of 17alpha-estradiol or 4-hydroxytamoxifen, an ERalpha AF-1 agonist/AF-2 antagonist, as a ligand.	hydroxytamoxifen	196-214	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-44
21479421-4	2008	Transient expression of p72, AIB1 and erbB-2 in human embryonic kidney 293T cells led to a synergistic promotion of the transactivation function of ERalpha in the presence of 17alpha-estradiol or 4-hydroxytamoxifen, an ERalpha AF-1 agonist/AF-2 antagonist, as a ligand.	hydroxytamoxifen	196-214	estrogen receptor 1	Homo sapiens	148-155
18409049-4	2008	Treatment with H-89, a specific PKA inhibitor, suppressed 4-hydroxytamoxifen-induced ErbB2 expression in control MCF-7 cells.	hydroxytamoxifen	58-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-90
18216173-5	2008	We used transgenic mice that expressed an AKT-MER fusion protein, the kinase activity of which could be regulated by the ligand of modified estrogen receptor (MER), 4-hydroxytamoxifen.	hydroxytamoxifen	165-183	thymoma viral proto-oncogene 1	Mus musculus	42-45
18216173-5	2008	We used transgenic mice that expressed an AKT-MER fusion protein, the kinase activity of which could be regulated by the ligand of modified estrogen receptor (MER), 4-hydroxytamoxifen.	hydroxytamoxifen	165-183	G protein-coupled estrogen receptor 1	Mus musculus	46-49
18216173-5	2008	We used transgenic mice that expressed an AKT-MER fusion protein, the kinase activity of which could be regulated by the ligand of modified estrogen receptor (MER), 4-hydroxytamoxifen.	hydroxytamoxifen	165-183	estrogen receptor 1 (alpha)	Mus musculus	140-157
18288420-5	2008	Treatment with ligand 17-beta estradiol diminished the HER2 expression in MCF-7 wild-type cells, an effect partially inhibited by treatment with 4-OH tamoxifen.	hydroxytamoxifen	145-159	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
18372406-6	2008	Further, we show that, although S118 is important for the stimulation of ERalpha activity by the selective ER modulator 4-hydroxytamoxifen (OHT), S104 and S106 are also required for the agonist activity of OHT.	hydroxytamoxifen	120-138	estrogen receptor 1	Homo sapiens	73-80
18347152-3	2008	Analysis of transfected K562, KD30, and KD225 cells in which FOXO3a activity can be induced by 4-hydroxytamoxifen showed that FOXO3a up-regulates ABCB1 expression at protein, mRNA, and gene promoter levels.	hydroxytamoxifen	95-113	forkhead box O3	Homo sapiens	61-67
18347152-3	2008	Analysis of transfected K562, KD30, and KD225 cells in which FOXO3a activity can be induced by 4-hydroxytamoxifen showed that FOXO3a up-regulates ABCB1 expression at protein, mRNA, and gene promoter levels.	hydroxytamoxifen	95-113	forkhead box O3	Homo sapiens	126-132
18347152-3	2008	Analysis of transfected K562, KD30, and KD225 cells in which FOXO3a activity can be induced by 4-hydroxytamoxifen showed that FOXO3a up-regulates ABCB1 expression at protein, mRNA, and gene promoter levels.	hydroxytamoxifen	95-113	ATP binding cassette subfamily B member 1	Homo sapiens	146-151
18006630-3	2008	This activation was blocked by treatment with estrogen receptor (ER) antagonists 4-hydroxytamoxifen and ICI-182,780.	hydroxytamoxifen	81-99	estrogen receptor 1	Homo sapiens	65-67
18223215-8	2008	Importantly, CEACAM6 silencing restored sensitivity of TAMr cells to 4-hydroxytamoxifen and proliferative response to 17beta-estradiol.	hydroxytamoxifen	69-87	CEA cell adhesion molecule 6	Homo sapiens	13-20
17986386-4	2008	Similarly, SeP mRNA was upregulated in response to activation of FoxO1a in rat hepatoma cells stably transfected with a hydroxytamoxifen-regulatable form of FoxO1a.	hydroxytamoxifen	120-136	selenoprotein P	Homo sapiens	11-14
17986386-4	2008	Similarly, SeP mRNA was upregulated in response to activation of FoxO1a in rat hepatoma cells stably transfected with a hydroxytamoxifen-regulatable form of FoxO1a.	hydroxytamoxifen	120-136	forkhead box O1	Rattus norvegicus	65-71
17986386-4	2008	Similarly, SeP mRNA was upregulated in response to activation of FoxO1a in rat hepatoma cells stably transfected with a hydroxytamoxifen-regulatable form of FoxO1a.	hydroxytamoxifen	120-136	forkhead box O1	Rattus norvegicus	157-163
18637494-4	2008	Tamoxifen requires "metabolic activation" catalyzed by cytochrome P450 2D6 (CYP2D6) to form hydroxylated metabolites-4-hydroxytamoxifen and endoxifen (N-desmethyl-4-hydroxytamoxifen)-both of which are much more potent than is the parent drug.	hydroxytamoxifen	117-135	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-74
17947222-1	2008	BACKGROUND: Tamoxifen is hydroxylated by cytochrome P450 (CYP) 2D6 to the potent metabolites 4-hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam), which are both conjugated by sulphotransferase (SULT)1A1.	hydroxytamoxifen	93-111	sulfotransferase family 1A member 1	Homo sapiens	215-223
18637494-4	2008	Tamoxifen requires "metabolic activation" catalyzed by cytochrome P450 2D6 (CYP2D6) to form hydroxylated metabolites-4-hydroxytamoxifen and endoxifen (N-desmethyl-4-hydroxytamoxifen)-both of which are much more potent than is the parent drug.	hydroxytamoxifen	117-135	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	76-82
18043895-7	2008	Only two metabolites 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen had significant antiproliferative activity and were able to induce TGFbeta2 and TbetaRII.	hydroxytamoxifen	21-39	transforming growth factor beta 2	Homo sapiens	142-150
18043895-7	2008	Only two metabolites 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen had significant antiproliferative activity and were able to induce TGFbeta2 and TbetaRII.	hydroxytamoxifen	21-39	transforming growth factor beta receptor 2	Homo sapiens	155-163
18197296-2	2008	We have recently demonstrated that BPA binds strongly to human estrogen-related receptor-gamma (ERR-gamma ) in a binding assay using [3H]4-hydroxytamoxifen ([3H]4-OHT).	hydroxytamoxifen	137-155	estrogen related receptor gamma	Homo sapiens	63-94
18197296-2	2008	We have recently demonstrated that BPA binds strongly to human estrogen-related receptor-gamma (ERR-gamma ) in a binding assay using [3H]4-hydroxytamoxifen ([3H]4-OHT).	hydroxytamoxifen	137-155	estrogen related receptor gamma	Homo sapiens	96-105
17900262-4	2007	To this end, we generated a 4-hydroxytamoxifen-inducible active FKHRL1 (FKHRL1-TM; a triple mutant of FKHRL1 in which all three Akt phosphorylation sites have been mutated)-estrogen receptor fusion protein expression system in CML-derived imatinib-resistant cell lines.	hydroxytamoxifen	28-46	forkhead box O3	Homo sapiens	64-70
17964775-4	2008	These ligands were further characterized and found to be competitive for 4-hydroxytamoxifen (4OHT) binding, a known reported antagonist ligand for ERRgamma, but functionally they did not enhance or disrupt affinity of the receptor for co-activator peptides.	hydroxytamoxifen	73-91	estrogen related receptor gamma	Homo sapiens	147-155
18827493-5	2008	The expression of AIB1, ERalpha, HER2 and pS2 was analyzed in the presence of 17beta-estradiol or 4-hydroxytamoxifen (Tam) by Western blot analysis.	hydroxytamoxifen	98-116	HEAT repeat containing 6	Homo sapiens	18-22
18827493-5	2008	The expression of AIB1, ERalpha, HER2 and pS2 was analyzed in the presence of 17beta-estradiol or 4-hydroxytamoxifen (Tam) by Western blot analysis.	hydroxytamoxifen	98-116	trefoil factor 1	Homo sapiens	42-45
17900262-5	2007	4-Hydroxytamoxifen inhibited cell growth and cell cycle progression, and subsequently induced apoptosis, accompanied by upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).	hydroxytamoxifen	0-18	TNF superfamily member 10	Homo sapiens	136-191
17900262-4	2007	To this end, we generated a 4-hydroxytamoxifen-inducible active FKHRL1 (FKHRL1-TM; a triple mutant of FKHRL1 in which all three Akt phosphorylation sites have been mutated)-estrogen receptor fusion protein expression system in CML-derived imatinib-resistant cell lines.	hydroxytamoxifen	28-46	forkhead box O3	Homo sapiens	72-78
17900262-5	2007	4-Hydroxytamoxifen inhibited cell growth and cell cycle progression, and subsequently induced apoptosis, accompanied by upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).	hydroxytamoxifen	0-18	TNF superfamily member 10	Homo sapiens	193-198
17900262-4	2007	To this end, we generated a 4-hydroxytamoxifen-inducible active FKHRL1 (FKHRL1-TM; a triple mutant of FKHRL1 in which all three Akt phosphorylation sites have been mutated)-estrogen receptor fusion protein expression system in CML-derived imatinib-resistant cell lines.	hydroxytamoxifen	28-46	forkhead box O3	Homo sapiens	72-78
18005256-4	2007	Bisphenol A functions as an inverse antagonist of estrogen-related receptor gamma to sustain the high basal constitutive activity of the latter and to reverse the deactivating inverse agonist activity of 4-hydroxytamoxifen.	hydroxytamoxifen	204-222	estrogen related receptor gamma	Homo sapiens	50-81
18365873-4	2007	Following treatment with the oestrogen analogue 4-hydroxy tamoxifen of murine embryonic stem cells expressing this protein, we have identified by microarray analysis, several potential targets of Dnmt3a mediated transcriptional repression including the cancer associated genes Ssx2ip, Hmga1 and Wrnip.	hydroxytamoxifen	48-67	DNA methyltransferase 3A	Mus musculus	196-202
18365873-4	2007	Following treatment with the oestrogen analogue 4-hydroxy tamoxifen of murine embryonic stem cells expressing this protein, we have identified by microarray analysis, several potential targets of Dnmt3a mediated transcriptional repression including the cancer associated genes Ssx2ip, Hmga1 and Wrnip.	hydroxytamoxifen	48-67	synovial sarcoma, X 2 interacting protein	Mus musculus	277-283
18365873-4	2007	Following treatment with the oestrogen analogue 4-hydroxy tamoxifen of murine embryonic stem cells expressing this protein, we have identified by microarray analysis, several potential targets of Dnmt3a mediated transcriptional repression including the cancer associated genes Ssx2ip, Hmga1 and Wrnip.	hydroxytamoxifen	48-67	high mobility group AT-hook 1	Mus musculus	285-290
18365873-4	2007	Following treatment with the oestrogen analogue 4-hydroxy tamoxifen of murine embryonic stem cells expressing this protein, we have identified by microarray analysis, several potential targets of Dnmt3a mediated transcriptional repression including the cancer associated genes Ssx2ip, Hmga1 and Wrnip.	hydroxytamoxifen	48-67	Werner helicase interacting protein 1	Mus musculus	295-300
17761695-4	2007	BPA preserves the ERR gamma"s basal constitutive activity, and protects the selective ER modulator 4-hydroxytamoxifen from its deactivation of ERR gamma.	hydroxytamoxifen	99-117	estrogen related receptor gamma	Homo sapiens	143-152
17929966-3	2007	A polymer conjugated to the 4-hydroxytamoxifen analogue with a six-carbon linker showed high affinity for both estrogen receptor alpha and estrogen receptor beta and potent antagonism of the estrogen receptor in cell-based transcriptional reporter assays.	hydroxytamoxifen	28-46	estrogen receptor 1	Homo sapiens	111-134
17929966-3	2007	A polymer conjugated to the 4-hydroxytamoxifen analogue with a six-carbon linker showed high affinity for both estrogen receptor alpha and estrogen receptor beta and potent antagonism of the estrogen receptor in cell-based transcriptional reporter assays.	hydroxytamoxifen	28-46	estrogen receptor 2	Homo sapiens	139-161
17929966-3	2007	A polymer conjugated to the 4-hydroxytamoxifen analogue with a six-carbon linker showed high affinity for both estrogen receptor alpha and estrogen receptor beta and potent antagonism of the estrogen receptor in cell-based transcriptional reporter assays.	hydroxytamoxifen	28-46	estrogen receptor 1	Homo sapiens	111-128
17929966-4	2007	These results suggest that the conjugation of 4-hydroxytamoxifen to a polymer results in a macromolecular conjugate that can display ligand in a manner that can be recognized by estrogen receptor and still act as a potent antiestrogen in cells.	hydroxytamoxifen	46-64	estrogen receptor 1	Homo sapiens	178-195
17664247-4	2007	In the present study, characterization of the glucuronidating activities of human UDP glucuronosyltransferases (UGTs) against isomers of 4-OH-TAM and endoxifen was performed.	hydroxytamoxifen	137-145	beta-1,3-glucuronyltransferase 2	Homo sapiens	82-110
17664247-4	2007	In the present study, characterization of the glucuronidating activities of human UDP glucuronosyltransferases (UGTs) against isomers of 4-OH-TAM and endoxifen was performed.	hydroxytamoxifen	137-145	beta-1,3-glucuronyltransferase 2	Homo sapiens	112-116
17664247-10	2007	These data suggest that several UGTs, including UGTs 1A10, 2B7, and 1A8 play an important role in the metabolism of 4-OH-TAM and endoxifen.	hydroxytamoxifen	116-124	beta-1,3-glucuronyltransferase 2	Homo sapiens	32-36
17664247-10	2007	These data suggest that several UGTs, including UGTs 1A10, 2B7, and 1A8 play an important role in the metabolism of 4-OH-TAM and endoxifen.	hydroxytamoxifen	116-124	beta-1,3-glucuronyltransferase 2	Homo sapiens	48-52
17716978-1	2007	Low concentrations of tamoxifen or its active metabolite 4-hydroxytamoxifen (OHT) induce estrogen receptor alpha (ERalpha)-dependent apoptosis.	hydroxytamoxifen	57-75	estrogen receptor 1	Homo sapiens	89-112
17716978-1	2007	Low concentrations of tamoxifen or its active metabolite 4-hydroxytamoxifen (OHT) induce estrogen receptor alpha (ERalpha)-dependent apoptosis.	hydroxytamoxifen	57-75	estrogen receptor 1	Homo sapiens	114-121
17646931-0	2007	Regulation of intracellular calcium release and PP1alpha in a mechanism for 4-hydroxytamoxifen-induced cytotoxicity.	hydroxytamoxifen	76-94	protein phosphatase 1 catalytic subunit alpha	Homo sapiens	48-56
17714751-0	2007	Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death.	hydroxytamoxifen	57-75	mitogen-activated protein kinase 3	Homo sapiens	23-29
17637499-4	2007	MATERIALS AND METHODS: Multipotent FDCP-mix cell lines engineered to permit the conditional induction of the constitutively active intracellular domain of mNotch1 (mN1(IC)) by the 4-hydroxytamoxifen (OHT)-inducible system were used to analyze the effects of activated mNotch1 on erythroid differentiation and on expression of Gata1, Fog1, Eklf, NF-E2, and beta-globin.	hydroxytamoxifen	180-198	notch 1	Mus musculus	155-162
17637499-4	2007	MATERIALS AND METHODS: Multipotent FDCP-mix cell lines engineered to permit the conditional induction of the constitutively active intracellular domain of mNotch1 (mN1(IC)) by the 4-hydroxytamoxifen (OHT)-inducible system were used to analyze the effects of activated mNotch1 on erythroid differentiation and on expression of Gata1, Fog1, Eklf, NF-E2, and beta-globin.	hydroxytamoxifen	180-198	notch 1	Mus musculus	164-167
17297448-3	2007	We examined the effect of Akt signaling in epidermal cells in transgenic mice expressing an Akt-Mer fusion protein whose kinase activity was conditionally activated by treatment with 4-hydroxytamoxifen (4OHT).	hydroxytamoxifen	183-201	thymoma viral proto-oncogene 1	Mus musculus	92-95
17615152-0	2007	A functional serine 118 phosphorylation site in estrogen receptor-alpha is required for down-regulation of gene expression by 17beta-estradiol and 4-hydroxytamoxifen.	hydroxytamoxifen	147-165	estrogen receptor 1	Homo sapiens	48-71
17458895-7	2007	Finally, the IGF-I-induced response on cell growth and ER-mediated transactivation can be inhibited with either ICI or 4-OH-Tam.	hydroxytamoxifen	119-127	insulin-like growth factor 1	Mus musculus	13-18
17556356-8	2007	This is in contrast to ERRgamma but resembles the situation for ERalpha (raloxifene or 4-hydroxytamoxifen complexes).	hydroxytamoxifen	87-105	estrogen receptor 1	Homo sapiens	64-71
17384075-4	2007	Specifically, we have used QCM-D, in combination with surface plasmon resonance (SPR) spectroscopy, to monitor the binding of ERalpha to a specific DNA (estrogen response element, ERE) and a nonspecific DNA in the presence of either the agonist ligand, 17b-estradiol, the partial antagonist ligand, 4-hydroxytamoxifen, or vehicle alone.	hydroxytamoxifen	299-317	estrogen receptor 1	Homo sapiens	126-133
17009105-4	2007	The effect of E2 on psoriasin/S100A7 was inhibited by 4-hydroxytamoxifen and ICI 182780 but not with a selective ERalpha antagonist.	hydroxytamoxifen	54-72	S100 calcium binding protein A7	Homo sapiens	30-36
17482685-6	2007	Indeed, a 4-hydroxytamoxifen activated E2F-1-ER fusion protein induced FOXO expression in the presence of cycloheximide.	hydroxytamoxifen	10-28	E2F transcription factor 1	Rattus norvegicus	39-44
17173074-4	2007	An E2F1-estrogen receptor fusion protein activated the endogenous p57 promoter in response to hydroxytamoxifen treatment in the presence of cycloheximide.	hydroxytamoxifen	94-110	E2F transcription factor 1	Homo sapiens	3-7
17173074-4	2007	An E2F1-estrogen receptor fusion protein activated the endogenous p57 promoter in response to hydroxytamoxifen treatment in the presence of cycloheximide.	hydroxytamoxifen	94-110	cyclin dependent kinase inhibitor 1C	Homo sapiens	66-69
17272397-6	2007	In HEK293 cells, SHP-1 was inhibited by raloxifene and 4-hydroxytamoxifen, whereas the latter additionally inhibited SHP-2.	hydroxytamoxifen	55-73	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	17-22
17348852-8	2007	The structure-activity relationships for the active ligands were further explored in a computational study where docked structures of the active compounds were compared with the X-ray crystal structures for the complexes of ER alpha with 4-hydroxytamoxifen and ER beta with raloxifene.	hydroxytamoxifen	238-256	estrogen receptor 1	Homo sapiens	224-232
17339440-6	2007	By temporally controlling the expression of T-bet-estrogen receptor alpha by the addition or removal of 4-hydroxytamoxifen (4-HT), we show that IFN-gamma, CD122, and CxCR3 are direct gene targets of T-bet whose expression are acutely regulated by T-bet activity.	hydroxytamoxifen	104-122	T-box transcription factor 21	Homo sapiens	44-49
17339440-6	2007	By temporally controlling the expression of T-bet-estrogen receptor alpha by the addition or removal of 4-hydroxytamoxifen (4-HT), we show that IFN-gamma, CD122, and CxCR3 are direct gene targets of T-bet whose expression are acutely regulated by T-bet activity.	hydroxytamoxifen	104-122	estrogen receptor 1	Homo sapiens	50-73
17339440-6	2007	By temporally controlling the expression of T-bet-estrogen receptor alpha by the addition or removal of 4-hydroxytamoxifen (4-HT), we show that IFN-gamma, CD122, and CxCR3 are direct gene targets of T-bet whose expression are acutely regulated by T-bet activity.	hydroxytamoxifen	104-122	interferon gamma	Homo sapiens	144-153
17339440-6	2007	By temporally controlling the expression of T-bet-estrogen receptor alpha by the addition or removal of 4-hydroxytamoxifen (4-HT), we show that IFN-gamma, CD122, and CxCR3 are direct gene targets of T-bet whose expression are acutely regulated by T-bet activity.	hydroxytamoxifen	104-122	interleukin 2 receptor subunit beta	Homo sapiens	155-160
17339440-6	2007	By temporally controlling the expression of T-bet-estrogen receptor alpha by the addition or removal of 4-hydroxytamoxifen (4-HT), we show that IFN-gamma, CD122, and CxCR3 are direct gene targets of T-bet whose expression are acutely regulated by T-bet activity.	hydroxytamoxifen	104-122	C-X-C motif chemokine receptor 3	Homo sapiens	166-171
17339440-6	2007	By temporally controlling the expression of T-bet-estrogen receptor alpha by the addition or removal of 4-hydroxytamoxifen (4-HT), we show that IFN-gamma, CD122, and CxCR3 are direct gene targets of T-bet whose expression are acutely regulated by T-bet activity.	hydroxytamoxifen	104-122	T-box transcription factor 21	Homo sapiens	199-204
17339440-6	2007	By temporally controlling the expression of T-bet-estrogen receptor alpha by the addition or removal of 4-hydroxytamoxifen (4-HT), we show that IFN-gamma, CD122, and CxCR3 are direct gene targets of T-bet whose expression are acutely regulated by T-bet activity.	hydroxytamoxifen	104-122	T-box transcription factor 21	Homo sapiens	199-204
17464340-0	2007	Effects of estradiol and 4-hydroxytamoxifen on the conformation, thermal stability, and DNA recognition of estrogen receptor beta.	hydroxytamoxifen	25-43	estrogen receptor 2	Homo sapiens	107-129
17135255-4	2007	Binding of SRC1a to flERE.ERalpha and to flERE.ERbeta was 17beta-estradiol (E2)-dependent and was nearly absent when ICI 182,780, raloxifene, or 4-hydroxytamoxifen were bound to the ERs.	hydroxytamoxifen	145-163	estrogen receptor 2	Homo sapiens	47-53
17464340-2	2007	We examined the effects of estradiol (E2), 4-hydroxytamoxifen (HT), and the estrogen response element (ERE) on the helical content and thermal unfolding of ERbeta.	hydroxytamoxifen	43-61	estrogen receptor 2	Homo sapiens	156-162
17047084-4	2006	The orphan nuclear receptor chicken ovalbumin upstream promoter transcription factor (COUP-TF)-I interacts directly with 4-hydroxytamoxifen (4-OHT)- and estradiol (E(2))-occupied ERalpha, corepressors NCoR and SMRT, and inhibit E(2)-induced gene transcription in breast cancer cells.	hydroxytamoxifen	121-139	nuclear receptor subfamily 2 group F member 1	Gallus gallus	86-96
17108112-2	2006	In this study, we investigated the effect of chronic PKB activation on cellular survival and proliferation using cytokine-dependent bone marrow-derived Ba/F3 cells, in which PKBalpha activation can be directly, and specifically, induced by addition of 4-hydroxytamoxifen (4-OHT).	hydroxytamoxifen	252-270	thymoma viral proto-oncogene 1	Mus musculus	174-182
16926159-6	2006	In the presence of 4-hydroxytamoxifen STAT3-ER was translocated in the nucleus of HepG2 cells in a phosphorylation-independent manner, and treatment with PDTC mitigated the response.	hydroxytamoxifen	19-37	signal transducer and activator of transcription 3	Homo sapiens	38-43
17897439-12	2007	Furthermore, Wnt1 rescues estrogen receptor-positive (ER+) breast cancer cells from the anti-proliferative effects of 4-hydroxytamoxifen (4-HT) and this activity can be blocked by an EGFR tyrosine kinase inhibitor.	hydroxytamoxifen	118-136	Wnt family member 1	Homo sapiens	13-17
17897439-12	2007	Furthermore, Wnt1 rescues estrogen receptor-positive (ER+) breast cancer cells from the anti-proliferative effects of 4-hydroxytamoxifen (4-HT) and this activity can be blocked by an EGFR tyrosine kinase inhibitor.	hydroxytamoxifen	118-136	epidermal growth factor receptor	Homo sapiens	183-187
17216603-6	2007	administration of 4-OHT on Cre-mediated, heart-specific inactivation of thioredoxin reductase 2.	hydroxytamoxifen	18-23	thioredoxin reductase 2	Mus musculus	72-95
17008385-5	2007	We studied the effects of estradiol and the clinically useful SERMs 4-hydroxytamoxifen and fulvestrant on the conformation of the full-length ERalpha dimer complex by comparing, in living human breast cancer cells, the amounts of energy transfer between fluorophores attached to different domains of ERalpha.	hydroxytamoxifen	68-86	estrogen receptor 1	Homo sapiens	142-149
17008385-6	2007	Estradiol, 4-hydroxytamoxifen, and fulvestrant all promoted the rapid formation of ERalpha dimers with equivalent interaction kinetics.	hydroxytamoxifen	11-29	estrogen receptor 1	Homo sapiens	83-90
17008385-7	2007	The amino- and carboxyl-terminal ERalpha domains both contain activation functions differentially affected by these ligands, but the positions of only the carboxyl termini differed upon binding with estradiol, 4-hydroxytamoxifen, or fulvestrant.	hydroxytamoxifen	210-228	estrogen receptor 1	Homo sapiens	33-40
17047084-4	2006	The orphan nuclear receptor chicken ovalbumin upstream promoter transcription factor (COUP-TF)-I interacts directly with 4-hydroxytamoxifen (4-OHT)- and estradiol (E(2))-occupied ERalpha, corepressors NCoR and SMRT, and inhibit E(2)-induced gene transcription in breast cancer cells.	hydroxytamoxifen	121-139	estrogen receptor 1	Gallus gallus	179-186
16889744-2	2006	Although its physiological ligand is unknown, ERRgamma has been shown to interact with synthetic estrogenic compounds such as 4-hydroxytamoxifen (4-OHT), tamoxifen, and diethylstilbestrol (DES).	hydroxytamoxifen	126-144	estrogen related receptor gamma	Homo sapiens	46-54
16828306-4	2006	By crossing neurogenin 2 (Ngn2-CreER) with Cre-reporter mice expressing YFP or GFP reporter genes, it was possible to observe living cells after treating slice cultures with 4-hydroxytamoxifen to induce Cre recombinase activation.	hydroxytamoxifen	174-192	neurogenin 2	Mus musculus	12-24
16782818-0	2006	A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta.	hydroxytamoxifen	26-42	estrogen receptor 2	Homo sapiens	84-106
16782818-1	2006	Evidence is presented that the estrogen antagonist 4-hydroxytamoxifen (HT) can occupy not only the core binding pocket within the ligand-binding domain of estrogen receptor (ER) beta but also a second site on its surface.	hydroxytamoxifen	51-69	estrogen receptor 2	Homo sapiens	155-182
16517757-4	2006	The enzyme activities of the SULT1A1 allozymes were studied with a variety of substrates, including PNP, 17beta-estradiol, 2-methoxyestradiol, catecholestrogens, the antiestrogen 4-hydroxytamoxifen (OHT), and dietary flavonoids.	hydroxytamoxifen	179-197	sulfotransferase family 1A member 1	Homo sapiens	29-36
16835357-0	2006	17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30.	hydroxytamoxifen	33-51	G protein-coupled estrogen receptor 1	Homo sapiens	140-145
16899133-11	2006	(b) 4-Hydroxytamoxifen (but not tamoxifen), genistein (but not genistin), daidzein, and probably other nutritional and chemopreventive anti-cancer agents could up-regulate expression of p27 via receptor protein tyrosine kinases (RPTKs), phosphoinositide 3-kinase (PI3K), phosphoinosite-dependent kinase (PDK), Akt/PKB and mTOR.	hydroxytamoxifen	4-22	interferon alpha inducible protein 27	Homo sapiens	186-189
16899133-11	2006	(b) 4-Hydroxytamoxifen (but not tamoxifen), genistein (but not genistin), daidzein, and probably other nutritional and chemopreventive anti-cancer agents could up-regulate expression of p27 via receptor protein tyrosine kinases (RPTKs), phosphoinositide 3-kinase (PI3K), phosphoinosite-dependent kinase (PDK), Akt/PKB and mTOR.	hydroxytamoxifen	4-22	AKT serine/threonine kinase 1	Homo sapiens	310-317
16899133-11	2006	(b) 4-Hydroxytamoxifen (but not tamoxifen), genistein (but not genistin), daidzein, and probably other nutritional and chemopreventive anti-cancer agents could up-regulate expression of p27 via receptor protein tyrosine kinases (RPTKs), phosphoinositide 3-kinase (PI3K), phosphoinosite-dependent kinase (PDK), Akt/PKB and mTOR.	hydroxytamoxifen	4-22	mechanistic target of rapamycin kinase	Homo sapiens	322-326
16828306-4	2006	By crossing neurogenin 2 (Ngn2-CreER) with Cre-reporter mice expressing YFP or GFP reporter genes, it was possible to observe living cells after treating slice cultures with 4-hydroxytamoxifen to induce Cre recombinase activation.	hydroxytamoxifen	174-192	neurogenin 2	Mus musculus	26-30
16567807-8	2006	The interruption of this signaling pathway by specific phosphatidylinositol 3-kinase or Akt inhibitors suppresses the cytokine-mediated effects on GABA(A)R, whereas activation of the conditionally active form of Akt1 (myr-Akt1.ER*) with 4-hydroxytamoxifen reproduces the effects.	hydroxytamoxifen	237-255	AKT serine/threonine kinase 1	Homo sapiens	212-216
16617145-6	2006	Using the H1299 ER-E2F1 cell line where E2F1 activity can be conditionally induced, E2F1 has been shown to upregulate the Smac/DIABLO expression at both mRNA and protein levels upon 4-hydroxytamoxifen treatment, resulting in an enhanced mitochondria-mediated apoptosis.	hydroxytamoxifen	182-200	E2F transcription factor 1 L homeolog	Xenopus laevis	40-44
16676322-2	2006	Here, we generated and characterized mice harboring a 4-hydroxytamoxifen (OHT)-inducible Cre recombinase-estrogen receptor fusion transgene under the control of the melanocyte-specific tyrosinase promoter, designated Tyr::CreER(T2).	hydroxytamoxifen	54-72	estrogen receptor 1 (alpha)	Mus musculus	105-122
16480962-0	2006	Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4.	hydroxytamoxifen	46-70	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	137-168
16617145-6	2006	Using the H1299 ER-E2F1 cell line where E2F1 activity can be conditionally induced, E2F1 has been shown to upregulate the Smac/DIABLO expression at both mRNA and protein levels upon 4-hydroxytamoxifen treatment, resulting in an enhanced mitochondria-mediated apoptosis.	hydroxytamoxifen	182-200	E2F transcription factor 1 L homeolog	Xenopus laevis	40-44
16617145-6	2006	Using the H1299 ER-E2F1 cell line where E2F1 activity can be conditionally induced, E2F1 has been shown to upregulate the Smac/DIABLO expression at both mRNA and protein levels upon 4-hydroxytamoxifen treatment, resulting in an enhanced mitochondria-mediated apoptosis.	hydroxytamoxifen	182-200	diablo, IAP-binding mitochondrial protein L homeolog	Xenopus laevis	122-126
16617145-6	2006	Using the H1299 ER-E2F1 cell line where E2F1 activity can be conditionally induced, E2F1 has been shown to upregulate the Smac/DIABLO expression at both mRNA and protein levels upon 4-hydroxytamoxifen treatment, resulting in an enhanced mitochondria-mediated apoptosis.	hydroxytamoxifen	182-200	diablo, IAP-binding mitochondrial protein L homeolog	Xenopus laevis	127-133
16787364-10	2006	In a computational study, docked structures of the active compounds were compared with the X-ray crystal structures for the complexes of ERalpha with 4-hydroxytamoxifen and ERbeta with raloxifene.	hydroxytamoxifen	150-168	estrogen receptor 1	Homo sapiens	137-144
16884532-9	2006	Higher glucuronidation activities were found by kinetic analysis for microsomes from the variant UGT1A424Pro/48Val-overexpressing cell line as compared with microsomes from wild-type UGT1A424Pro/48Leu-overexpressing cells against TAM and against both the trans and cis isomers of 4-OH-TAM.	hydroxytamoxifen	280-288	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	97-102
16239258-0	2006	The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.	hydroxytamoxifen	104-120	G protein-coupled estrogen receptor 1	Homo sapiens	31-36
16475008-2	2006	A 4-hydroxytamoxifen (4-OHT)-eluting PDD was applied around the carotid or femoral artery of a mouse strain carrying both the tamoxifen-inducible and smooth muscle cell (SMC)-specific Cre-recombinase (SM-Cre-ER(T2)) transgene and a stop-floxed beta-galactosidase gene in the Rosa26 locus: the SM-CreER(T2)(ki)/rosa26 mouse.	hydroxytamoxifen	2-20	galactosidase, beta 1	Mus musculus	244-262
16475008-2	2006	A 4-hydroxytamoxifen (4-OHT)-eluting PDD was applied around the carotid or femoral artery of a mouse strain carrying both the tamoxifen-inducible and smooth muscle cell (SMC)-specific Cre-recombinase (SM-Cre-ER(T2)) transgene and a stop-floxed beta-galactosidase gene in the Rosa26 locus: the SM-CreER(T2)(ki)/rosa26 mouse.	hydroxytamoxifen	2-20	gene trap ROSA 26, Philippe Soriano	Mus musculus	275-281
16475008-2	2006	A 4-hydroxytamoxifen (4-OHT)-eluting PDD was applied around the carotid or femoral artery of a mouse strain carrying both the tamoxifen-inducible and smooth muscle cell (SMC)-specific Cre-recombinase (SM-Cre-ER(T2)) transgene and a stop-floxed beta-galactosidase gene in the Rosa26 locus: the SM-CreER(T2)(ki)/rosa26 mouse.	hydroxytamoxifen	2-20	gene trap ROSA 26, Philippe Soriano	Mus musculus	310-316
16317586-1	2006	Human sulfotransferase 1A1 (SULT1A1) is involved in the metabolism of a number of substances including 4-hydroxytamoxifen.	hydroxytamoxifen	103-121	sulfotransferase family 1A member 1	Homo sapiens	6-26
16317586-1	2006	Human sulfotransferase 1A1 (SULT1A1) is involved in the metabolism of a number of substances including 4-hydroxytamoxifen.	hydroxytamoxifen	103-121	sulfotransferase family 1A member 1	Homo sapiens	28-35
16884532-10	2006	A significantly (P < 0.02) lower Km value (approximately 1.6-fold to 1.8-fold) was observed for both 4-OH-TAM isomers, while a near-significant (P = 0.053) decrease in Km was observed for TAM for the UGT1A424Pro/48Val variant as compared with wild-type UGT1A4.	hydroxytamoxifen	104-112	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	203-208
16884532-10	2006	A significantly (P < 0.02) lower Km value (approximately 1.6-fold to 1.8-fold) was observed for both 4-OH-TAM isomers, while a near-significant (P = 0.053) decrease in Km was observed for TAM for the UGT1A424Pro/48Val variant as compared with wild-type UGT1A4.	hydroxytamoxifen	104-112	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	203-209
16884532-11	2006	The Vmax/Km ratio for the UGT1A424Pro/48Val variant was significantly (P < or = 0.005) higher than that observed for the wild-type UGT1A4 isoform for both the trans and cis isomers of 4-OH-TAM after normalization for UGT1A4 expression by western blotting.	hydroxytamoxifen	187-195	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	26-31
16884532-11	2006	The Vmax/Km ratio for the UGT1A424Pro/48Val variant was significantly (P < or = 0.005) higher than that observed for the wild-type UGT1A4 isoform for both the trans and cis isomers of 4-OH-TAM after normalization for UGT1A4 expression by western blotting.	hydroxytamoxifen	187-195	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	26-32
16884532-11	2006	The Vmax/Km ratio for the UGT1A424Pro/48Val variant was significantly (P < or = 0.005) higher than that observed for the wild-type UGT1A4 isoform for both the trans and cis isomers of 4-OH-TAM after normalization for UGT1A4 expression by western blotting.	hydroxytamoxifen	187-195	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	134-140
16515477-10	2006	The selective estrogen receptor modulators 4-hydroxytamoxifen and 4-hydroxytoremifene antagonize ERRgamma.	hydroxytamoxifen	43-61	estrogen related receptor gamma	Homo sapiens	97-105
16093440-8	2005	Growth inhibition by MSA and MSA + 4-hydroxytamoxifen in all cell lines was preceded by a specific decrease in ER(alpha) mRNA and protein without an effect on ER(beta) levels.	hydroxytamoxifen	35-53	estrogen receptor 1	Homo sapiens	111-113
16367757-3	2006	Here, we show that the 4-hydroxytamoxifen (4-OHT) mediated activation of a C-Raf-estrogen receptor fusion protein leads to the induction of both the PPARbeta and Cox-2 genes, concomitant with a dramatic increase in PGI2 synthesis.	hydroxytamoxifen	23-41	peroxisome proliferator activated receptor delta	Homo sapiens	149-157
16367757-3	2006	Here, we show that the 4-hydroxytamoxifen (4-OHT) mediated activation of a C-Raf-estrogen receptor fusion protein leads to the induction of both the PPARbeta and Cox-2 genes, concomitant with a dramatic increase in PGI2 synthesis.	hydroxytamoxifen	23-41	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	162-167
16037132-13	2005	Finally, ERalpha dissociation from CHIP by various ERalpha ligands, including 17beta-estradiol, 4-hydroxytamoxifen, and ICI 182,780, interrupted CHIP-mediated ERalpha degradation.	hydroxytamoxifen	96-114	estrogen receptor 1	Homo sapiens	9-16
16037132-13	2005	Finally, ERalpha dissociation from CHIP by various ERalpha ligands, including 17beta-estradiol, 4-hydroxytamoxifen, and ICI 182,780, interrupted CHIP-mediated ERalpha degradation.	hydroxytamoxifen	96-114	estrogen receptor 1	Homo sapiens	51-58
16037132-13	2005	Finally, ERalpha dissociation from CHIP by various ERalpha ligands, including 17beta-estradiol, 4-hydroxytamoxifen, and ICI 182,780, interrupted CHIP-mediated ERalpha degradation.	hydroxytamoxifen	96-114	estrogen receptor 1	Homo sapiens	51-58
16216906-5	2005	Evaluating the response to ER antagonists like 4-hydroxytamoxifen (OHT) and ICI 182 780 (ICI), we observed an up-regulation of ER beta and a dose-dependent inhibition of H295R cell proliferation.	hydroxytamoxifen	47-65	estrogen receptor 2	Homo sapiens	127-134
16091424-4	2005	N-cadherin was fused at its C-terminus to a modified estrogen receptor ligand-binding domain (NcadER) that binds 4-hydroxytamoxifen (4OHT) and expressed in L cells, which lack an endogenous cadherin.	hydroxytamoxifen	113-131	cadherin 2	Homo sapiens	0-10
16884532-0	2006	Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.	hydroxytamoxifen	34-52	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	78-84
16533026-10	2005	However, when 4-hydroxytamoxifen (100 microM) was used as the substrate, P450 2B6, P450 3A4, P450 3A5, P450 1B1, P450 1A1, and P450 2D6 all produced detectable concentrations of alpha,4-dihydroxytamoxifen.	hydroxytamoxifen	14-32	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	73-121
16093440-9	2005	Estradiol and 4-hydroxytamoxifen induction of endogenous ER-dependent gene expression (pS2 and c-myc) as well as ER-dependent reporter gene expression (ERE(2)e1b-luciferase) was also attenuated by MSA in all cell lines before effect on growth inhibition.	hydroxytamoxifen	14-32	estrogen receptor 1	Homo sapiens	57-59
16093440-9	2005	Estradiol and 4-hydroxytamoxifen induction of endogenous ER-dependent gene expression (pS2 and c-myc) as well as ER-dependent reporter gene expression (ERE(2)e1b-luciferase) was also attenuated by MSA in all cell lines before effect on growth inhibition.	hydroxytamoxifen	14-32	trefoil factor 1	Homo sapiens	87-90
16093440-9	2005	Estradiol and 4-hydroxytamoxifen induction of endogenous ER-dependent gene expression (pS2 and c-myc) as well as ER-dependent reporter gene expression (ERE(2)e1b-luciferase) was also attenuated by MSA in all cell lines before effect on growth inhibition.	hydroxytamoxifen	14-32	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	95-100
16093440-10	2005	Taken together, these data strongly suggest that specific decrease in ER(alpha) levels by MSA is required for both MSA potentiation of the growth inhibitory effects of 4-hydroxytamoxifen and resensitization of tamoxifen-resistant cell lines.	hydroxytamoxifen	168-186	estrogen receptor 1	Homo sapiens	70-72
15788686-0	2005	4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.	hydroxytamoxifen	0-18	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
15685451-6	2005	We, therefore, determined the effect of endoxifen and 4-OH-Tam on 17beta-estradiol (E2)-induced PR mRNA expression in an estrogen receptor-positive human breast cancer cell line.	hydroxytamoxifen	54-62	progesterone receptor	Homo sapiens	96-98
15685451-12	2005	When 10(-10) M E2 was used, induction of the PR expression was observed in 2 h and reached its maximum at 24 h. In this assay, neither endoxifen nor 4-OH-Tam alone produced any change in the PR mRNA expression.	hydroxytamoxifen	149-157	progesterone receptor	Homo sapiens	45-47
15685451-13	2005	However, both endoxifen and 4-OH-Tam decreased the E2-induced PR expression with similar potency.	hydroxytamoxifen	28-36	progesterone receptor	Homo sapiens	62-64
15828819-4	2005	The relative binding affinity values for estrogen receptor alpha (ERalpha) for n = 2 and 3 were very high (85 and 53%) and surpassed even that of hydroxytamoxifen (38.5%), the active metabolite of tamoxifen.	hydroxytamoxifen	146-162	estrogen receptor 1	Homo sapiens	41-64
15828819-4	2005	The relative binding affinity values for estrogen receptor alpha (ERalpha) for n = 2 and 3 were very high (85 and 53%) and surpassed even that of hydroxytamoxifen (38.5%), the active metabolite of tamoxifen.	hydroxytamoxifen	146-162	estrogen receptor 1	Homo sapiens	66-73
15828819-5	2005	Ruthenocene derivatives act as anti-estrogens as effective (n = 2) or slightly more effective (n = 3-5) than hydroxytamoxifen on ERalpha-positive breast cancer cell lines but, unlike ferrocifens, do not show antiproliferative effects on ERalpha-negative breast cancer cell lines.	hydroxytamoxifen	109-125	estrogen receptor 1	Homo sapiens	129-136
15788686-0	2005	4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.	hydroxytamoxifen	0-18	cyclin dependent kinase inhibitor 1B	Homo sapiens	128-135
15788686-0	2005	4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.	hydroxytamoxifen	0-18	BCL2 apoptosis regulator	Homo sapiens	155-160
15728727-6	2005	In vivo, an engineered coactivator containing the peptide motif is able to strongly enhance the transcriptional activity of liganded ERalpha, particularly in the presence of 4-hydroxytamoxifen.	hydroxytamoxifen	174-192	estrogen receptor 1	Homo sapiens	133-140
15737202-2	2005	After topical treatment with the inducing agent 4-hydroxytamoxifen (4OHT), ODC activity and putrescine levels were dramatically increased in the epidermis but not in the dermis of transgenic mice.	hydroxytamoxifen	48-66	ornithine decarboxylase, structural 1	Mus musculus	75-78
15647843-3	2005	To address this issue, we have established M1/STAT3ER cells, where STAT3 is selectively activated by 4-hydroxytamoxifen (4HT).	hydroxytamoxifen	101-119	signal transducer and activator of transcription 3	Mus musculus	46-51
15647843-3	2005	To address this issue, we have established M1/STAT3ER cells, where STAT3 is selectively activated by 4-hydroxytamoxifen (4HT).	hydroxytamoxifen	101-119	signal transducer and activator of transcription 3	Mus musculus	67-72
15361836-5	2004	This construct, v-ErbB:ER, requires beta-estradiol or 4-OH tamoxifen for activation.	hydroxytamoxifen	54-68	epidermal growth factor receptor	Mus musculus	18-22
15595833-5	2004	To test the role of Nef oligomerization in Hck activation, we fused Nef to the hormone-binding domain of the estrogen receptor (Nef-ER), allowing us to control its dimerization with 4-hydroxytamoxifen (4-HT).	hydroxytamoxifen	182-200	estrogen receptor 1	Homo sapiens	109-126
15588086-0	2004	Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.	hydroxytamoxifen	83-101	estrogen receptor 1	Homo sapiens	30-47
15588086-3	2004	We have recently reported the design, synthesis, and preliminary evaluation of a doxorubicin-formaldehyde conjugate targeted, via 4-hydroxytamoxifen, to the estrogen receptor (ER) and antiestrogen binding site (AEBS), which are commonly present in breast cancer cells.	hydroxytamoxifen	130-148	estrogen receptor 1	Homo sapiens	157-174
15588086-3	2004	We have recently reported the design, synthesis, and preliminary evaluation of a doxorubicin-formaldehyde conjugate targeted, via 4-hydroxytamoxifen, to the estrogen receptor (ER) and antiestrogen binding site (AEBS), which are commonly present in breast cancer cells.	hydroxytamoxifen	130-148	estrogen receptor 1	Homo sapiens	176-178
15588086-12	2004	The data support the hypothesis that uptake of 4-hydroxytamoxifen targeted doxorubicin-formaldehyde conjugate is mediated by both the antiestrogen binding site and estrogen receptor.	hydroxytamoxifen	47-65	estrogen receptor 1	Homo sapiens	164-181
15531727-1	2004	The anti-estrogen 4-hydroxytamoxifen (TAM) and vitamin A-related compounds, the retinoids, in combination act synergistically to inhibit growth of breast cancer cells in vitro and in vivo.	hydroxytamoxifen	18-36	Myeloproliferative syndrome, transient (transient abnormal myelopoiesis)	Homo sapiens	38-41
15684716-8	2005	Expression of MybER, a 4-hydroxytamoxifen-activatable form of c-Myb, blocks differentiation in wildtype and APC mutant Immorto-cell lines as well as LIM1215 human colon carcinoma cells.	hydroxytamoxifen	23-41	MYB proto-oncogene, transcription factor	Homo sapiens	62-67
15375189-6	2005	These studies indicated that ER agonists, such as 17beta-estradiol or estrone, promoted the interaction of ER with the coactivator peptides, whereas antagonists such as 4-hydroxytamoxifen or ICI-182,780 did not.	hydroxytamoxifen	169-187	estrogen receptor 1	Homo sapiens	29-31
15361836-5	2004	This construct, v-ErbB:ER, requires beta-estradiol or 4-OH tamoxifen for activation.	hydroxytamoxifen	54-68	estrogen receptor 1 (alpha)	Mus musculus	23-25
15317858-5	2004	Transfection of constitutive or 4-hydroxytamoxifen-inducible versions of Akt1 results in higher messenger RNA and protein levels of Cu/Zn-SOD.	hydroxytamoxifen	32-50	AKT serine/threonine kinase 1	Homo sapiens	73-77
15351741-0	2004	SRA coactivation of estrogen receptor-alpha is phosphorylation-independent, and enhances 4-hydroxytamoxifen agonist activity.	hydroxytamoxifen	89-107	steroid receptor RNA activator 1	Homo sapiens	0-3
15351741-0	2004	SRA coactivation of estrogen receptor-alpha is phosphorylation-independent, and enhances 4-hydroxytamoxifen agonist activity.	hydroxytamoxifen	89-107	estrogen receptor 1	Homo sapiens	20-43
15351741-6	2004	SRA enhanced ERalpha activity stimulated by 4-hydroxytamoxifen, but was unable to convert this mixed antiestrogen to an ERbeta agonist.	hydroxytamoxifen	44-62	steroid receptor RNA activator 1	Homo sapiens	0-3
15351741-6	2004	SRA enhanced ERalpha activity stimulated by 4-hydroxytamoxifen, but was unable to convert this mixed antiestrogen to an ERbeta agonist.	hydroxytamoxifen	44-62	estrogen receptor 1	Homo sapiens	13-20
15525597-8	2004	These data demonstrated that the ERE sequence impacts estradiol-and 4-hydroxytamoxifen-occupied ERalpha and ERbeta interaction with coregulators as measured by transcriptional activity in mammalian cells.	hydroxytamoxifen	68-86	estrogen receptor 1	Homo sapiens	96-103
15525597-8	2004	These data demonstrated that the ERE sequence impacts estradiol-and 4-hydroxytamoxifen-occupied ERalpha and ERbeta interaction with coregulators as measured by transcriptional activity in mammalian cells.	hydroxytamoxifen	68-86	estrogen receptor 2	Homo sapiens	108-114
15304079-4	2004	The enzymatic activity of the PKCdelta catalytic domain fusion protein was induced in human keratinocytes treated with 4-hydroxytamoxifen, and its activation triggered loss of mitochondrial membrane potential and apoptosis.	hydroxytamoxifen	119-137	protein kinase C delta	Homo sapiens	30-38
15161930-0	2004	Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.	hydroxytamoxifen	102-120	estrogen related receptor gamma	Homo sapiens	45-76
15161930-2	2004	Although no natural ligand is known, ERRgamma is deactivated by the estrogen receptor (ER) agonist diethylstilbestrol and the selective ER modulator 4-hydroxytamoxifen but does not significantly respond to estradiol or raloxifene.	hydroxytamoxifen	149-167	estrogen related receptor gamma	Homo sapiens	37-45
15161930-3	2004	Here we report the crystal structures of the ERRgamma ligand binding domain (LBD) complexed with diethylstilbestrol or 4-hydroxytamoxifen.	hydroxytamoxifen	119-137	estrogen related receptor gamma	Homo sapiens	45-53
15161930-7	2004	Comparison of the ligand-bound LBDs of ERRgamma and ERalpha reveals small but significant differences in the architecture of the ligand binding pockets that result in a slightly shifted binding position of diethylstilbestrol and a small rotation of 4-hydroxytamoxifen in the cavity of ERRgamma relative to ERalpha.	hydroxytamoxifen	249-267	estrogen related receptor gamma	Homo sapiens	39-47
15161930-7	2004	Comparison of the ligand-bound LBDs of ERRgamma and ERalpha reveals small but significant differences in the architecture of the ligand binding pockets that result in a slightly shifted binding position of diethylstilbestrol and a small rotation of 4-hydroxytamoxifen in the cavity of ERRgamma relative to ERalpha.	hydroxytamoxifen	249-267	estrogen receptor 1	Homo sapiens	52-59
15161930-7	2004	Comparison of the ligand-bound LBDs of ERRgamma and ERalpha reveals small but significant differences in the architecture of the ligand binding pockets that result in a slightly shifted binding position of diethylstilbestrol and a small rotation of 4-hydroxytamoxifen in the cavity of ERRgamma relative to ERalpha.	hydroxytamoxifen	249-267	estrogen related receptor gamma	Homo sapiens	285-293
15161930-7	2004	Comparison of the ligand-bound LBDs of ERRgamma and ERalpha reveals small but significant differences in the architecture of the ligand binding pockets that result in a slightly shifted binding position of diethylstilbestrol and a small rotation of 4-hydroxytamoxifen in the cavity of ERRgamma relative to ERalpha.	hydroxytamoxifen	249-267	estrogen receptor 1	Homo sapiens	306-313
15386482-0	2004	Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A.	hydroxytamoxifen	52-70	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
15386482-0	2004	Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A.	hydroxytamoxifen	52-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-100
15386482-1	2004	The effects of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen on transport attributable to P-glycoprotein were studied using Caco-2 cell monolayers in a transwell system, with rhodamine-123 as an index substrate for inhibition studies.	hydroxytamoxifen	51-69	ATP binding cassette subfamily B member 1	Homo sapiens	99-113
15313422-5	2004	In human cancer cells, inhibition of HDACs controls the expression of the ERalpha gene and the transcriptional activity in response to partial antiestrogens such as 4-hydroxytamoxifen.	hydroxytamoxifen	165-183	estrogen receptor 1	Homo sapiens	74-81
15316080-4	2004	To investigate FOXN1 function we expressed an inducible form of the protein, FOXN1ER, that is activated by 4-hydroxytamoxifen in primary human epidermal keratinocytes.	hydroxytamoxifen	107-125	forkhead box N1	Homo sapiens	15-20
15317858-5	2004	Transfection of constitutive or 4-hydroxytamoxifen-inducible versions of Akt1 results in higher messenger RNA and protein levels of Cu/Zn-SOD.	hydroxytamoxifen	32-50	superoxide dismutase 1	Homo sapiens	132-141
15280403-9	2004	VEGF-D expression was enhanced by oestrogen in MCF-7 and T47D breast cancer cells, and was blocked by hydroxytamoxifen.	hydroxytamoxifen	102-118	vascular endothelial growth factor D	Homo sapiens	0-6
15067010-5	2004	In culture with stem cell factor, FLT3 ligand, and IL-6, a 4-hydroxytamoxifen-inducible form of c-Myc (Myc/ERT) enabled murine Lin(-)Sca-1(+) HSCs to proliferate with the surface phenotype compatible with HSCs for more than 28 days.	hydroxytamoxifen	59-77	kit ligand	Mus musculus	16-32
15245432-7	2004	Cyclin D2 expression was enhanced by antiestrogens, ICI 182,780 and 4-hydroxytamoxifen, and membrane-impermeable bovine serum albumin-conjugated E2, indicating the effects via membrane E2-binding sites.	hydroxytamoxifen	68-86	cyclin D2	Homo sapiens	0-9
15056732-4	2004	A kinase assay showed that antiestrogens (4-hydroxytamoxifen and ICI 182.780) rapidly induce p38 activity.	hydroxytamoxifen	42-60	mitogen-activated protein kinase 14	Homo sapiens	93-96
15067010-5	2004	In culture with stem cell factor, FLT3 ligand, and IL-6, a 4-hydroxytamoxifen-inducible form of c-Myc (Myc/ERT) enabled murine Lin(-)Sca-1(+) HSCs to proliferate with the surface phenotype compatible with HSCs for more than 28 days.	hydroxytamoxifen	59-77	FMS-like tyrosine kinase 3	Mus musculus	34-38
15067010-5	2004	In culture with stem cell factor, FLT3 ligand, and IL-6, a 4-hydroxytamoxifen-inducible form of c-Myc (Myc/ERT) enabled murine Lin(-)Sca-1(+) HSCs to proliferate with the surface phenotype compatible with HSCs for more than 28 days.	hydroxytamoxifen	59-77	interleukin 6	Mus musculus	51-55
15067010-5	2004	In culture with stem cell factor, FLT3 ligand, and IL-6, a 4-hydroxytamoxifen-inducible form of c-Myc (Myc/ERT) enabled murine Lin(-)Sca-1(+) HSCs to proliferate with the surface phenotype compatible with HSCs for more than 28 days.	hydroxytamoxifen	59-77	myelocytomatosis oncogene	Mus musculus	98-101
15067010-5	2004	In culture with stem cell factor, FLT3 ligand, and IL-6, a 4-hydroxytamoxifen-inducible form of c-Myc (Myc/ERT) enabled murine Lin(-)Sca-1(+) HSCs to proliferate with the surface phenotype compatible with HSCs for more than 28 days.	hydroxytamoxifen	59-77	myelocytomatosis oncogene	Mus musculus	103-106
15067010-5	2004	In culture with stem cell factor, FLT3 ligand, and IL-6, a 4-hydroxytamoxifen-inducible form of c-Myc (Myc/ERT) enabled murine Lin(-)Sca-1(+) HSCs to proliferate with the surface phenotype compatible with HSCs for more than 28 days.	hydroxytamoxifen	59-77	SH2 domain containing 1B2	Mus musculus	107-110
15067010-6	2004	c-Myc activated by 4-hydroxytamoxifen augmented telomerase activities and increased the number of CFU-Mix about 2-fold in colony assays.	hydroxytamoxifen	19-37	myelocytomatosis oncogene	Mus musculus	2-5
15174161-3	2004	Photocaged derivatives of hydroxytamoxifen (NB-Htam) and guanidine tamoxifen (NB-Gtam) have been synthesized that selectively antagonize ER alpha- and ER beta-mediated transcription at classic estrogen response elements (EREs) in response to light.	hydroxytamoxifen	26-42	estrogen receptor 1	Homo sapiens	137-145
15174161-3	2004	Photocaged derivatives of hydroxytamoxifen (NB-Htam) and guanidine tamoxifen (NB-Gtam) have been synthesized that selectively antagonize ER alpha- and ER beta-mediated transcription at classic estrogen response elements (EREs) in response to light.	hydroxytamoxifen	26-42	estrogen receptor 2	Homo sapiens	151-158
15157572-11	2004	The estrogen receptor antagonist 4-hydroxytamoxifen could attenuate these inhibitive effects of both E2 and ZEA.	hydroxytamoxifen	33-51	cystatin 12, pseudogene	Homo sapiens	101-111